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Abstract 
Parkinson’s Disease is among the most common neurodegenerative disease 
affecting individuals worldwide.  In addition to the motor symptoms that are present in the 
disease there are significant cognitive impairments that people with Parkinson’s Disease 
experience as part of the disease process that cause significant disability.  The concept of 
protective factors against cognitive decline, known as cognitive reserve, have been 
investigated and demonstrated in other dementia populations.  These indicators include 
pre-morbid IQ, education level and participation in lifestyle activities.  This study aimed to 
investigate whether cognitive reserve is present in people with Parkinson’s Disease, with 
consideration given to existing measures and the influence of mood disorders on cognition 
in the population. 
88 Participants were administered a comprehensive neuropsychological battery 
including overall and specific cognitive function measures, pre-morbid IQ, lifestyle activity 
participation, mood and demographic factors.  Cognitive decline scores were calculated by 
comparison of current and pre-morbid IQ scores and these compared to potential cognitive 
reserve measures and mood factors. 
Previously identified indicators of cognitive reserve were not confirmed in the 
results, though the regular playing of musical instruments was identified as a potential 
factor for further investigation.  Pre-morbid IQ and education demonstrated an increase in 
decline rather than a decrease which is attributed to Wilder’s law of initial values.  Mood 
factors were shown to affect cognition in the Parkinson’s Disease population highlighting 
their importance in the treatment of the disease.  
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Chapter 1: Overview of the Thesis 
Parkinson’s Disease (PD) is the second most common neurological disorder in 
Australia, affecting more than 64,000 individuals.  The disease is both disabling and 
degenerative with affected individuals requiring increasing levels of assistance with 
Activities of Daily Living (ADLs) and supported accommodation later in life.  PD has both 
physical and cognitive symptoms and while the physical symptoms are more recognised for 
their disabling effects, the cognitive symptoms can be equally severe and can adversely 
affect the individual’s ability to cope with their changing physical abilities. 
The progression of the cognitive aspects of PD is poorly understood, likely in part 
due to the focus on treating the physical symptoms of the disease.  Understanding the 
progression of the cognitive aspects of disease, and identifying any factors that may be 
predictive or preventative in the development of these cognitive impairments, could add 
valuable information to the treatment plans of individuals with the condition. 
This research examines cognitive impairments in individuals with PD.  It examines 
the possible influence on current cognition in a PD population of three key factors: pre-
morbid functioning, participation in lifestyle activities, and mood.  The research examines 
whether these three factors appear to have any protective or predictive influence in the 
development of cognitive deficits in individuals with PD.    Each of these three factors is 
investigated via comparison of current cognitive function (measured using the Repeatable 
Battery for the Assessment of Neuropsychological Status; RBANS) with a measure of pre-
morbid function (the National Adult Reading Test; NART).  By examining the level of 
cognitive decline present in groups which vary on each of the three  factors, it is possible to 
investigate the effect that each of these has on both current level of functioning and 
changes in functioning over the course of the disease. 
2 
 
 
Identification of pre-morbid, lifestyle or mood based factors that affect 
performance on cognitive tasks may demonstrate that PD is not a singular progression 
path, but rather is treatable through therapeutic programmes targeting associated 
conditions (such as anti-depressant medication).  It is hoped that this, in turn, may lead to 
an ability to improve the overall quality of life ofpeople with the disease. 
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Chapter 2: Introduction to Parkinson’s Disease 
2.1 Parkinson’s Disease 
Parkinson’s Disease (PD) is a chronic, progressive neurological condition of largely 
unknown aetiology.  It is estimated to be the second most common neurological disorder, 
after Alzheimer’s Disease, and is said to affect 1-2% of the population aged sixty and above 
(de Lau and Breteler, 2006).  The condition is characterised by the cardinal symptoms; 
bradykinesia, resting tremor, rigidity and postural instability. Although two of these 
symptoms are needed for a diagnosis to be made, many individuals become conscious of 
the disease by the presence of a unilateral or bilateral tremor.  While PD is generally 
recognised for its motor symptoms, there exist many non-motor manifestations of the 
disease including cognitive, sensory and autonomic disturbances (Albanese, 2003).  
Cognitive dysfunctions that occur as a result of PD can often be as debilitating as the motor 
disturbances, but their impact is less understood. 
2.2 Epidemiology  
A 2005 study estimated that there were between 4.1 million and 4.6 million 
individuals with PD in the most populous countries of the world, with that figure expected 
to rise to between 8.7 million and 9.3 million by 2030 (Dorsey et al., 2005).  A 2011 study 
reviewed previous estimates of the prevalence of PD and concluded that it was too difficult 
to give an accurate estimate of worldwide incidence due to reporting differences between 
countries (Muangpaisan, Mathews, Hori & Seidel, 2011). 
An Australian government report (2011) estimates that there are currently 64,000 
individuals in Australia living with PD of which 52% are male and 48% female.  It also 
reports that approximately 3962 of these individuals are aged between 35 and 54 years old 
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and 80% are over the age of 65.  It is also reported that 12,000 individuals with PD are of 
working age meaning that early and effective detection of the cognitive deficits in PD are 
crucial to determine so that these individuals can obtain tailored support to assist them 
stay in the workforce.  
2.3 Early-Onset Parkinson’s Disease 
PD is a degenerative condition that is diagnosed by clinical observation of 
expressed symptomatology.  As such, it is typically diagnosed in older individuals, with the 
majority of diagnoses occurring over the age of 60.  However some people develop 
symptoms substantially earlier (<55 years) and are diagnosed with the sub-condition 
known as Early Onset Parkinson’s Disease.   
Research has shown that people who develop early onset PD tend to respond 
better to anti-Parkinsonian medication than those who commence treatment in their 
sixties or older (Wickremaratchi, Ben-Shlomo & Morris, 2009). Unfortunately, however, 
these individuals tend to be at an increased risk of developing dyskinesias as a result pf 
long term medication use (Giovannini et al., 1991; Wickrematchi et al., 2009).  Those who 
develop early onset PD experience slower disease progression than their older 
counterparts, both physically and cognitively (Wickrematchi et al., 2009).  However they 
tend to experience worse outcomes long term, with higher incidence of symptoms such as 
dementia that can lead to increased disability and mortality rates (Wickremaratchi et al., 
2009). 
2.4 Diagnosis 
PD is often interpreted as referring to a cluster of conditions rather than a single 
disease entity (Tolosa, Wenning & Poew, 2006).  Currently, there are no medical based 
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tests that can definitively diagnose a living individual with PD; PD can only be accurately 
diagnosed through examination of neurological pathology, generally post mortem (Lee, 
Williams & Storey, 2012).  As such, the diagnosis of PD relies primarily on the assessment of 
clinical findings (de Lau & Breteler, 2006).  A diagnosis by clinical examination requires a 
clinician to observe a resting tremor as well as at least two of bradykinesia, cogwheel 
rigidity or postural abnormalities (Aarsland et al., 2001).  In some cases clinicians will also 
test for a response to a dopaminergic agent, such as Levodopa, as an indicator for diagnosis 
(Aarsland et al., 2001). 
PD presents as a cluster of symptoms that can often vary from person to person, 
both in terms of symptom cluster and symptom severity.  This results in a lack of clarity 
surrounding diagnosis and, as such, interpretation of diagnostic criteria can differ between 
clinicians (Lee, Williams & Storey, 2012). This difference can be emphasised depending on 
whether the clinician is assessing solely for idiopathic PD or include symptoms of a 
Parkinsonian type condition in their diagnosis.  Studies have found that because of this lack 
of clarity and consistency between clinicians the diagnostic error can occur in up to 20% of 
people with PD (Albanese, 2003).  
2.4.1 Differential Diagnoses 
Parkinsonian features can occur as a result of many conditions making it important 
for clinicians to differentiate between PD and other conditions with symptom overlap when 
making a diagnosis.  Essential tremor, multi-system atrophy, progressive supranuclear 
palsy, and cortico-basal degeneration all share symptoms with PD (Tolosa, Wenning & 
Poewe, 2006).   
The accurate diagnosis of PD is crucial in order to allow the correct treatment to be 
initialised for those who experience from the condition. This makes investigations into 
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methods of consistent and accurate identification of the disease imperative in order to 
continue to develop best practice treatment regimens and techniques. 
2.4.2 Imaging Techniques 
Although most clinicians have access to imaging techniques such as computerised 
tomography (CT) or magnetic resonance imaging (MRI) to assist with diagnosis, to date 
there are no clinical hallmarks that appear on this type of scanning (de Lau & Breteler, 
2006). At best these scans can be used for the purposes of ruling out differential diagnoses, 
assessing cerebral atrophy and assessing age related brain changes (Hirano, Shintoh & 
Eidelberg, 2012; Tolosa et al., 2006).  The cost of these techniques, along with their inability 
to definitively diagnose the disease, means that they are infrequently utilised in diagnosis 
of PD. 
Individuals with PD can occasionally demonstrate a MRI signal void in the 
substantia nigra (Tolosa et al., 2006).  However, this tends to be detectable only by using 
high field MRI scanners which are expensive to use and unavailable to most clinicians 
(Tolosa et al., 2006).  Single photon emission computerised tomography (SPECT) and 
positron emission tomography (PET) have emerged in clinical practice as more useful ways 
of imaging those with suspected PD, as they carry with them the ability to examine neuro-
chemical brain changes (Tolosa et al., 2006).  However, like their imaging counterparts, 
these techniques are generally inconclusive and expensive to perform (Tolosa et al., 2006).  
2.4.3 Diagnostic Instruments 
Several diagnostic criteria and staging instruments used in the assessment of PD 
exist including the Hoehn and Yahr Scale, demonstrated in Figure 1, and the Unified 
Parkinson’s Disease Rating Scale (UPDRS). These scales rate the level of impairment in 
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those with PD with the first levels of both scales representing early stage disease and the 
last later stage disease processes. Those with idiopathic PD can be benchmarked against 
either scale with the UPDRS being more commonly employed in current clinical practice. 
Stage Hoehn and Yahr Scale Modified Hoehn and Yahr Scale 
1 
Unilateral involvement only usually with 
minimal or no functional disability 
Unilateral involvement only 
1.5 - Unilateral and axial involvement 
2 
Bilateral or midline involvement without 
impairment of balance 
Bilateral involvement without 
impairment of balance 
2.5 - 
Mild bilateral disease with recovery on 
pull test 
3 
Bilateral disease: mild to moderate disability 
with impaired postural reflexes; physically 
independent 
Mild to moderate bilateral disease; 
some postural instability; physically 
independent 
4 
Severely disabling disease; still able to walk 
or stand unassisted 
Severe disability; still able to walk or 
stand unassisted 
5 
Confinement to bed or wheelchair unless 
aided 
 
Wheelchair bound or bedridden 
unless aided 
 
Figure 1. Hoehn and Yahr Scale 
 
The employment of such rating scales and diagnostic criteria is imperative in 
ensuring correct and consistent diagnosis of PD across clinicians.  In turn, it is essential for 
correct management of people with PD as several similar disease processes can closely 
represent PD.  
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2.5 Causes and Risk Factors 
The most recognised risk factor in development of PD is a genetic component.  
Many studies have shown that those with a family history of PD are at higher risk of 
developing the condition (de Lau & Breteler, 2006).  However, the hereditary link is not 
definitive; some individuals develop PD without a familial history, and some people with PD 
have children who do not develop the condition. 
Other risk factors have been investigated for PD, with many studies having shown 
that pesticide exposure may be a causative risk for the condition.  The majority of studies 
examining pesticide exposure, however, are flawed due to the inability to isolate single 
toxins due to concomitant exposures and the fact that studying pesticide exposure relies 
heavily on individual recall (Hubble, Cao, Hassanein, Neuberger & Koller, 1993).   
De Lau and Breteler (2006) reported that drinking coffee and smoking tobacco may 
lower the risk of developing PD.  Nicotine has been shown to force the release of 
dopamine, thus acting in a neuro-protective manner against the development of PD.  The 
long term use of dopamine agonists such as anti-emetics or antipsychotic medication has 
also been shown to induce Parkinsonism due to their anti-cholinergic effects (Tolosa et al., 
2006). 
2.6 Pathophysiology 
Parkinson’s Disease is thought to develop due to neuronal loss in the substantia 
nigra and the development of Lewy bodies (de Lau & Breteler, 2006).  Dopaminergic 
neurons are primarily found in the ventral tegmental area (VTA) of the midbrain, substantia 
nigra pars compacta, and arcuate nucleus of the hypothalamus (Ceravola, Rossie, Kiferle & 
Bonuccelli, 2010).  Thus depletion of these neurons can lead to insufficient formation and 
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action of dopamine in the basal ganglia.  In turn this leads to under-stimulation of the 
motor cortex and associated, characteristic motor symptoms recognised as “Parkinsonism”.  
The basal ganglia play an important function in both motor activity and cognition.  
In each case they act as a decision making gateway in the brain allowing the translation of 
internal decision to active outcomes.  Chiefly they allow or suppress the transmission of 
actions to further parts of the brain; in a healthy brain they allow appropriate actions to 
occur and inappropriate actions to be suppressed (Koziol & Budding, 2009).  In people with 
Parkinson’s Disease, however, suppression by the basal ganglia of unwanted or 
inappropriate signals may be impaired, leading to both motor and cognitive symptoms.  In 
the motor context, such symptoms include difficulty commencing an activity (such as 
walking) or inability to stop a movement once it has begun, resulting in tremor.  Similar 
problems in starting and stopping may be seen in cognitive functioning too (Koziol & 
Budding, 2009).  Maintaining attention, for example, requires focusing on a salient stimulus 
while at the same time suppressing distracting actions. In a person with PD attention may 
be poorly modulated resulting, for instance, in difficulty maintaining attention on a book 
being read because of constant distraction to a bird at the window.  Similarly, inability to 
selectively encourage and suppress appropriate and inappropriate actions respectively can 
result in unwanted action, even after a conscious decision against that action. In such cases 
the brain may be able to determine an appropriate course of action based on information 
but be unable to suppress contra-indicated action.  Thus, regardless of the decision that 
takes place in the brain the outward expression of that decision may be inappropriate 
(Koziol & Budding, 2009). 
The reduced dopamine action in the basal ganglia seen in Parkinson’s Disease, 
then, impedes the brain’s ability to encourage and suppress actions, both in the motor 
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sense and the cognitive sense.  This can be observed in the expressed symptoms of the 
disease. 
2.7 Symptoms of Parkinson’s Disease 
2.7.1 Motor Symptoms 
The motor symptoms of PD include tremor at rest, muscle rigidity, slowed 
movement (bradykinesia) and shuffling gait (de Lau & Breteler, 2006).  People with PD can 
sometimes have great difficulty in commencing a physical activity and may require 
assistance in commencing some activities.  These symptoms represent the underlying brain 
physiology described in the previous section.  Muscle rigidity, for example, is representative 
of the inability to suppress the inappropriate action of tensing the muscles while at the 
same time encouraging the appropriate action of relaxing the muscles.  The inappropriate 
action is therefore sent to the fronto-striatal cortex and the muscle remains rigid despite 
the person’s will to relax it. 
The motor symptoms of PD have received much of the attention given to the 
disease and its treatment because they can be very physically disabling for the person.  As 
the disease progresses it becomes more and more difficult for the individual to perform 
desired motor actions and hence they become less physically mobile and require increasing 
assistance to perform activities of daily living. 
2.7.2 Non-Motor Symptoms  
Although PD is primarily diagnosed by its motor symptoms, many non-motor 
symptoms also occur.  Non-motor symptoms have a huge impact on both people with PD 
and their families but may be over-shadowed by physical symptoms and, as a result, are 
often overlooked (Breen & Druyte, 2013).  Untreated, this can lead to both stress and the 
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development of psychological conditions, not only in those who have the disease but also 
their care-givers, friends and family.  Non-motor symptoms, then, are a major contributor 
to reduction in quality of life for people who experience PD and their carer’s and families, 
and hence examining and diagnosing non-motor issues is crucial in order to allow 
appropriate education and treatment to take place (Hinnell et al., 2012 in Breen & Druyte, 
2013).  This in turn means that developing more comprehensive ways of diagnosing and 
predicting outcomes for affected individuals is paramount to ensure that those with PD are 
well informed and receive appropriate treatment. 
Common non-motor symptoms include mood disturbance, particularly anxiety and 
depression, and psychiatric disturbances such as hallucinations and delusions.  Fatigue is 
also common in the PD population.  Other physical manifestations of the disease can also 
occur including worsening pain, bowel and urinary incontinence, sexual dysfunction, 
dizziness, fainting and drooling.  These symptoms worsen with the progression of the 
disease as the control and perception of the relevant muscles worsens. 
A substantial number of people with PD also experience some kind of cognitive 
disturbance as a result of their condition (Klepac, Trkulja, Relja & Babic, 2008).  Cognitive 
problems can range from specific cognitive deficits, to mild cognitive impairment (MCI) to a 
Parkinson’s Disease Dementia (PDD).  Cognitive disturbances experienced in PD are 
discussed further in Chapter 3. 
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Chapter 3: Cognition and Parkinson’s Disease 
Although the more well-known symptoms of Parkinson’s Disease (PD) are the 
motor symptoms, many people with PD also experience dementia or other cognitive 
dysfunction.  It is estimated that as many as 90% of people with PD experience some sort of 
cognitive impairment (Dubois et al., 1991 in Montel & Bungener, 2008).  Research into PD 
suggests that the disease can impact on numerous cognitive domains, including memory, 
language, attention, visuospatial, visuoconstructional and executive dysfunction (Hanna-
Pladdy, Jones, Cabanban, Pahwa & Lyons, 2013; Kudlicka, Clare & Hindle, 2011).  
Deficits arising from PD primarily occur in the domains of executive functioning and 
attention, accompanied frequently by impairment in cortical driven areas such as the 
memory, language and visuospatial functions; areas that are often affected in dementia of 
the Alzheimer’s type (Litvan et al., 2011).  This constellation of symptoms present in PD, 
with particular relevance given to executive dysfunction and attention deficits, is 
representative of a sub-cortical syndrome as seen in conditions such as Huntington’s 
Disease (HD) and Multiple Sclerosis (MS) (Litvan et al., 2011).   
3.1 Cognitive Domains Affected in PD 
3.1.1 Executive functioning 
Executive functions can be defined as ‘mental processes involved in goal directed 
behaviour’ (Marinus et al., 2003) or capacities that enable successful ‘independent, 
purposive, self-serving behaviour’ (Lezak, Howieson & Loring, 2004, page 34).  Executive 
dysfunction is common in a variety of neurological conditions and typically leads to deficits 
in volition, planning, problem solving, purposive action and effective performance (Kudlicka 
et al., 2011).  
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A systematic review of executive function in PD revealed that executive function 
deficits are present in 31% of people with PD and that these deficits occur across all areas 
of executive function (Montel & Bungener, 2008).  This incidence rate may be under-
reported due to difficulties in accurately assessing executive functioning abilities, 
particularly based on observational assessment or clinical interview.  A difficulty in 
measuring executive functioning well noted in many empirical studies is that the 
interpretation of measures is inconsistent (Kudlicka et al., 2011). Within structured settings 
overt cognitive difficulties seldom appear to exist whereas in new or everyday situations 
impairment in task management, planning, monitoring and attention and inhibition may 
become apparent, and this may affect self-reporting or reporting of symptoms by others 
who typically see the individual in familiar environments (Kudlicka et al., 2011).   
It is postulated that in PD dopaminergic depletion leads to the disruption of 
communication between the basal ganglia and the fronto-striatal circuits which, in turn, 
affect the frontal lobes and lead to deficits in higher level functioning (Koziol & Budding, 
2009).  Deficits in executive function are a plausible, even expected, expression of this 
pathology, with the basal ganglia unable to suppress or encourage inappropriate or 
appropriate responses to a set of stimuli (Koziol & Budding, 2009). 
One interesting aspect of executive dysfunction in individuals with PD is that they 
experience quite pronounced problems with internally guided behaviour while externally 
guided behaviour often remains intact (Marinus et al., 2003).  Internally guided behaviour 
is initiated by the individual while externally guided behaviour is driven by external stimuli. 
Thus many people with PD do not initiate or begin tasks and activities in everyday living, 
but respond well to externally provided cues and prompts.  
The ramifications of executive dysfunction on activities of daily living (ADLs) are 
well documented and can lead to increased disability, carer burden and health care costs 
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making it imperative to take into account executive function impairment in PD (Kudlicka et 
al., 2011).  Executive dysfunction has been shown to decrease coping strategies.  For 
instance Montel and Bungener (2008) demonstrated that people with PD associated 
executive dysfunction utilised more passive coping strategies than active coping strategies 
compared with a cognitively intact population due to deficits in mental flexibility.  The 
authors also concluded that executive dysfunction led to greater social and occupation 
dysfunction in the affected population (Montel & Bungener, 2008).   
Executive function deficits are usually the first cognitive problem to be identified in 
people with PD (Lee et al., 2013), though some studies have identified the executive 
dysfunction much later, in older people, with longer disease durations (Montel & 
Bungener, 2008).  Kudlicka, Clare and Hindle (2013) suggested that the attentional aspects 
of executive function impairment can appear in milder forms of PD, but the difficulties in 
abstract reasoning occur only in more serious cases.  This could be a reason for this 
conjecture around the incidence of executive functions in the disease depending on which 
aspects of executive function the instruments used measure.  They are a hallmark cognitive 
symptom of sub-cortical conditions and as such their study in the PD population is crucial. 
3.1.2 Attention 
Attention is that set of cognitive functions which directs and maintains cognitive 
resources toward salient stimuli while excluding non-salient distractors.  It is a key 
component in planning and problem solving because these functions depend on keeping 
relevant factors in working memory without the confounding influence of non-relevant or 
distracting information. In PD a lack of dopaminergic activity appears to disrupt the basal 
ganglia’s normal capacity to suppress distracting or inappropriate signals.  Thus distracting 
signals and directives which would ordinarily be supressed by the basal ganglia are instead 
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relayed to the pre-frontal cortex and cause difficulty maintaining attention to the salient 
stimuli or problem (Koziol & Budding, 2009).   
Attention deficits can be very disruptive to an individual’s day to day functioning 
(Perneczky et al., 2008).  They cause downstream effects on decision making and planning 
processes that are already inhibited in PD, but also make the completion of complex tasks 
even more difficult, particularly those that require monitoring over a period of time.  In 
practical terms this may include activities such as cooking or driving.  The combination of 
deficits present in task initiation, motor functioning and attention impact greatly on the 
capacity of many people with PD to effectively complete their ADLs and to live 
independently (Perneczky et al., 2008). 
3.1.3 Memory 
PD can reduce an individual’s ability to encode and retrieve new memories.  Green 
et al. (2002) determined that memory deficits were present in more than 30% of a sampled 
PD population and Hannah-Pladdy et al. (2013) reported memory impairments as the most 
common deficits found in the PD population.   
Memory deficits in PD most frequently occurred in the domains of verbal learning 
and delayed recall.  These types of deficits are indicative of problems encoding information 
correctly.  However, unlike individuals who experience Alzheimer’s disease, people with PD 
are able to benefit from probing or semantic cues, suggesting that information may be 
encoded correctly, but is difficult to access (Emre, 2003a).  This is very similar to the 
differences seen in internally / externally guided behaviours in the population and is 
consistent with what would be expected in a subcortical pathology.  That is, the 
information is encoded and likely retrieved correctly, but the basal ganglia’s inhibited 
ability to selectively send and block messages to the pre-frontal cortex results in poor 
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retrieval of the encoded information and associated functional inability to remember the 
information in everyday life (Koziol & Budding, 2009). 
Working memory, too, is affected by the same pathology; the stimulus inhibition 
deficiency can both prevent erroneous information being supplied to the working memory 
and can fail to keep required information available to the working memory (Koziol & 
Budding, 2009).  Deficits in working memory further confound the ability for people with 
PD to solve complex problems by holding information in their mind and manipulating it to 
produce a result.  This can act to further impair the already damaged functions of planning 
and decision making for individuals with PD. 
3.1.4 Language 
Language skills allow an individual to communicate through perception and 
generation of language.   Though they are not considered common in PD, some people who 
experience PD can have deficits in their language abilities.  In a similar fashion to memory 
retrieval deficits, individuals who experience PD can sometimes experience difficulties with 
language generation due to the deregulation of signal control in the basal ganglia (Koziol & 
Budding, 2009).  This deficit is usually expressed as delayed speech and can inhibit a person 
with PD’s ability to actively participate in conversation in the same way that initiation 
difficulties in their executive function can inhibit participation in activities (Koziol & 
Budding, 2009).   
Dysarthria can also affect individuals with PD due to the motor components of the 
disease, but expresses as slurred or unclear speech rather than a difficulty in language 
production.   
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3.1.5 Visuo-Spatial Skills 
Visuo-Spatial skills allow and individual to perceive the details of an object visually, 
interpret visual cues, and make judgements of depths and distances.  Some people with PD 
have been shown to experience deficits in this area in studies such as Possin, Filoteo, Song 
& Salmon (2008), who inferred an effect on working memory through difficulty encoding 
and maintaining information in a PD population.  Practically, this may express as difficulty 
in performing tasks such as visualising a road map to allow the individual to select a series 
of turns to take to reach a particular destination when driving.  However, the study did 
indicate that spatial and object deficits were distinct within the population, with recall 
delays detracting from performance on object tasks, but not affecting performance on 
spatial tasks.  This indicates that it is the encoding process which affects spatial tasks, and 
the recall process which affects object tasks.  
3.2 Aetiology of Decline 
The pattern of cognitive decline in PD is reported differently between research 
studies.  Most studies indicate that deficits in executive function and attention deficits are 
the earliest to appear, while deficits in visuospatial / constructional skills and memory 
deficits, particularly free recall, become evident later in disease progression (Kulisevsky & 
Pagonabarraga, 2009).  Stuss and Alexander (2000) propose that executive dysfunction may 
in fact underpin the dysfunction present in other cognitive domains.  Other studies, 
however, have indicated that executive function deficits are typically found in older people 
with longer disease durations (Bohnen et al., 2009; Montel & Bungener, 2008). 
The rate of cognitive decline in PD can vary considerably.  Muslimovic, Schmand, 
Speelman and de Haan (2007) demonstrated slow decline over the first 2.5 years following 
diagnosis, however this rate of decline is heavily influenced by a number of external 
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factors.   Hely, Reid, Adena, Halliday and Morris (2008) reported, for instance, that both age 
and disease duration impact on the rate of decline with older individuals experiencing more 
rapid decline than their younger counterparts.  Conversely, however, Hely et al. report that 
19% of individuals with PD develop PD Dementia within 19 years of diagnosis regardless of 
age of onset.   
3.3 Early Cognitive Decline 
Cognitive decline in PD is often thought of as affecting only those people with PD 
who receive a diagnosis of Mild Cognitive Impairment (MCI) or Parkinson’s Disease 
Dementia (PDD).  However, individuals with PD who do not meet diagnostic criteria for 
either of these conditions have been found to experience mild deficits across multiple 
cognitive domains as part of their disease progression (Hanna-Pladdy et al., 2013).  Barone 
et al. (2011) estimate that these deficits affect 25% of people newly diagnosed with PD. 
The progression of impairment seen in early decline in PD is reported 
contradictorily, similarly to the aetiology of PD Dementia.  Some studies have indicated that 
people in the early stages of PD present with prominent memory impairment (Emre, 
2003b), while others have noted the executive function deficits and attention difficulties in 
the early part of the disease (Lee et al., 2013).  In either case, the overall symptomatology 
of people  with early cognitive decline in PD is that they mirror the deficits seen in MCI and 
PD Dementia, but are of lesser severity (Emre, 2003b). 
A likely driver of early cognitive impairment in PD is extra-nigral pathology; i.e. 
pathology that occurs in areas of the brain outside of the substantia nigra (Hanna-Pladdy et 
al., 2013).  Cortical thinning in fronto-temporal regions in early PD is thought to be 
responsible for the early executive decline. Hypometabolism of cerebral glucose in 
tempero-parietal regions is implicated in PD-MCI (Hirano, Shinotoh & Eidelberg, 2011; 
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Perneczky et al., 2008).  While the dopamine depletion that occurs in PD is well 
documented it is unclear whether cognitive deficits arise from structural deterioration or 
neurotransmitter depletion (Hanna-Pladdy et al., 2013). 
While early cognitive deficits may not be apparent when conducting day to day 
activities of daily living (ADLs) their accurate and early identification is essential to not only 
ensure ongoing monitoring of further deficits but to potentially predict those at risk of 
developing MCI or Parkinson’s Disease Dementia (PDD). 
3.4 Mild Cognitive Impairment 
MCI is a sub-condition diagnosed in people with PD whose ability to function in 
everyday activities is compromised by poor cognition (Goldman et al., 2012).  Though MCI 
has been diagnosed according to a variety of conditions in the past, the Movement 
Disorders Society Taskforce has recently codified a set of criteria for the diagnosis, 
improving the consistency of diagnosis across the PD population (Litvan et al, 2012).  MCI is 
diagnosed on a threshold basis where every day functioning occurs at a level that is 
considered impaired against a ‘normal’ level of functioning (Litvan et al, 2012; Mak et al. 
2013).  Accordingly it may not represent an actual decline but a failure to function at a 
normal level.  For example, a person with PD may have had impaired attention before they 
were diagnosed with PD which would contribute to a diagnosis of MCI at the time of their 
PD diagnosis.  Conversely, an individual who had had a particularly high level of attention 
ability before the onset of the condition and who since declined to a normal level of 
functioning would not receive a diagnosis of MCI. Thus it is important to state for clarity 
that a diagnosis of MCI in an individual with PD is not necessarily indicative of a decline in 
function, and a lack of diagnosis is not evidence of a lack of decline in function. 
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A study by Lee et al. (2013) reports that one fifth of people with PD experience MCI 
with 19% having quantifiable cognitive deficits upon diagnosis.   MCI symptoms are the 
same as those experienced in early cognitive decline in PD (attention deficits, executive 
dysfunction, visuospatial and / or memory impairments) but are understood to be more 
disabling (Emre, 2003b).  Typically, a diagnosis of MCI is dependent on a person with PD 
being defined as impaired on one or more areas of cognitive function (Litvan et al, 2012; 
Naismith, Mowszowski & Diamond, 2013) without experiencing a level of impairment that 
would qualify for a diagnosis of Parkinson’s Disease Dementia (Litvan et al, 2012; Marras et 
al., 2013).  
A number of studies report MCI as a prodromal state of PDD, with studies 
demonstrating conversion rates from MCI to PDD at 30% over a 2.5 year period and 60% 
over a 4 year period, therefore meaning that the early detection of cognitive decline in PD 
is crucial (Goldman et al., 2012; Lee et al., 2013; Litvan et al., 2012). Of particular 
importance making arrangements for the future such as granting the Power of Attorney 
and being prepared for issues around the capacity to make decisions about finances, 
accommodation and healthcare can be facilitated while the person is still in an able state to 
contribute to these decisions personally.  There is also an important opportunity to provide 
people with PD, carers and families with education around the likely outcomes of the 
disease and what it will mean for them in the future.  Better understanding of factors that 
influence disease progression allows more concrete information to be provided and allows 
the people with PD and their families to be better prepared for the disease progression. 
3.5 Parkinson’s Disease Dementia 
Dementia is the term used to describe the symptoms of several illnesses that affect 
the brain and cognitive functioning.  Dementia is a degenerative process associated with 
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decline in function across a number of areas and is often indicated by memory loss, 
confusion, apathy or behavioural changes.  Over time, the loss of function associated with 
dementia can be debilitating.   
The most common and most well understood cause of dementia is Alzheimer’s 
Disease (AD) and as such the term “dementia” is often used to characterise the cognitive 
and functional decline caused by this condition.  The neuronal plaques and tangles caused 
by this disease occur in the cortex of the brain and typically result in focal cortical 
neurological deficits such as prominent amnestic and word finding problems.  In contrast, 
however, PD affects sub-cortical structures (see Chapter 3:) in the brain stem and basal 
ganglia.  People with PD thus do not typically manifest the same set of cortical cognitive 
deficits.  Cognitive decline resulting from sub-cortical pathologies, like PD, is instead 
characterised by prominent executive dysfunction, memory dysfunction and impaired 
visuo-spatial skills (Vingerhoets, Verleden, Santens, Miatton & de Rueck, 2003). 
Estimation of the incidence of PDD in the PD population varies greatly between 
studies, ranging between 15% and 70% (Demakis, 2007).  While some research attributes 
this to measurement differences between studies (Demakis, 2007) others postulate that 
dementia in PD populations may be significantly under-diagnosed and poorly recognised 
because the executive deficits occurring early in the disease may be less easily recognisable 
than the prominent memory and word finding deficits associated with cortical pathologies 
like AD (Marinus et al., 2003).  
 It should be noted that individuals with PD can experience cognitive impairment 
without meeting a diagnosis of PDD, with as many as 24% of people who experience PD 
having some cognitive impairment at the onset of the disease (Stella et al., 2007). This can 
both contribute to the lack of recognition of PDD in the population and to mask the 
severity of the condition. 
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However, individuals who develop PDD require a different approach to those 
individuals with PD without dementia.  PDD is associated with a higher risk of mortality 
than PD without dementia (Aarsland et al., 2001).  People with PDD are also more likely to 
require nursing home placement and they cause greater care-giver distress than their non-
demented counterparts (Aarsland et al., 2001). 
3.6 Diagnostic Tools 
An important consideration when examining cognitive impairment in PD is the 
diagnosis of MCI and PDD, not only in terms of classification but also in terms of the 
strengths and weaknesses of the diagnostic tools used to assess at-risk individuals.  Few 
neuropsychological tools exist solely for the assessment of those with PD.  The Mini-Mental 
Parkinson (MMP), Scales for the Outcomes of PD- Cognition (SCOPA COG), Parkinson 
Neuropsychometric Dementia Assessment (PANDA) and the PD Cognitive Rating Scale (PD-
CRS) are all specific to PD but are brief and often fail to detect some of the subtle deficits 
associated with PD-MCI (Marras et al., 2013; Reyes et al., 2009).  Reyes et al. (2009) 
indicate that SCOPA-COG, in particular, is sensitive to only a limited set of cognitive 
functions that are impaired in PD. 
To effectively identify PDD, a range of tests across all cognitive domains needs to 
be administered examining executive function, memory, attention, information processing 
speed, visuospatial constructional and language abilities (Dubois et al., 2007).  While these 
fuller neuropsychological assessments offer a more accurate picture of the individual’s 
cognitive functioning, they are often deemed inappropriate in clinical practice due to the 
lengthier time they take to administer; the cost of administration and the relatively low 
value they are currently perceived to add to management, treatment and outcomes for the 
person with PD (Dubois et al., 2007).  Many neuropsychological assessment tools can also 
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be affected by the motor components of the disease which can lead to over reporting of 
impairment in some areas due to difficulties in completing physical tasks (Dubois et al., 
2007).  
Anti-Parkinsonian medications have also been recognised as having some effect on 
cognitive performance (Schoenberg et al., 2012).  As the severity of motor symptoms 
increase, the amount of medication required increases. Hence there may be some 
increased impact on cognition due to medication with increase in age.  However, the 
impact of increased motor symptoms without medication is more likely to affect cognitive 
test performance than the impact of the medication itself, making this a difficult area to 
control for in research. 
The high correlation between PDD and quality of life, level of motor impairment 
and levodopa dosage emphasises the importance of accurate diagnosis of these cognitive 
aspects of the disease (Hanna-Pladdy et al., 2013).  Similarly, the effects of MCI and even 
the mild cognitive deficits associated with early decline can have a significant impact on an 
individual’s function, and better understanding of these could lead to improvement in 
treatments and outcomes for people with PD. 
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Chapter 4: Mood and Cognition 
Due to the high prevalence of common mood disorders and the potential that they 
have for cognitive side effects it is imperative to examine the impact both anxiety and 
depression have on people with Parkinson’s Disease (PD).  Anxiety and depression are both 
commonly associated with PD, with a higher incidence of both reported among people with 
PD than in the general population (Rodriguez-Blasquez, Frades-Payo, Forjaz, de Pedro-
Cuesta & Martinez-Martin, 2009).  Depression is one of the most common psychiatric 
disturbances experienced by people with PD with research estimating that up to 50% will 
meet criteria for clinical depression at some stage throughout their disease duration 
(Ravina et al., 2007).  While the majority of these people will have mild clinical depression 
around 17% will meet criteria for major depressive disorder necessitating ongoing 
treatment with therapy, anti-depressant medication and in some cases electro-convulsant 
therapy (ECT) (Ferreri, Agbokou & Gauthier, 2006; Reijnders et al., 2008).   Anxiety is 
present in around 40% of people with PD, and has been shown to be present before the 
onset of motor symptoms in some cases (Ceravola et al., 2010). 
Mood is also an important factor to consider in clinical practice, especially when 
considering the potential presence of a dementing process, with clinical guidelines 
recommending the identification and subsequent treatment of mood disorders prior to the 
diagnosis of a subcortical degenerative process (Ceravola et al., 2010).  The cognitive 
effects of depression are well documented with memory, attention and slowed processing 
speed all being identified as potentially affected by persistent low mood.  This can also 
affect performance on other cognitive measures, including the National Adult Reading Test 
(Watt & O’Carroll, 2009). Ceravola et al. (2010) determined that people with PD who met 
criteria for depression and remained untreated for it demonstrated increased disability and 
a higher need for treatment for PD symptoms.   
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Despite this, research suggests that depression is both under-identified and under-
treated in the PD population, with one research study finding that two thirds of people 
with PD who met criteria for clinical depression were not previously diagnosed and hence 
not receiving any treatment for their psychiatric mood disturbance (Ceravola et al., 2010; 
Ravina et al., 2007). Ravina et al. (2007) found that most individuals who receive 
pharmacotherapy for depression have moderate to severe presentations.   
4.1 Depressive Symptoms in people with PD  
The under-diagnosis of depression is, at least in part, attributable to the high 
overlap that depressive symptoms have with PD with symptoms; fatigue, insomnia, sleep 
disturbances, restlessness, psycho motor slowing and retardation, reduced mimics, 
reduced sex drive and apathy are regularly identified as manifestations of PD rather than 
depression itself (Lemke et al., 2004; Ravina et al., 2007; Rodriguez-Blazquez et al., 2009).  
Such is the intertwining of the conditions that in 2006 a recommendation was made by 
NINDS/NIMH to include depression as a diagnostic criterion for PD in the DSM (Marsh et 
al., 2005). 
Research suggests that those individuals who experience depressive symptoms as a 
result of PD have a tendency to have a different constellation of symptoms compared to 
those individuals solely with primary depression. Richards (cited in Ferreri et al., 2006) cites 
that those with PD experience more anxiety, pessimism, suicidal ideation, cognitive deficits, 
irritability and ruminations whereas purely psychiatric populations experience more early 
morning awakening, pervasive low mood and pessimistic thoughts about not only 
themselves but the world and their future as well.  Major depressive disorder has also been 
identified as a risk factor increasing the likelihood of the development of PD Dementia 
(Ceravola et al., 2010).  
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Depression in PD can act both to exacerbate symptoms and to reduce the 
effectiveness of disease treatments (Uekermann et al., 2003).  Depressive symptomatology 
impacts on the individual’s ability to conduct activities of daily living and, by doing so, 
reduces an already impaired quality of life independent of any effects from the motor 
symptoms of the disease (Leentjens et al., 2012; Lemke et al., 2004).  Depressed people 
with PD are up to 83% more likely to be judged as needing symptomatic therapy for PD 
compared to non-depressed subjects (Ravina et al., 2007).  This indicates that the 
treatment of depression symptoms may help people with PD to better manage their other 
symptoms, and hence highlights the importance of treating the depression that occurs in 
PD. 
4.2 Symptoms of Anxiety in PD 
While depression and anxiety have a high overlap in symptoms distinct anxiety 
syndromes can be seen within the PD population.  Leentjens (2008) found that up to 30% 
or PD patience experience panic disorder while 11% meet the criteria for Generalised 
Anxiety Disorder.  Hanna and Cronin-Golomb (2011) suggests that these anxiety symptoms 
have even more detrimental effects than depression on the PD population.  Anxiety in 
people with PD is often cyclic; anxiety can lead to an increased perception of motor 
symptoms, more severe gait problems, dyskinesias, freezing, on/off fluctuations (Leentjens, 
2008), and these symptoms can then lead to increased anxiety. 
The most common anxiety symptoms in PD are panic attacks, particularly in off 
states, Generalised Anxiey Disorder (GAD) and social phobias (Ceravola et al., 2010). Panic 
Disorder is observed in as many as 19% of those with PD.  Ceravola et al. (2010) also 
postulates that the autonomic dysfunction that typically accompanies PD that causes 
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symptoms such as fluctuations in heart rate and blood pressure may play an underlying 
role in the development and maintenance of anxiety disorders.  
4.3 Diagnosis of Mood Disorders in PD 
The overlap in symptoms between PD and common mood disorders means that 
accurate diagnosis of anxiety or depression in the population is fraught with difficulty.  
Most quantitative depression measures such as the Beck Depression Inventory (BDI), 
Geriatric Depression Scale (GDS) and the Hamilton Depression Scale (HAM-D) include 
questions that examine psychomotor agitation which can spuriously increase the rate of 
those who are identified as experiencing depression on these measures (Rodriguez-
Blasquez et al., 2009).  Conversely, this symptom could also be hidden by the bradykinesia 
that is often present in people with PD (Ceravola et al., 2010).  Similarly anxiety is often 
under diagnosed because of symptom overlap with autonomic symptoms such as fatigue, 
cognitive difficulties and sleep disturbances.  For clinical and research purposes it is 
important utilise methods that are able to accurately identify mood disturbance in the PD 
population.   
While impractical for many research studies, due to funding and time constraints, 
research suggests that the most accurate identification of mood disturbance is completed 
via the use of quantitative questionnaires in combination with structured psychiatric 
interviews such as the Structured Clinical Interview for Diagnostics (SCID) (Lemke et al., 
2004). In the absence of time and funding to use these best practice measures, many 
clinicians currently rely on subjective reports of feelings of emptiness, hopelessness and 
anhedonia to make a diagnosis (Lemke et al., 2004). 
The Hospital Anxiety and Depression Scale (HADS) has been identified as an 
effective screening tool in PD as it omits many of the somatic symptoms that can occur in 
28 
 
 
PD (Muslimovic, Post, Speelman & Schmand, 2005; Rodriguez-Blasquez et al., 2009).  The 
HADS is a 14 item questionnaire that asks participants to rate the regularity of feelings that 
they have experienced that pertain to mood disorders and provides a separate rating for 
levels of anxiety and depression.  The HADS is a relatively inexpensive and brief assessment 
that has been demonstrated to be both reliable and valid in PD populations (Rodriguez-
Blasquez et al., 2009).  The research application of the HADS, particularly in populations 
where motor symptoms are present, is an area of interest for further research. 
4.4 Origins of Mood Disorders  
A somewhat contentious issue throughout the literature on mood and PD is 
whether or not the mood disturbances that exist in PD are exogenous or endogenous in 
nature and a wealth of literature exists supporting both notions.  Organic theories of 
depression in PD postulate that the dysregulation of neurotransmitters dopamine, 
serotonin and norepinephrine plays a major role in the occurrence of depression (Ferreri et 
al., 2006).  It is thought that this change in neurotransmitter function may also be the 
reason that psychiatric symptoms are often better while the person is an ‘off’ state (Lemke 
et al., 2004).  Autopsy studies reveal that depressed people with PD present with 
degeneration of the nucleus ceruleus- the major brain centre for noreadrenaline (Lemke et 
al., 2004).  Additional evidence for endogenous depression is the fact that it’s found to be 
highly treatable with pharmacotherapy such as selective serotonin re-uptake inhibitors, 
serotonin norepinephrine reuptake inhibitors and tricyclic antidepressants (Lemke et al., 
2004). However, while the anticholinergic effects of antidepressants may have the 
additional benefit of improving motor symptoms they can worsen cognitive symptoms so 
need to be used with caution.   
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Some research suggests that depression can be exogenous or reactive in nature. 
This is understandable given the unpredictability of symptoms, degenerative nature of the 
disease and general difficulty in coping with a loss of independence over time (Leentjens et 
al., 2013).  Whether it is exogenous or endogenous, the correct identification and 
treatment of depression is important from a disease management perspective with 
depression being found to lead to poorer long term outcomes with faster disease 
progression of physical symptoms as well as greater cognitive decline, caregiver distress 
and decreased quality of life and medication compliance being found in those with 
depression and PD (Menza et al., 2009). 
4.5 Psychiatric Disorders in PD 
In addition to cognitive decline and dementia, people with PD can sometimes 
experience psychosis as a part of their disease progression.  Psychiatric delusions, usually 
accompanied with hallucinations, are reported in up to 10% of people with PD (Ceravola et 
al., 2010).  Delusions present typically involve aspects of jealousy, persecution or 
abandonment (Ceravola et al., 2010).   
It is thought that the hallucinations experienced by people with PD are likely the 
result of the formation of Lewy bodies (Ceravola et al., 2010).  Alternatively, prolonged use 
and high dosages of anti-Parkinsonian medications can result in hallucinations.  The 
particular medications are dopamine agonists, and prolonged use and/or high dosages can 
result in over-stimulation of the D3 and D4 dopamine receptors (Ceravola et al., 2010).  
This risk is particularly relevant to individuals with early onset PD as they would typically 
use anti-Parkinsonian medication for a longer period of their life. In addition, this also 
means that those who are first diagnosed are susceptible to psychotic type symptoms 
while their medication is titrated and a suitable dosage is ascertained.  
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Those with PD who experience psychosis demonstrate faster disease progression 
and a worse prognosis both in terms of higher mortality rates and a greater need of 
placement in residential aged care facilities (Ceravola et al., 2010).  Therefore the risk of 
development of psychosis needs to be taken into account in devising treatment plans for 
people with PD, particularly in terms of the use of dopamine agonists to treat Parkinsonian 
symptoms.  Nevertheless, the relatively low incidence of psychiatric disorders in the 
population as well as limitations on time and participant pool means that psychiatric 
disorders in PD were not considered as part of this research. 
  
31 
 
 
Chapter 5: Cognitive Reserve Theories 
An area that is currently of interest in neurological literature is the notion of 
cognitive reserve.  According to this theory some individuals have pre-morbid neurological, 
cognitive and lifestyle factors that are protective against cognitive decline, despite the 
presence of brain pathology.  This notion has primarily been investigated in cortical 
dementias, and AD most clearly.  There are differences, however, between cortical and 
sub-cortical brain pathologies and it appears important to examine the notion of cognitive 
reserve in sub-cortical diseases such as PD.  The possibility that some people with PD may 
be more or less protected from associated cognitive decline by pre-morbid brain and 
lifestyle factors is a central question of the current research. 
5.1 Reserve Theories 
Reserve theories attempt to explain findings that the amount of neurological 
damage to a brain and the cognitive impairment associated with it do not follow a 
consistent relationship; that is, two individuals who experience similar amounts of damage 
to their brain, through trauma or disease, can have very different levels of cognitive 
deficits, even if these deficits are in the same function(s).  The theory of reserve, then, is 
that there exists some factor in the individual’s brain that protects them against cognitive 
deficits as a result of damage (Stern, 2002).  Reserve theories exist in both active and 
passive forms.   
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5.2 Passive: Brain Reserve 
Brain reserve is a passive theory of reserve which posits that those individuals with 
physically larger brains, more neurons or more synapses, can sustain more damage than 
those with smaller brains, fewer neurons or fewer synapses, without experiencing the 
same amount of cognitive deficit (Barnett, Salmond, Jones & Sahakian, 2006).  In simple 
terms, the basis of this theory is that if there is more brain to begin with, the individual can 
sustain more damage and still retain enough neurons and synapses to function in a 
relatively unimpaired fashion.   
Brain reserve has been measured in a variety of ways depending on the equipment 
and funding available to the study.  Katzman (1988 in Valenzuela, 2008) found that 
individuals with more large pyramidal neurons retained better cognitive functions than 
their counterparts throughout dementia.  This aspect, however, is difficult to measure, and 
hence other measures of brain reserve have been utilised including head circumference, 
head girth, and intra-cranial volume (ICV).  These measures have typically not 
demonstrated a relationship across the entire spectrum, but rather indicate an increase in 
impairment caused by dementia at the low end of the scale. 
A study by Mortimer, Snowdon and Markesbery (2003) investigated a population of 
nuns using head circumference as a measure of brain reserve.  While their results indicated 
that there was a relationship between the head circumference and dementia, again at the 
lower end of the scale, they indicated that head circumference has only a moderate 
correlation with ICV, and they believed a more accurate measure of ICV, such as MRI 
(Magnetic Resonance Imaging) or CT (Computerised Tomography), would demonstrate a 
stronger relationship.    
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5.3 Active: Cognitive Reserve 
“Cognitive reserve” is an active theory of reserve based on brain compensation for   
tissue lost to disease.  In this model, functions originally performed by parts of the brain 
now diseased are instead performed by non-diseased tissue capable of taking over the role 
(Sachdev & Valuenzuela, 2009).  Cognitive reserve, then, is a measure of the efficiency of 
the brain.  A highly efficient brain will perform more functions with a similar number of 
neurons than a less efficient brain (i.e. one with less cognitive reserve).  It follows, then, 
that in two brains experiencing similar amounts of damage the more efficient brain would 
be able to perform more cognitive functions within the remaining undamaged neurons and 
synapses and hence the individual with greater cognitive reserve experiences less cognitive 
deficit as a result of the damage.  The protective nature of cognitive efficiency has been 
demonstrated to be relevant to dementia populations across a number of studies that have 
been collated and reviewed by Valenzuela and Sachdev (2006b) to demonstrate a large 
overall effect for cognitive reserve helping to delay or prevent cognitive decline. 
Cognitive reserve can be measured in a number of ways.  Valenzuela (2008) 
proposes three types of measurement as being of interest in determining cognitive reserve; 
pre-morbid IQ, cognitive efficiency, and behavioural or environmental measures.  Other 
studies have also identified education level as a valuable measure of cognitive reserve 
(Jones et al., 2011). 
5.3.1 Pre-Morbid IQ 
Pre-morbid IQ is an estimate of overall cognitive functioning before the effects of a 
disease, brain injury or a dementing process.  Several studies have indicated that pre-
morbid IQ can be the most powerful measure, where individuals with a higher IQ have a 
greater cognitive reserve than their counterparts (Albert & Teresi, 1999).  
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This extends to the PD population, where a study by Koerts, L. Tucha, Lange and O. 
Tucha (2013) identified pre-morbid IQ as a delineator of cognitive reserve by examining 
comparative incidence of MCI for different IQ groups.  Pre-morbid IQ can be estimated 
from an individual’s level of education, or via a specific measure such as the National Adult 
Reading Test (NART).   
The NART asks participants to pronounce a list of words of increasingly difficult 
pronunciation and counts the errors made.  The test is structured such that the words 
cannot be pronounced correctly phonetically and hence the participant must demonstrate 
existing knowledge of the word’s pronunciation in order to pronounce it correctly.  The 
error score is then converted to an overall IQ score based on a standardised score 
conversion.  The NART addresses a domain of crystallised intelligence that is thought to be 
relatively well protected from the effects of brain injuries, be they obtained by accident or 
disease.  By measuring this area of intelligence, then, the NART gives an indication of the 
level of intelligence of the individual before their accident or the onset of their disease; a 
pre-morbid IQ.  The NART is a valuable measure as it is administered quickly and does not 
require physical input from the participant, something that is often affected in acquired 
brain injuries (Nelson & Willison, 1991).  The reliability and validity of the NART have been 
assessed by a number of studies through comparison with other measures of IQ, including 
the WAIS, and have demonstrated strong correlations between the two measures (Nelson 
& Willison, 1991). 
Richards and Sacker (2003) indicated that the NART is an effective measure of pre-
morbid IQ and is therefore an appropriate measure to use in studies investigating the 
influence it as a factor.  The NART has been validated in dementia populations and 
demonstrated to be valid for use in the populations (McGurn et al., 2004 in Starr & Lonie, 
2008).  
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5.3.2 Cognitive Efficiency 
Cognitive efficiency is a measure of the lateral thinking capabilities of the brain; 
that is, a brain with higher cognitive efficiency is practiced in approaching and solving the 
same or similar problems in a variety of different ways.  The implication of this, then, is that 
the more cognitively efficient brain has greater plasticity and is able to approach similar 
problems through a number of methods or pathways (Stern et al., 2003).  While this is an 
important aspect of measuring reserve, it is not a practical measure to use in a research or 
clinical situation; there is no standard method for quantifying the cognitive efficiency of an 
individual and hence proxy measures are used instead (Stern, 2002).  
As can be demonstrated in (Stern, 2012) much evidence exists for brain training to 
ward off neurological diseases such as Alzheimer’s Disease with studies finding that those 
who participate in brain training exercises not only warding off the development and 
progression of disease but enhancing their cognitive ability as well.  
5.3.3 Lifestyle Factors 
Behavioural and environmental factors that have implications in the development 
of dementia have been identified in a number of studies including Qui, de Ronchi and 
Fratiglioni (2007) who identified factors such as education, social networks, physical activity 
and mentally stimulating leisure activities as preventative in the development of dementia.  
These same factors have been identified by Stern (2003) and Valenzuela (2008).  If these 
factors are protective against dementia it follows that they may be considered indicators of 
an individual’s cognitive reserve. 
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5.3.4 Physical Activity   
The role of physical activity in maintaining good health, both from a physical and 
mental perspective is well established (Stern, 2012).  Balsamo et al. (2013) found that 
physical exercise acts as a protective mechanism against cognitive decline in older 
individuals. However this study examined current exercise as a means of delaying further 
decline in individuals already diagnosis with a cognitive impairment and did not look at the 
effects of exercise earlier in life as a means of building up reserve.  Dik, Deeg, Visser and 
Jonker (2003) investigated the effects of participation in physical activities earlier in life and 
found evidence that this participation helped to retain processing speed in older 
individuals, but not overall cognition.  However, Dik et al. did suggest that their findings 
were evidence to support the theory of physical activity developing cognitive reserve in the 
Alzheimer’s Disease population. 
While participation in physical activities appears to have some treatment benefits 
at any stage of life, the motor symptoms present in a population such as those with PD or 
simply the effects of the aging process may limit the efficacy of exercise as a therapeutic 
aid against disease progression.  
Research into the effects of exercise has focussed on prevention of disease 
progression in cortical dementias.  Hence it is an area which still needs to be explored in 
populations that experience sub cortical dementias such as PD. 
5.3.5 Leisure Activities 
Involvement in mentally stimulating leisure activities has been demonstrated to 
have a positive effect on cognition (Mitchell et al., 2012).  A review article by Valenzuela 
and Sachdev (2006a) highlighted the importance of considering involvement in mentally 
stimulating leisure activities in the cognitive process of dementias.  Mentally stimulating 
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leisure activities is a broad umbrella that can refer to a large number of activities.  For the 
purposes of research, a subset of these factors has been selected, both for their 
measurability and their commonality; while it may be mentally stimulating to attempt to 
learn pi to 100 decimal places there are few individuals in the population to give this 
statistical power.   Mentally stimulating activities that are of interest to research, then, 
include speaking a second language, playing a musical instrument, artistic pursuits, reading 
and travel.  Similarly to physical activity, participation in mentally stimulating leisure 
activities has been demonstrated to have positive effects in the Alzheimer’s Disease 
population.  Scaremeas and Stern (2003) reviewed a number of studies in this area 
highlighting reduced incidence of dementia for those involved in complex mental leisure 
activities and higher survival rates among dementia patients with high involvement in 
leisure activities.   
5.3.6 Musical Activities 
Hanna-Pladdy and MacKay (2011) demonstrated that older individuals who had 
spent a significant amount of time in their lives playing musical instruments had preserved 
brain function, particularly in the areas of memory, naming and executive functions.  
Zatorre, Chen and Penhune (2007) highlighted the fact that the basal ganglia are involved 
in movement timing, a critical component in playing an instrument, and that people with 
PD have been shown to have impairment in this area.  Further research by Hanna-Pladdy 
and Gajewski (2012) has highlighted this area as important for future studies into brain 
training and cognitive reserve. 
5.3.7 Bilingualism 
Antoniou, Gunasekera and Wong (2013) postulated that speaking a second 
language enhances cognitive reserve by utilising a number of cognitive processes such as 
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inductive reasoning, sound discrimination, working memory, task switching, rule learning 
and semantic memory activating multiple brain networks predominately in the frontal and 
temporal lobes.  Recent neuro-imaging studies have demonstrated that those who are 
bilinguals can withstand more neurodegenerative change than monolinguals of similar 
intellectual capacity (Schweizer, Ware, Fischer, Craik & Bialystok, 2012). 
However, speaking a second language may be as much a measure of the passive 
model brain reserve as of the active model cognitive reserve.  Luk, Bialystok, Craik and 
Grady (2011) used diffusion tensor imaging to demonstrate that those who are bilingual 
have greater connectivity between their corpus callosum and frontal lobes suggesting that 
speaking a second language may increase inter-neuronal connectivity hence act as a 
mechanism for brain reserve.  The study demonstrated that those with individuals who are 
bilingual are more likely to maintain white matter integrity compared to their monolingual 
counterparts (Luk et al., 2011).   
By whichever of these mechanisms it occurs, there is evidence to suggest that 
speaking a second language has an effect on the decline associated with dementia.  Recent 
research demonstrates that while lifelong bilinguals can develop symptoms of Alzheimer’s 
Disease they tend to do so at an older age than their monolingual counterparts (Gold, 
Johnson & Powell, 2013). 
While these effects have been found to exist in cortical conditions such as 
Alzheimer’s Disease they are yet to be studied in sub cortical disease states such as PD.  
However, it has been shown that bilinguals typically have better control over their 
executive functioning, which is thought to stem from practice at task switching (Bialystok, 
2011; Gold et al., 2013).  Given that executive functioning is one of the areas most affected 
by subcortical dementias this makes speaking a second language an area of interest in this 
population. 
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5.3.8 The Lifetime of Experiences Questionnaire 
Valenzuela and Sachdev (2007) consolidated these social, physical and mentally 
stimulating leisure activity factors into the Lifetime of Experiences Questionnaire (LEQ) 
allowing a quantitative measure of these factors which, in turn, could be used as a measure 
of cognitive reserve.  The LEQ provides a measure of different types of life experiences 
across three stages of life; young adult, adult, older adult.  At each stage of life individuals 
are asked to rate the frequency of their level of involvement in a number of life activities, 
including playing musical instruments, involvement in clubs and charities, level of physical 
activities and speaking multiple languages.  The LEQ then addresses a score to each type of 
activity to provide a quantitative level of involvement in each type of activity at each stage 
of life.  These scores can be used to measure these levels of involvement, by section, life 
stage or overall, as a research tool to check whether or not relationships exist between 
levels of such activities and other outcomes.   
In the case of cognitive reserve, analysis against LEQ scores allows a number of 
questions to be addressed.  It has already been discussed that research has identified the 
types of activities measured by the LEQ as being associated with cognitive reserve (Stern, 
2003; Valenzuela, 2008). However, this quantitative measure allows further investigation 
into the efficacy of particular types of activity at particular stages of life in preventing 
cognitive decline.  In terms of clinical interest, the life stages of the questionnaire provide 
the opportunity to identify particular activity types that may help to slow decline after 
diagnosis, and hence these activities could be included in treatment plans for people with 
PD to help reduce the cognitive impact of their disease.   
Valenzuela (2008) has shown that a relationship exists between LEQ scores and 
cognitive decline in Alzheimer’s Disease dementia populations.  However, there remains a 
need for further research to properly establish the LEQ as a valid measure of cognitive 
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reserve in Alzheimer’s Disease and to investigate whether this can extend to other 
populations such as those with subcortical dementias.  It is important, then, to further 
investigate the role of the LEQ in measuring cognitive reserve as successful proving of such 
would allow deeper investigation of the potential links and treatment outcomes to be 
justified, potentially across multiple neurodegenerative conditions.    
One potential issue with the LEQ as a measure of involvement in activities across 
life stages is the self-report structure of the questionnaire.  Studies have demonstrated that 
over reporting of participation can occur in self-report format, particularly when the 
activity is regarded as socially desirable (Adams et al., 2005).  This has been shown to relate 
directly to physical exercise, which is one of the activities measured on the LEQ (Rzewnicki, 
Auweele & De Bourdeaudhuij, 2003). 
5.3.9 Education 
Education is another measure that has traditionally been associated with cognitive 
reserve (Valenzuela & Sachdev, 2006b).  Education, as a measure, refers to the level of 
formal education that an individual has received during their lifetime.  Typically, education 
is referred to by the highest year of schooling completed by the individual, with tertiary 
and post graduate education considered higher again than college level;  it does not take 
into account the quality of the education received.  Jones et al. (2011) identified education 
level as the most widely used measure of cognitive reserve across all diseases and both 
Armstrong et al. (2012) identified education as a valid measure of cognitive reserve in the 
PD population.  Wilson, Barnes and Bennett (2003), however, determined that education 
level was only responsible for 6% of the variation in cognitive activity, another measure of 
cognitive reserve.  Furthermore, Pai and Chan (2001) investigated the effects of education 
on cognitive performance in the PD population and found that individuals experienced 
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more decline than those with lower education.  This result was attributed to more 
educated individuals being more sensitive to decline, but it does raise doubt about the 
validity of education as a measure of cognitive reserve in the PD population. One 
impediment to using education as a measure of cognitive reserve in a study involving PD is 
the lack of educational opportunities that were available to participants who are of an age 
to participate in the research.     
5.4 Threshold / Linear Modelling 
In both active and passive theories of reserve, there are two schools of thought as 
to the manner in which reserve protects against dementia.  One of these is that there is a 
linear protective relationship between reserve and cognitive decline; i.e. higher levels of 
reserve are associated with lower levels of impairment.  The second manner is a threshold 
model which, rather than suggesting that the protection offered by reserve is theoretically 
infinite, there exists a level of reserve above which an individual does not experience 
impairing deficits.   
This threshold model is particularly evident in studies measuring brain reserve; 
typically these studies have demonstrated that there is a relationship at the lower end of 
the scale, but one which is not so demonstrable at the higher end of the scale (Valenzuela, 
2008).  However, Mortimer, Snowdon and Markesbery (2003) discovered a similar 
phenomenon when measuring decline against education level, a factor that has been used 
to measure cognitive reserve both from a behavioural perspective and as an indicator of 
pre-morbid IQ. 
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5.5 Cognitive Reserve in Parkinson’s Disease 
The question of whether pre-morbid IQ, education and lifestyle factors appear to 
moderate the cognitive effects of PD is central to the current research.  There are a very 
limited number of studies that have investigated cognitive reserve in PD directly, and only 
two that have demonstrated a positive effect for reserve in the PD population.  Koerts et al. 
(2012) demonstrated a positive protective effect for pre-morbid IQ in PD by measuring the 
instance of cognitive impairment against pre-morbid IQ in a PD population.  Armstrong et 
al. (2010) demonstrated a protective relationship with education, often regarded as a proxy 
for pre-morbid IQ, using a similar methodology.  However a study by Pai and Chan (2001) 
had demonstrated the reverse effect for education, demonstrating a higher level of decline 
among those who had attained higher levels of education.  The influence of lifestyle factors 
on cognitive reserve in the PD population has not previously been studied, except for the 
inclusion of PD in more generalised dementia populations.  Given the limited body of 
research, and the conflicting nature of the results, it is clear that the role of cognitive 
reserve in PD remains poorly understood.  
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Chapter 6: Study One - Cognitive Reserve in Parkinson’s 
Disease 
6.1 Aim and Hypotheses 
Much research into cortical dementias (notably AD) has supported the idea that 
people high in “cognitive reserve” (indexed usually as premorbid IQ or education) may 
experience less cognitive decline than people with lower “cognitive reserve”, despite 
similar levels of actual brain pathology.  Very little research exists on the cognitive reserve 
hypothesis in sub-cortical dementias.  The current study sought to examine whether 
premorbid IQ and education are predictors of cognitive decline in a Parkinson’s Disease 
population.  Just three previous studies appear to address this issue with two finding a 
positive relationship between IQ or Education (Armstrong et al., 2010; Koerts et al., 2013)  
and one study finding an inverse relationship between education and cognitive decline (Pai 
& Chan, 2001).  Identifying factors that predict the amount of decline experienced by 
people with PD is important in providing treatment regimes suited to the individual. 
Based on the reviewed research the following were hypothesised: 
1. Pre-morbid IQ will be negatively correlated with cognitive decline in 
Parkinson’s Disease. 
2. Education level will be negatively correlated with cognitive decline in 
Parkinson’s Disease. 
3. Education level will correlate highly with pre-morbid IQ. 
4. Pre-morbid IQ and education will be associated with performance in 
cognitive domains affected by Parkinson’s Disease but not with 
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performance in cognitive domains less commonly affected by Parkinson’s 
Disease.  Specifically, pre-morbid IQ and education will be associated with 
performance on measures of executive function and attention, but not 
with performance on measures of visuo-spatial and language functions.    
5. Standardised scores on subtests will demonstrate a relationship with pre-
morbid IQ indicating that functional starting point has an effect on 
functional end point. 
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6.2 Methodology 
6.2.1 Participants 
A sample of 88 participants was obtained from both geriatric and neurological 
outpatient clinics at the Royal Hobart Hospital, the tertiary treatment centre for public 
patients with Parkinson’s Disease.  Ethical approval to access patients from these clinics 
was obtained from The Tasmanian Health and Medical Research Ethics Committee 
(approval number: H10104). 
Participants were selected on the basis that they had a diagnosis of Idiopathic 
Parkinson’s disease, regardless of disease duration, medication and disease state.  Patients 
with concomitant neural problems, such as stroke or multiple sclerosis, were excluded.  The 
sample consisted of 52 males and 36 females representative of the population sample.  
For statistical analyses years of education, disease duration, whether or not the 
individual was taking dopaminergic agents and sex were also obtained. 
6.2.2 Selection of Measures 
In order to determine whether or not a factor is predictive in prevention of 
cognitive change we must first determine a method by which to measure an individual’s 
level of cognitive functioning and the change in their functioning over time.  Though there 
are several well established instruments that are used for the measurement of cognitive 
function, selecting one that is appropriate for use in a study involving a population of 
individuals with Parkinson’s Disease is not straightforward.  Consideration must be given to 
determine an instrument that is minimally affected by the motor component of the disease 
to allow accurate measurement of the individual’s functioning.  Conversely, the instrument 
must assess the cognitive domains that are affected by the disease’s progression in order 
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to demonstrate the individual’s decline accurately.  Though the timeframe of this study did 
not allow for a longitudinal design, it is advantageous to consider measures that can be 
readministered after a time period in order to provide comparisons of cognitive function.   
Additionally, in order to determine cognitive decline a baseline measure must be 
established.  It is not within the limitations of this research to conduct multiple interviews 
with participants, hence there is a need to utilise a separate measure to determine baseline 
functioning as a point of comparison.  This measure too must meet the above requirements 
of being appropriate to the population, but with the proviso that it cannot be affected by 
those aspects of cognitive function that are influenced by the progression of Parkinson’s 
Disease.  
The combination of these two requirements means that decline must be 
determined by comparison of a more general level of functioning estimated through two 
different approaches; one that is influenced by disease progression to give a contemporary 
level of functioning, and one that is not to provide a baseline for comparison.    
Affected Cognitive Domains 
The cognitive domains that are affected by the progression of Parkinson’s Disease 
are discussed in detail in chapter 2.  However, for the purpose of completeness it is 
worthwhile to briefly recap them here.  Individuals who experience decline as the result of 
a sub cortical dementia such as Parkinson’s Disease typically experience reduction in ability 
in executive functions (related to goal directed activities and planning) and attention 
(staying oriented to tasks).   Memory deficits are also present in many individuals with 
Parkinson’s Disease, though these are less consistent and measurement may be affected by 
attention deficits. 
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To align with the requirements outlined above, then, it is necessary to determine a 
measure of cognitive function that assesses attention and/or executive domains, with 
measurement of memory also advantageous, to give a rating to current cognitive function.  
Conversely, a measure that is unaffected by any of these domains, executive function, 
attention or memory, must also be determined to provide a baseline level of functioning. 
Intelligence Quotient 
The most commonly used measure of an individual’s cognitive function is 
Intelligence Quotient or IQ.  IQ is generally thought of as an aggregation of a number of sub 
domains of cognitive functioning which allows for it to be estimated in a number of ways to 
give an overall estimate of functioning. 
IQ is a useful measurement because of its commonality amongst instruments, that 
is, there are several measures that approximate IQ in different ways.  Similarly, many of the 
available instruments measure IQ on the same scale, with a standardised mean and 
standard deviation, which allows simple comparison of scores without the need for 
complex algorithms to convert between the outcomes of one measure and another.  
Because these measures are normalised against a standard distribution this means that 
placement of an individual within the curve, via their instrument score, should have the 
same meaning for each instrument.  This allows direct comparison between the measures 
in a way that can be easily interpreted. 
For example, the Wechsler Adult Intelligence Scale (WAIS) and the Repeatable 
Battery for the Assessment of Neuropsychological Status (RBANS) both measure IQ with a 
mean of 100 and a standard deviation of 15.  Because both are measuring the same 
underlying construct on the same scale it is expected that an individual would score the 
same or similar on each measure.  This has been demonstrated, and is in fact part of the 
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basis of the validity assessment of the RBANS.  While the WAIS can have learning effects 
when given to the same individual multiple times, the RBANS has multiple forms to make it 
suitable for longitudinal studies.  In a case where a baseline IQ assessment was performed 
using the WAIS, change in cognition at a later time could not be assessed by repeating the 
same measure because of the learning effects present in the instrument.  However, 
because the RBANS measures the same construct and uses the same output scale, the 
outcomes of the RBANS taken at a later time could be compared to the baseline WAIS 
score to give a measurement of change of function. 
While all of the above points make IQ useful as a scale for comparison, it also 
introduces incorrect assumptions of similarity.  Consideration must be given to whether the 
measures selected for comparison are genuinely assessing the same underlying ability or 
are simply measuring different constructs. 
Measures of Cognition  
Wechsler Adult Intelligence Scale 
The most well established measure of IQ is the Wechsler Adult Intelligence Scale 
(WAIS), currently in its fourth revision.  The WAIS gives a measurement of intelligence 
based on an aggregation of four index scores which are, in turn, aggregations of subtest 
scores that are relevant to that cognitive domain.  The sub domains measured by the WAIS 
are Verbal Comprehension, Working Memory, Perceptual Organisation and Processing 
Speed.  The WAIS IQ score is normalised around a mean of 100 and a standard deviation of 
15.  
While the WAIS is a well-established measure it has some features that make it less 
than ideal for research in a Parkinson’s Disease based population.  For one, it is slow to 
administer with a single assessment taking approximately two hours to complete.  
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Secondly, there are a number of subtests of the WAIS, including block design and coding, 
which are both time based and require motor skills from the participant.  Including these 
tests in assessment would adversely affect the cognitive scores of participants with 
Parkinson’s Disease based on their physical disability rather than any representation of 
their cognitive abilities. 
Repeatable Battery for Assessment of Neuropsychological Status 
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) 
is another measure that produces an estimate of IQ by combination of sub domain scores. 
The domains measured by the RBANS are Immediate Memory, Visuospatial / 
Contstructional, Attention, Language and Delayed Memory.  Similarly to the WAIS, the 
RBANS produces a measure of IQ that is normalised around a mean of 100 and a standard 
deviation of 15. 
The RBANS has several advantages over the WAIS for use in a Parkinson’s Disease 
based population.  It takes around 30 minutes to administer, which is more useful in 
research than the two hours taken to administer the WAIS.  Attention is measured as its 
own sub domain, which provides a measure of interest in Parkinson’s Disease where 
attention is one of the domains affected by disease progression.  It also separates memory 
into two sub domains, Immediate Memory and Delayed Memory, which are also of interest 
in Parkinson’s Disease progression.  Like the WAIS, however, it does not directly measure 
any aspects of executive function.  The RBANS has three subtests that require motor 
components, Coding, Figure Copy and Figure Recall.  Of these, only coding is timed and 
hence is the only task that should be adversely affected by the motor component of 
Parkinson’s Disease.  This may lead to a reduction in attention scores across the sample.  
The Figure Copy and Figure Recall tests require the drawing of a complicated figure, which 
requires a motor component, however the scoring of these tests is around the placement, 
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size and relationships of the various figure components and hence is relatively unaffected 
by deficiencies in motor skills. 
The RBANS has been validated against the WAIS in research and has been shown to 
have strong reliability and construct validity.  Results between the WAIS and the RBANS are 
highly correlated indicating that they are measuring the same underlying construct.  That 
is, an individual who is assessed on each measure would be expected to produce the same 
result on each measure.  Yang, Garrett-Meyer, Schneider, Gollomp and Tilley (2009) have 
raised questions about the reliability and sensitivity of the RBANS in detecting deficits in 
early dementia populations, but other studies, such as Morgan, Linck, Scott, Adams and 
Mold (2010) have demonstrate distinction of measurement on the same indexes.  While 
there is some division in the research, there is evidence available to support the use of the 
RBANS in the PD population. 
The RBANS has an additional utility in research because it is repeatable.  The 
questionnaire has multiple forms which mean that it can be administered on multiple 
occasions without the risk of learning effects.  This makes the RBANS a useful tool for 
longitudinal studies that need to measure cognitive functioning at multiple time points, and 
in doing so, measure cognitive change. 
Beatty et al. (2003) highlighted the use of the RBANS in dementia populations, and 
specifically in PD.  The authors indicated that because of its strong reliability, well 
researched normative data, and comparatively short administration time the RBANS is a 
valuable measure in this population. 
The Digit Span subtest of the RBANS differs from the Digit Span subtest of the WAIS 
in that it includes on less aspect of testing by comparison.  Both tests require the 
participant to remember lists of numbers of growing length and repeat them to the 
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interviewer verbally in the order that they were given.  Each test has the same patterns of 
sequence length, the same failure conditions, and the same scoring.  However, the WAIS 
Digit Span test has an additional section where the participant is asked to repeat the 
numbers in the reverse order than they were supplied in.  This allows some extra 
information to be gathered from the WAIS Digit Span test than is gathered from the RBANS 
test.  This information is useful in a Parkinson’s Disease population.  
National Adult Reading Test 
The National Adult Reading Test (NART) measures IQ differently to the other tests 
described.  The NART provides an estimate of pre-morbid intelligence, i.e. intelligence 
before injury or disease occurred.  This measure is provided through utilisation of a test 
that assesses crystallised intelligence.  Specifically, the test requires participants to read 
aloud a list of words of varying degree of obscurity and the number of errors in 
pronunciation are recorded by the assessor.  The number of errors is then checked against 
a scale to provide an estimate of the individual’s IQ.  The NART uses the same scale as both 
the WAIS and the RBANS for measurement of IQ, normalised around a mean of 100 with a 
standard deviation of 15.  
The NART is appropriate for use in a Parkinson’s Disease population because it 
takes only a few moments to administer and it does not include any components that 
require motor skills based interaction from the participant.  The crystallised intelligence 
domain that is measured is based on language skills which are not affected by the 
progression of Parkinson’s Disease or other dementias (Christensen et al., 2007).   
The NART has been validated against the WAIS and has been shown to be a valid 
and reliable measure.  Outcomes of the NART have been compared with the WAIS in 
control samples and have shown to correlate highly (Nelson & Willison, 1991).  This 
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indicates that the NART is measuring the same underlying construct as the WAIS while 
removing the effects of pathology or injury on the construct. 
The NART has been used in several studies as a measure of pre-morbid IQ, both in 
general dementia populations and in PD populations.  Previous studies investigating 
cognitive reserve in PD, Armstrong et al. (2010), Koerts, L. Tucha, Lange and O. Tucha 
(2013) and Pai and Chan (2001) have all used the NART as a measure of pre-morbid IQ in 
the PD population.   
An Australian version of the NART, the AUSNART, has been developed (Hennessy & 
Mackenzie, 1995).  While the population of this study consisted of Australians, the volume 
of research around the NART and its use in research in the PD population led to its 
selection ahead of the AUSNART in this study. 
Brixton Spatial Anticipation Test 
The Brixton Spatial Anticipation Test requires participants to predict a picture in a 
sequence based on previous values in a sequence of similar pictures.  The test employs a 
constantly changing rule set to assess participant’s executive function in terms of their 
planning and reactivity to changes in the sequence.  The number of incorrect responses are 
tallied and compared to norms to provide a measure of the participant’s executive function 
ability.   
The Brixton Spatial Anticipation Test is relatively quick to administer and does not 
require any motor components, only requiring participants to view pictures and provide 
verbal responses to the assessor.  This makes it a useful tool to use to obtain a measure of 
executive function ability in a Parkinson’s Disease population. 
BIRT Memory and Information Processing Battery 
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The BIRT Memory and Information Processing Battery (BMIPB) provides a 
quantitative measure of an individual’s processing speed that allows for the effect of the 
person’s motor speed.  It does this by having the participant perform two tasks, one which 
asks them to cross out all the multiples of 11 in a row of 5 numbers within a time limit and 
then providing a similar task that requires them to cross out an 11 in a similar grid 
structure, but with only the number 11 shown in each row.  The scores for each of these 
tasks are then combined to provide a measure of an individual’s processing speed that is 
moderated based on their motor speed as measured by the second test.   
The BMIPB only requires a short time to administer, and the allowance that it 
makes for motor speed in determining information processing speed makes it a useful 
measure for use in Parkinson’s Disease populations.  While information processing speed is 
not thought to be affected directly by disease progression it can have an effect on an 
individual’s performance on tests of cognitive ability and hence it is a useful construct to 
measure in research involving cognition. 
Measuring Cognitive Decline 
In order to test the cognitive reserve theory a measure of change in cognition must 
be determined for comparison between participants.  It is not enough to compare current 
level of functioning, as this would assume that all participants began at a similar level of 
functioning which is not the case in any real population based study.  Ideally, change in 
cognition would be measured in a longitudinal fashion, with a baseline measurement taken 
before the onset of the disease and another taken at some point during the disease’s 
progression.  This is simply not a realistic approach however; it would require some 
knowledge of which individuals are likely to develop Parkinson’s Disease before they are 
diagnosed with it and then waiting for a number of years to assess their functioning post 
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disease onset.  Currently the best predictors of Parkinson’s Disease are hereditary 
relationships and hence this type of research could require a generational type timeframe 
to identify and test participants. 
Given, then, that a pre-morbid cognitive assessment is unlikely to be present for 
many, if any, individuals with Parkinson’s Disease and the limitation of reasonable time 
periods on research, a baseline measure of cognitive functioning must be obtained in 
another manner.  One way to achieve this is by using a measure of pre-morbid IQ that is 
not affected by the disease progression to provide a baseline assessment of cognitive 
ability.  Therefore, when a prior measure of IQ is not available, cognitive decline can be 
measured by using a measure that gives an indication of pre-morbid IQ compared to a 
measure of current function (Paolo, Troster, Ryan & Koller, 1997).  The NART provides just 
such a measure of pre-morbid IQ in the Parkinson’s Disease population.  The RBANS has 
been validated for use in sub cortical populations, including people with Parkinson’s 
Disease, and therefore provides a useful measure of current functioning in the population 
(Randolph, 1998). 
Both the NART and the RBANS provide a measure of IQ that is normalised around a 
mean of 100 and a standard deviation of 15 allowing direct comparison between the 
measures.  While the measures have not been tested directly to assess that they are 
measuring the same construct, each has been validated against the WAIS and demonstrate 
that they are measuring the same IQ construct measured by that instrument.  While this is 
imperfect it is reasonable to assume that the RBANS and the NART measures of IQ and pre-
morbid IQ respectively can be compared to give a measure of change in cognitive function. 
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Factors Affecting Cognition 
There are a number of demographic factors that have been demonstrated to affect 
cognition, or at least performance on cognitive assessments, in previous research.  These 
include factors such as age and sex, and these should be recorded and examined in a 
research project involving cognition (de Lau & Breteler, 2006).  Weintraub and Burn (2011) 
indicated that in the PD population males often experience greater cognitive decline, and 
females experience higher levels of depression.  Additionally, given that decline in cognitive 
function is a known aspect of Parkinson’s Disease it is worthwhile recording the amount of 
time that the individual has experienced disease pathology and hence the amount of time 
that the disease has been causing damage to their brain. 
The effect of aging on cognition is well documented with a clear decline 
demonstrated in several cognitive functions as age progresses.  These differences in 
cognition that are present due to normal aging are accounted for within at least some of 
the measures used in this study.  The RBANS, for example, has normative data based on 
age groupings and scores that are determined for this study use these norms to reduce the 
effect of changes in cognition as a result of aging.  Nevertheless, such normative data is not 
available for all of the measures used.  Significantly, the normative data for the NART used 
in the study does not take age into account.  In this case, the effects of aging on cognition 
could potentially skew the results of the research and hence age needs to be recorded and 
its effects examined and accounted for. 
Similarly, cognitive abilities differ between the sexes.  Specifically, males typically 
score higher than females in the visuospatial domain and females score higher than males 
in the language domain.   
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Parkinson’s Disease is a degenerative condition and hence it would be anticipated 
that deficits in cognition would become worse over the course of the disease. However, 
much of the research into cognitive decline and Parkinson’s Disease is contradictory in 
nature, with some studies suggesting that disease duration is unrelated to cognitive decline 
while others suggest that it correlates highly with length of disease duration (Tremblay, 
Achim, Macoir & Monetta, 2013). 
6.2.3 Materials 
The National Adult Reading Test (NART; Nelson & Willison, 1991)  
The NART is a 50-item phonetically irregular word list presented in order of 
increasing difficulty (Appendix A1). Participants are asked to read the list of words aloud 
and the number of errors that they make is recorded.  The words cannot be pronounced by 
common rules of pronunciation such as phonetic decoding.  Total errors are then compared 
against norms to give an estimate of IQ. 
 
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; Randolph, 
1998) 
The RBANS is a cognitive screening assessment which measures several cognitive 
domains (Immediate Memory, Visuospatial, Language, Attention, and Delayed Memory) 
across 12 subtests (list learning, story memory, figure copy, line orientation, naming, 
semantic fluency, digit span, coding,  list recall,  list recognition, story memory recall and 
figure recall). These items are scored individually to provide index scores across the five 
domains which are then used to provide an overall standard score.  It has several parallel 
forms meaning that it can be given to the same participant repeatedly to assess change.  
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Australian normative data was used for data comparison, as developed by Green et al. 
(2008). 
 
Wechsler Adult Intelligence Scale, 3rd ed, Digit Span Subtest. (WAIS-III Digit Span, Wechsler, 
1997) 
The Digit Span test from the WAIS (revision 3) was used in this study rather than 
the test from the RBANS. This task, which is more commonly used as one of the core 
subtests of the Wechsler Adult Intelligence Scale- III assesses immediate attention span and 
working memory by asking participants to immediately recall increasingly larger strings of 
numbers firstly in order, then backwards until the participant gets two strings of the same 
length incorrect.  
 
The Brixton Spatial Anticipation Test (Brixton, Burgess & Shallice, 1996) 
The Brixton examines visual concept formation and reasoning using 56 items to 
examine whether participants can recognise rules that account for pattern variations. This 
test has been found to have age effects with those in their 60’s and 70’s performing worse 
than those in their 20’s (Lezak et al., 2004) This test assesses executive function. 
 
Birt Motor and Information Processing Battery (BMIPB - Information Processing Task A; 
Coughlan, Oddy & Crawford, 2007) 
The Birt Motor and Information Processing (BMIPB) examines participant’s 
processing speed across two tasks, one which is designed to measure motor speed and one 
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which is designed to measure overall processing speed.  The results on these two tasks are 
then matched together to give an adjusted processing speed score that compensates for 
difficulties in motor function. 
 
FAS Verbal Fluency (Benton & Hamsher, 1989) 
The FAS verbal fluency test measures an individual’s ability to generate language.  
The test asks participants to list as many words as they can that begin with a particular 
letter (F, then A, then S) in a one minute period.  The number of real and distinct works is 
then assessed and measured against normative data to give an indication of the functional 
level of the individual. 
 
6.2.4 Procedure 
Participants were administered a battery of assessments including the National 
Adult Reading Test, the Brixton Spatial Anticipation Test and the Repeatable Battery for the 
Assessment of Neuropsychological Status.  The Digit Span test of the RBANS was replaced 
by the Wechsler Adult Intelligence Scale Digit Span Subtest (third edition).  Most 
participants completed the entire interview in a single session, though in some cases it was 
necessary to split the interview across two sessions.  Additional demographic variables, 
age, sex, disease duration and education level were also recorded as part of the interview. 
Assessments were conducted by trained research assistants at the Royal Hobart 
Hospital.  Training of the assessors was conducted by a trained Neuropsychologist in the 
administration of all assessment tools.  Standardised administration and scoring, as 
outlined in respective manuals, was adhered to and age-based norms were used in scoring 
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where they could be sourced.  All assessments were reviewed for accuracy by a trained 
clinical psychologist.   
6.2.5 Design and Analysis 
An additional variable, cognitive decline, was calculated from the instrument 
results collected in the study.  This variable was used to indicate change in cognitive 
function from pre-morbid to current functioning.  This variable was calculated by 
subtracting current IQ level (as measured by the RBANS) from estimated pre-morbid IQ 
level (NART IQ) and dividing the result by the pre-morbid IQ and multiplying by 100 to give 
decline as a percentage of original function.  E.g.  An individual with a NART score of 125 
and a RBANS score of 100 would have a cognitive decline score of (125 – 100) / 125 * 100 
or 20% decline.  This decline measure was used to measure change of cognition in further 
analyses in this study. 
NART groupings were created in two different ways to assess relationship with 
cognitive decline.  The NART-TriSplit variable was created to split the sample as evenly as 
possible giving the maximum number of participants to each group.  This resulted in three 
groupings of 29, 28 and 28 participants respectively.  These groups represented NART 
scores of < 102, 102 – 112, and > 112.  A univariate analysis was run with NART-TriSplit as 
the independent variable and cognitive decline as the dependent variable to analyse 
between groups effects.   
The NART-SDGroup was created by placing participants in groups by standard 
deviation around the normal mean on the scale.  That is, groups were created for 
individuals with NART scores 60 – 85, 85 – 100, 100 – 115 and 115 – 130.  Note that for the 
purposes of avoiding duplication, individuals who landed on the borderline were put into 
the higher group, e.g. an IQ of 100 would place a participant in the 100-115 group.  The 
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group sizes in this variable were 2, 20, 42, and 20 respectively. A univariate analysis was run 
with NART-SDGroup as the independent variable and cognitive decline as the dependent 
variable to analyse between groups effects.  Estimated marginal means were calculated to 
demonstrate the direction of effects. 
Education level was split into groups based on the level of schooling completed.  
Individuals were grouped based on primary to high school (education <=10), college 
(education 11-12) or tertiary (education >= 13) giving group sizes of 43, 9 and 32 
respectively.  A univariate analysis was run with education group as the dependent variable 
and cognitive decline as the dependent variable to determine between groups effects.  
Estimated marginal means were calculated to demonstrate the direction of effects. 
Previous research has demonstrated that Education and NART scores are highly 
correlated.  To confirm the relationship in the current research, a univariate analysis was 
run with Education group as the independent variable and NART score as the dependent 
variable.  
Age groups were calculated for participants based on those participants who were 
under the age of 65 years and those who were 65 or over.  This cut off was chosen to 
correspond with the life stages in the Lifetime of Experiences Questionnaire that will be 
discussed further in Study 2.  This split gave groups of 24 and 60 participants respectively.  
Differences in decline between age groups were assessed using a t-test with age group as 
the independent variable and cognitive decline as the dependent variable. 
Decline scores were calculated for a number of the individual measures in a similar 
fashion to overall cognitive decline.  Where the score was not standardised around a mean 
of 100 and a standard deviation of 15, conversions were calculated to produce scores of 
this type to allow comparison with NART scores.  These comparisons were made for the 
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RBANS Immediate and delayed memory composite indexes, the Brixton spatial anticipation 
test, the BIRT memory and information processing battery standard, motor and adjusted 
scores, WAIS digit span, FAS test of semantic fluency, Trail making test parts A and B, and 
the line orientation and list recognition sub tests of the RBANS.  In each case the decline 
score was calculated as (NART score – standardised test score) divided by NART score.  
These decline scores were then analysed against NART-TriSplit groups using an analysis of 
variance to determine whether or not pre-morbid IQ predicted reduction in decline. 
Standardised scores were also compared to NART TriSplit groups to determine 
whether initial cognitive level / score had an effect on the individual’s measured cognition 
with the disease.  Standard scores were examined against NART TriSplit groups using 
analyses of variance for the Brixton Spatial Anticipation Test and the BMIPB Adjusted 
measures. 
An age-of-diagnosis score was calculated for each participant by taking their 
current age and subtracting their disease duration.  This was then analysed against NART-
TriSplit groups using an analysis of variance to determine whether estimated pre-morbid IQ 
has an effect on the age of diagnosis. 
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6.3 Results 
Univariate analysis of NART-TriSplit with cognitive decline did not result in a 
significant relationship (F(2,81) = 2.643, p = 0.077).  The means plot (Figure 2) 
demonstrated that the direction of the relationship was positive, opposite to that which 
had been hypothesised.   
 
Figure 2. NART 3-way split group means for Cognitive Decline 
 
Analysis of the same effect with the NART split into four groups (<85, 85-100, 100-
115, 115+) rather than three similarly did not demonstrate a significant relationship with 
cognitive decline (F(3,80) = 0.888, p = 0.451) and nor did education group (F(3,80) = 1.295, 
p = 0.282). 
Univariate analysis to check whether the NART and Education measures were 
measuring the same construct as anticipated revealed a significant positive relationship 
between NART and Education group (F(2,82) = 16.645, p = 0.000, η2 = 0.289) with the three 
education groups (high school, college, tertiary) as the independent variable. This indicated 
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that the measures were related as anticipated with an increase in education level 
associated with an increase in NART score.  Mean NART scores for each of the education 
groups are shown in Figure 3. 
 
Figure 3. Mean NART scores by Education Group 
 
Analysis of age effects revealed a significant relationship between age group and 
cognitive decline (F(1,82) = 7.889, p = 0.006, η2 = 0.088).  Univariate analyses to check age 
group relationships with RBANS total score (F(1,84) = 7.441, p = 0.008, η2 = 0.081) and 
NART IQ score (F(1,83) = 1.390, p = 0.242) were performed to check the reliability of this 
result.  Estimated marginal means for each age group for each of these analyses is given in 
Table 1. 
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Table 1  
Mean Cognitive Scores for Age Groupings 
Age Group Mean Decline (%) Mean RBANS Total Mean NART FSIQ 
Under 65 8.1 95.0 104.6 
65 and Over 17.6 85.0 107.3 
 
Based on these results, analyses of relationships for NART-TriSplit and Education 
group against cognitive decline were performed again using age group as a covariate.  Both 
the NART-TriSplit (F(3,80) = 4.261, p = 0.008, η2 = 0.138) and the Education group (F(4,79) = 
3.089, p = 0.020, η2 = 0.135) demonstrated significant relationships with cognitive decline 
when age group was included as a covariate. 
Table 2 
Means for NART Tri-Split Groups with Age Group as a covariate 
NART Tri-Split Group Mean Cognitive Decline (%) Std Error 
1 ( < 102) 10.557 2.719 
2 ( 102 – 112 ) 15.067 2.535 
3 ( > 112 ) 18.706 2.630 
 
Table 3  
Cognitive Decline by Education Group with Age Group as a covariate 
Education Group Mean Cognitive Decline (%) Std Dev 
Primary to High  School 13.35 14.93 
College 20.21 15.80 
Tertiary 15.44 14.01 
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Significant relationships were demonstrated between NART-TriSplit groups and 
several of the tests measured.  The results of the analyses are summarised in Table 4.  
Consistent with the overall analysis, these significant relationships, with line orientation 
and delayed memory, demonstrated that greater decline was associated with higher levels 
of pre-morbid functioning. 
Table 4  
Test score relationships with NART TriSplit groups 
Measure df F value η2 Significance (p) 
RBANS Immediate Memory 2,82 0.234 0.006 0.792 
RBANS Line Orientation 2,81 8.025 0.185 0.001 
RBANS Delayed Memory 2,82 3.975 0.088 0.023 
RBANS List Recognition 2,80 4.214 0.095 0.018 
WAIS Digit Span 2,82 0.900 0.021 0.411 
FAS Semantic Fluency 2,82 4.172 0.092 0.019 
Brixton Spatial Anticipation Test 2,76 9.155 0.194 0.000 
BIRT Information Processing 2,71 19.430 0.354 0.000 
BIRT Motor Speed 2,75 8.991 0.193 0.000 
BIRT Adjusted 2,71 18.000 0.336 0.000 
 
Follow up analysis of BMIPB adjusted scores (rather than change in scores) for each 
of the NART TriSplit groups was run to determine the underlying cause of the significance 
of the relationship.  The analysis did not demonstrate a significant relationship.  Means, 
maxima and minima for each of the groups are shown in Table 5.  Note that values have 
been adjusted to the standard scale (mean 100, std dev 15) for ease of comparison. 
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Table 5 
BMIPB Adjusted x NART TriSplit group descriptive data 
Pre-Morbid IQ 
Group 
N Mean Std Dev Minimum Maximum 
1 (< 102) 23 85.0 13.73 60 110 
2 (102 – 112) 26 86.9 9.28 70 115 
3 (> 112) 25 83.2 12.82 60 110 
 
Similar analysis for the Brixton Spatial Anticipation Test with NART TriSplit groups 
gave a very similar non-significant result.  Descriptive data is shown in Table 6. 
Table 6 
Brixton Spatial Anticipation Test x NART TriSplit group descriptive data 
Pre-Morbid IQ 
Group 
N Mean Std Dev Minimum Maximum 
1 (< 102) 25 64.6 9.78 55 85 
2 (102 – 112) 29 70.7 10.75 55 90 
3 (> 112) 25 67.0 11.55 55 85 
 
The relationship between NART Group and age of diagnosis was insignificant 
(F(2,82) = 0.618, p = 0.541).  Nevertheless, the means of the groups, shown in Table 7, 
indicate that mean age of diagnosis increases with pre-morbid IQ.  This information may be 
misleading, however, as the relationship is statistically insignificant. 
Table 7 
Age of Onset Means for NART TriSplit Groups 
NART TriSplit Group Mean Age of Onset Std Dev 
1 (<102) 60.3 11.44 
2 (102-112) 62.1 8.65 
3 (112+) 63.3 9.70 
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6.4 Discussion 
Contrary to hypothesis one, higher pre-morbid IQ was not associated with reduced 
decline in cognition. In fact, while initial analyses did not produce a significant relationship, 
examination of means indicated an inverse relationship where those individuals with higher 
pre morbid IQ experienced the largest loss in cognitive functioning across all cognitive 
domains.  This relationship was later confirmed using age group as a covariate.  Previous 
research into cortical dementias (AD) found that those with higher pre-morbid IQ 
experienced less cognitive deterioration and slower developing disease progression than 
their counterparts with lower pre morbid IQ; the opposite result to the findings of this 
study.  However, cognitive reserve has seldom been studied in sub-cortical populations so 
it may be that the relationships identified in said research simply do not hold in sub-cortical 
dementia populations.  Interestingly this finding is in broad agreement with Pai and Chan 
(2001) who found a similar inverse relationship between cognitive decline and education in 
PD. 
One possible explanation for this inverse relationship may be that those with a 
higher pre-morbid IQ have more cognitive ability to lose and that any cognitive 
deterioration that does occur may be more pronounced than the deterioration that occurs 
at a lower level. This phenomenon may be explained by Wilder’s law of initial values which 
postulates that those with more of ‘something’ have more to lose hence demonstrate 
greater loss than those with little to lose (Wilder, 1967).  This explanation is reinforced by 
the fact that measures such as the BMIPB and Brixton demonstrate relationships between 
decline and pre-morbid IQ but not between test scores and pre-morbid IQ.  That is, lower 
pre-morbid IQ does not relate to lower performance on the Brixton, but higher change in 
cognitive functioning is related to lower performance.  Another possible explanation for 
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this relationship is that it is a type I error, though the effect size demonstrated falls into the 
large category and hence this seems unlikely. The current findings suggest that regardless 
of initial IQ, individuals who experience Parkinson’s Disease end up with a similar, reduced, 
level of functioning.  Accordingly it appears on present results that those who have a higher 
pre-morbid IQ experience a larger decline to the same level as those with a lower pre-
morbid IQ.  This is a strong indication of a lack of cognitive reserve, at least measured by 
pre-morbid IQ, on these indexes in this population. 
Consistent with these findings for pre-morbid IQ, analyses demonstrated that 
individuals with higher levels of education experienced more decline than those with lower 
levels of education, contrary to hypothesis 2.  Education is an established measure of 
cognitive reserve in cortical dementias and correlates highly with another established 
measure in pre-morbid IQ, hence this result is also unexpected.  Like the pre-morbid IQ 
relationship, initial analysis did not demonstrate a significant relationship, rather a weak 
trend in increasing means.  Adding age group as a covariate, however, confirmed the 
significance of the relationship. It should be noted that the effect size for this relationship 
was slightly lower than that with pre-morbid IQ, with the education relationship falling into 
the medium category.  However, given the result with pre-morbid IQ and the high 
correlation between pre-morbid IQ and education the presence of this relationship is not 
surprising.  Nevertheless, it does lend weight to the existence of the relationship due to the 
fact that the level of education completed is a straight forward demographic measure and 
not an abstractly measured concept like pre-morbid IQ.  There is also existing research to 
support this relationship with Pai and Chan (2001) demonstrating the same education 
effect among their PD sample.  However, the implication that obtaining higher levels of 
education is detrimental to an individual who contracts Parkinson’s Disease is implausible, 
hence this is likely also attributed to the law of initial values argument that an individual 
with more to lose will lose more. 
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One aspect of the education group analysis that should be noted is that the 
relationship between education and cognitive decline is not as clearly demonstrated in the 
group means as it is for pre-morbid IQ.  In fact, the college group has the highest mean 
decline, higher than the tertiary group, as can be seen in Table 3.  This could be explained 
by the comparatively low numbers of participants that fell into the college group, with the 
majority either leaving after high school or going on to tertiary education; a representation 
of educational opportunities available to the sample population for the relevant age group.  
The error terms in the smaller group is far higher, and hence the relationship is based on 
the relationship of the means of the high school and tertiary groups which demonstrate a 
large mean difference with those receiving tertiary education experiencing more decline.   
Another consideration is that education may be flawed as a proxy for IQ due to 
inconsistent access to it based on gender and socio-economic status.   These factors can 
create artificial discrepancies between otherwise similar individuals depending on their 
varying access to educational opportunities.  Education correlated highly with pre-morbid 
IQ in this study and hence it is likely that individuals have had similar educational 
opportunities.  This suggests that in this study at least this issue may have been avoided.  
Nevertheless it is important to consider this possibility when using education as a 
predictive measure of decline rather than as a retrospective comparison measure. 
A systematic review by Hindle, Matryr and Clare (2013) that examined cognitive 
reserve in PD stipulated that a good measure of cognitive reserve should have a beneficial 
effect when examined cross sectionally, produce a slower rate of decline and not prevent, 
but rather slow the onset of dementia in PD.   Despite the evidence for an inverse effect 
with those with lower IQ experiencing less severe cognitive deterioration there was 
evidence in the current study to suggest that those with a higher pre-morbid IQ 
experienced a later disease diagnosis.  This supports the notion that while IQ does not act 
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as a means of protection once disease onset has occurred, it may ward off or slow the 
development of the disease in its initial stages. 
Beyond the above, the findings of this study of cognitive reserve contradict the 
findings in much AD literature that premorbid IQ and education are associated with 
reduced cognitive decline.  There are, however, some previous studies that have indicated 
cognitive reserve in the Parkinson’s Disease population.  Koerts et al. (2012) for example 
demonstrated that cognitive reserve existed in a sample of 48 people with Parkinson’s 
Disease.  However, these studies determined “reserve” differently to the current study.  
Koerts et al. delineated their sample into pre-morbid IQ groups and then looked at the 
percentage of each group that experienced impairment, where impairment was defined as 
a score on a measure that was 1.5 standard deviations below the mean.  For example, if 
considering the RBANS FSIQ, this would mean that anyone who scored below 77.5 was 
defined as impaired.  They demonstrated that individuals with higher pre-morbid IQ 
reached these impairment thresholds later than those with lower pre-morbid IQ and 
indicated that this was proof of cognitive reserve.  An aspect of this that needs to be 
considered is that a person with a pre-morbid IQ of 77 who remained at 77 in current 
testing would indicate an impairment in the low IQ group and hence would be interpreted 
as showing decline without having actually lost any function.  At the same time, and 
individual who had a pre-morbid IQ of 125 and a current IQ of 78 would be deemed not to 
have experienced a reduction in function.  This does not demonstrate protection against 
decline per se, but rather protection against reaching a measured threshold to define an 
individual as impaired; i.e. if an individual is higher functioning to begin with they are less 
likely to reach a level of incapacity than someone who begins at a lower level of 
functioning.   
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Similarly, Armstrong et al. (2012) demonstrated reserve by measuring the 
percentage of pre-morbid IQ groups who were diagnosed with Mild Cognitive Impairment 
(MCI).  As with Koerts et al. (2012) however, the diagnosis of MCI required a score at or 
below 1.5 standard deviations below the mean on one of the administered cognitive 
measure, biasing the diagnosis toward those with lower pre-morbid function. 
It is suggested that the threshold based approach to index “cognitive reserve” used 
by Koerts et al. (2012) and Armstrong et al. (2012) results in a group effect whereby all 
individuals are treated equally at end point regardless of their pre-morbid function.  A 
strength of the current study is that it utilises an ipsative approach. That is, it looks at 
individual discrepancies between premorbid functioning and ‘current’ functioning on 
measures across several cognitive domains.  Individual differences are tremendously 
important to examine in PD as individuals differ substantially in the clusters of symptoms 
they experience, hence the type and degree of cognitive impairment they encounter.  One 
other study of cognitive reserve in PD that has taken an individual differences approach, Pai 
and Chan (2001), demonstrated a similar result for education to that seen in the current 
study.  The study compared current cognitive performance, measured by the CASI, with 
formal education level and found that individuals demonstrated similar levels of 
functioning regardless of their education level.  While this is not a direct pre and post 
comparison, education is often considered to be a proxy measure of pre-morbid IQ, and 
hence it would be anticipated that participants with higher education levels would have 
had higher levels of cognitive functioning prior to the progression of the disease.  This lack 
of a protective relationship is supported by the findings of the current study.  
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6.5 Limitations 
The method of calculating decline as a difference in NART and RBANS scores 
introduces a potential error; while both the NART and the RBANS have been shown to 
correlate highly with the results of the WAIS and both measure IQ on the same scale there 
remains the possibility that the outcomes of the scales are not tightly related enough to 
accurately measure change in cognitive function in this manner.  Investigation into the 
relationship between NART scores and RBANS scores in a control population would be 
beneficial to further justify the use of these measures as effective pre and post comparison 
tools.  Further, this ideally needs to be extended into a Parkinson’s Disease population, 
before disease can affect cognition, to confirm the comparison in this population.  This, 
however, is impractical if not impossible.   
The most robust method of testing cognitive reserve is to have both pre and post 
measures – e.g. before an individual has surgery or experiences a TBI.  However, unless an 
individual has participated in a study prior to the onset of their dementia it is near 
impossible to conduct pre and post dementia research meaning that the majority of 
research examining cognitive changes in dementias has to employ a cross sectional or 
longitudinal study design. Most studies examining cognitive reserve tend to employ a cross 
sectional research design as longitudinal designs become difficult. Due to the advanced age 
of many participants attrition is an issue with many participants becoming too disabled by 
their disease process to participate in further research or passing away before follow up 
occurs. Cross sectional research allows researchers to get higher study numbers. However, 
the issue in employing this design is the difficulty in finding measures that are robust.  
To investigate the demonstrated relationships further it would be useful to conduct 
a longitudinal study allowing the same measure to be administered as a starting point and 
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a change in function, and, given the repeatable nature of the RBANS, the data in this study 
could potentially be used as the baseline data for such a comparison. 
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Chapter 7: Study Two – Demographics, Life Experience and 
Parkinson’s Disease 
7.1 Aim and Hypotheses 
This study investigated the possibility that pre-morbid demographic factors and life 
experiences might affect cognitive decline in people with Parkinson’s Disease.  The 
fundamental reasons for the research were both to identify factors in the participant’s 
history that may contribute to protection against decline, and to identify any activities 
associated with a slowing of cognitive decline once PD has been diagnosed.  Factors such as 
exercise, for example, have been identified as moderating variables in Alzheimer’s Disease 
populations and hence should be investigated with Parkinson’s Disease populations. 
Based on the previous reviewed research, it was hypothesised that: 
1. Age will have a positive relationship with decline such that cognitive decline 
increases as the disease progresses. 
2. Disease duration will have a positive relationship with decline such that decline 
increases over time as the disease progresses. 
3. There will be no difference in the decline process between males and females. 
4. Individuals with higher levels of life experience will demonstrate less severe 
cognitive decline. 
5. Participation in physical activity, particularly post diagnosis, will have a positive 
effect on cognition. 
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7.2 Methodology 
7.2.1 Participants 
This study was investigated using data collected from the same research group as 
in studies one.  For information on participants in the study please see study one (section 
6.2.1). 
7.2.2 Selection of Measures 
The rationale for the selection of the cognitive measures chosen for this study is 
the same as has been stated in section 6.2.2. 
7.2.3 Materials 
The following materials were used that were also used in the first study.  Please 
refer to the materials section of study one for full details. 
 The National Adult Reading Test (NART; Nelson & Willison, 1991)  
 Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; 
Randolph, 1998) 
 Wechsler Adult Intelligence Scale, 3rd ed, Digit Span Subtest. (WAIS-III Digit Span, 
Wechsler, 1997) 
 The Brixton Spatial Anticipation Test (Brixton, Burgess & Shallice, 1996) 
 Birt Adult Memory and Information Processing Battery (BMIPB - Information 
Processing Task A; Coughlan, Oddy & Crawford, 2007) 
 FAS Test of Verbal Fluency (Benton & Hamsher, 1989) 
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Life Experiences Questionnaire (LEQ; Valenzuela & Sachdev, 2007) 
The LEQ (Appendix A) is a questionnaire that measures an individual’s level of 
participation in activities during their lifetime, with a focus on cognitively stimulating 
activities. Participants are asked to fill out the questionnaire which examines individual’s 
lifetime participation across three time periods, young adulthood (<30 years old), middle 
age (30-65 years old) and later life (65+ years old). The LEQ is then scored to provide a 
quantitative rating across the three time points. 
7.2.4 Procedure 
The battery of neuropsychological assessments was administered as per study one 
(section 6.2.4).   
7.2.5 Design and Analysis 
As in study one, an additional variable, cognitive decline, was calculated from the 
instrument results collected in the study.  This variable was used to indicate change in 
cognitive function from pre-morbid to current functioning.  This variable was calculated by 
subtracting current IQ level (as measured by the RBANS) from pre-morbid IQ level (NART 
IQ) and dividing the result by the pre-morbid IQ and multiplying by 100 to give decline as a 
percentage of original function.  For example, an individual with a NART score of 125 and a 
RBANS score of 100 would have a cognitive decline score of (125 – 100) / 125 * 100 or 20% 
decline.  This decline measure was used as to measure change of cognition in further 
analyses in this study. 
Additional variables were calculated to facilitate analysis of Lifetime of Experiences 
Questionnaire (LEQ) results and demographic variables. 
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 LEQ Young Adult Overall was calculated by summing the values of the general 
section questions of the young adult section of the LEQ.  The general section 
questions refer to the questions that are rated on regularity, between never and 
daily, and are repeated at each life stage in the questionnaire. 
 LEQ Mid Life Overall was calculated by summing the values of the general section 
questions of the mid-life section of the LEQ. 
 LEQ Late Life Overall was calculated by summing the values of the general section 
questions of the late life section of the LEQ. 
 LEQ instrument played was calculated at each life stage by determining whether or 
not the frequency of instrument playing was more frequently than monthly at that 
life stage.  This was used to split the sample into those who regularly played an 
instrument and those who did not. 
 LEQ age group was used to split participants into groups at each of the LEQ life 
stages (<= 30, 31-64, 65+).  There were no participants below the age of 44, hence 
the first of these groups was empty. 
 Education group was used to classify participants into those who finished school at 
primary, secondary, college or tertiary levels.   
Pearson’s correlations were used to determine the direction of relationships 
between LEQ overall scores at each life stage and cognitive decline.  Correlations were 
examined for negative values of a size that was deemed worthy of further investigation 
(initially, <= -0.2).  The negative correlation indicates that as the index score increases 
cognitive decline decreases and hence there is potential for that factor to be protective 
against cognitive decline. 
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Analyses of variance were used to analyse the effects of the general questions 
repeated at each of the life stages with RBANS total decline.  In each case the LEQ scores 
were grouped in to three levels; Rarely (1-2), Sometimes (3-4) and Often (5-6).  The 
questions that were analysed are: 
 How regularly did you see your family (never [1] – daily [6]) 
 How regularly did you play an instrument (never[1] – daily [6]) 
 How regularly did you practice art (never [1] – daily [6]) 
 How regularly did you engage in sport at a mild level (never [1] – daily [6]) 
 How regularly did you engage in sport at a moderate level (never [1] – daily [6]) 
 How regularly did you engage in sport at a vigorous level (never [1] – daily [6]) 
 How regularly did you read (never [1] – daily [6]) 
 How regularly did you practice speaking a second language (never [1] – daily [6]) 
 Did you travel (Yes [1] or No [2]) 
 Did you have other hobbies (Yes [1] or No [2]) 
 For Mid and Late life stages, did you engage in further study (Yes [1] or No [2]) 
Further analyses were performed for individual test performance and decline with 
LEQ factors at all life stages.  These analyses were performed for each of the RBANS 
composite indexes, FAS Semantic Fluency, WAIS digit span, Brixton Spatial Anticipation test 
and BIRT Memory and Information Processing Battery adjusted scores.  As in the overall 
decline analysis, LEQ scores were split into three levels.  In each case the LEQ scores were 
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analysed with test performance and with decline on that test, calculated as (NART - test 
score) / NART.   
Age groups were calculated based on those participants who were under the age of 
65 and those who were 65 or over.  This cut off was chosen to line up with the life stages in 
the Lifetime of Experiences Questionnaire.  This split gave groups of 24 and 60 participants 
respectively.  Differences in decline between age groups were assessed using a t-test with 
age group as the independent variable and cognitive decline as the dependent variable. 
The effect of disease duration, measured in years since diagnosis, was determined 
through a univariate analysis with disease duration as the independent variable and 
cognitive decline as the dependent variable.  Estimated marginal means were calculated to 
determine the direction of the effect.  Disease duration was further examined against 
decline scores on individual measures; FAS, Brixton Spatial Anticipation Test, WAIS Digit 
Span and BMIPB adjusted scores.   These were examined as univariate analyses of variance 
with duration and then duration group as the independent variable.  Duration group was 
defined by grouping participants with duration less than 2 years, 2-5 years, 5-10 years and 
10+ years.  These duration group boundaries were selected to give the most even spread of 
participants across the groups.   
RBANS total and NART FSIQ scores were also compared to disease duration using 
analyses of variance to determine whether outcomes on either of these measures changed 
over time; specifically time since diagnosis. 
Sex differences were examined with a t-test examining between groups effects for 
males and females.  Cognitive decline was used as the dependent variable.  This analysis 
was repeated using an analysis of variance with age group as a covariate to account for the 
age differences between male and females.  Estimated marginal means were calculated to 
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determine the direction of the effect.  Tests of between group effects for sex were also 
calculated for RBANS total scores and NART scores, in each case using age group as a 
covariate.  
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7.3 Results 
Correlations were examined between the calculated cognitive decline measure and 
each of the LEQ life stage overall scores.   
Table 8  
LEQ Overall Scores Correlated with Cognitive Decline 
 LEQ Young Adult Overall LEQ Mid Life Overall LEQ Late Life Overall 
Cognitive Decline 0.002 0.023 -0.143 
 
Of the three overall scores, none demonstrated a significant correlation with the 
cognitive decline measure.  Only the Late life overall score indicated a relationship in the 
protective direction; i.e. increase in late life activity being associated with lower levels of 
decline. 
Analyses of variance were examined between each of the LEQ questions that 
applies at each life stage and cognitive decline to identify factors that have an effect on the 
decline process.  Note that this result was also demonstrated using a multiple regression 
analysis, the output of which is included in Table C.6 in Appendix C.  The factors that 
indicated a relationship in the protective direction are listed in Table 9. 
Table 9  
LEQ Items with significant relationships with Cognitive Decline 
Factor and Life Stage df F η2 Significance (p) 
Young Adult     
Playing an Instrument 2,76 3.189 0.077 0.047 
 
Playing an instrument was the only index that indicated a significant relationship 
with overall decline at any life stage.  To investigate the effect of playing an instrument 
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further, an additional variable was created that split the LEQ Instrument categories into 
two levels rather than three for each of the life stages.  T-tests were then run to compare 
the means of the instrument playing and non-instrument playing group at each life stage.  
Table 10  
Mean Decline between Instrument Groups at each Life Stage 
Life Stage Mean (N) 
instrument <= 3 
Mean (N) 
instrument > 3 
t-value η2 Significance (p) 
Young Adult 16.83 (62) 8.20 (17) 2.153 0.238 0.034* 
Mid Life 16.63 (65) 7.60 (14) 2.086 0.231 0.040* 
 
Table 10 shows significant relationships between regularly playing an instrument 
and a reduction in decline at both the young adult and mid phases of life.  There was a 
small decline observed in the late life group, though this relationship was not significant. 
This is likely due to the fact that there was only one participant who regularly played a 
musical instrument later in life.  A further analysis was conducted for groups who played an 
instrument at all in later life to those who didn’t (instrument score > 1), but even this 
loosening of the group rules only brought the number in the instrument group up to 5 and 
did not demonstrate a significant relationship. 
Time with family was inspected in a similar fashion to playing of a musical. 
Inspection of scores revealed that almost all participants had indicated that they had seen 
their family daily, the highest score possible, at all stages of life.  The Late Life Family scores 
were split into two groups, one where participants had given the response of daily and one 
where they had given anything less and a t-test conducted on these two groups.   
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Table 11  
Late Life Family Groups and Cognitive Decline 
 Mean (N) 
Family = 6 
Mean (N) 
Family < 6 
t-value Significance(p) 
Late Life 12.2 (49) 20.94 (5) 1.173 0.246 
 
Table 11 indicates that there is not a significant relationship between cognitive 
decline and time spent with family, though there is some indication that this may be 
limited by the number of participants in the study with less than daily contact with their 
families.  It is possible, however, that this relationship is due to individuals with more 
decline being less able to contact or visit their families rather than their increased decline 
being a result of their lack of contact with their families. 
Other items that showed correlations in Table 9 were also further analysed with t-
tests but did not demonstrate significant relationships; Travel at Young Adult (t = 1.611, p = 
0.111), further study at mid-life (t = 0.916, p = 0.363). 
One other item that correlated with cognitive decline was moderate physical 
exercise in the mid-life stage (0.251, p = 0.026), though this was a positive correlation and 
hence would indicate that individuals with higher exercise levels experience higher 
amounts of decline.  This is a relatively small correlation and conflicts with previous 
research.  The result was followed up with an analysis of variance for mid-life moderate 
exercise level which demonstrated no significant relationship (p = 0.341). 
Correlations between individual test scores and LEQ scores demonstrated 
significant correlations between FAS and WAIS Digit span scores for playing an instrument 
at various life stages.  These correlations are given in Table 12.  As with RBANS total scores, 
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the effects are not seen in the late life group and this may be due to the small number of 
instrument players in that sample group. 
Table 12  
LEQ Instrument correlations at various life stages 
 Young Adult Mid Life Late Life 
FAS 0.262 (p = 0.018) 0.263 (p = 0.018) -0.130 (p = 0.350) 
FAS Decline -0.239 (p = 0.033) -0.294 (p = 0.008) 0.002 (p = 0.991) 
WAIS Digit Span 0.171 (p = 0.125) 0.305 (p = 0.005) 0.069 (p = 0.619) 
WAIS Digit Span Decline -0.088 (p = 0.436) -0.318 (p = 0.004) -0.088 (p = 0.529) 
 
WAIS digit span score was also significantly positively correlated with travel at the 
young adult life stage (0.311, p = 0.004). 
The Brixton Spatial Anticipation Test decline only demonstrated one significant 
negative correlation with time spent with family in the late life stage ( -0.446, p = 0.001).  
This result is most likely similarly due to group size limitations with almost all participants 
choosing the highest possible score on this index.   
BIRT Memory and Information Processing Speed Battery adjusted speed decline 
had very few significant correlations with LEQ measures.  The only significant negative 
correlation with decline was in the ambiguous “other hobbies” measure at a young adult 
age (-0.277, p = 0.018).  This may be representative of other factors, not measured 
explicitly on the LEQ, that have an effect on Information Processing Speed in Parkinson’s 
Dementia. 
An odd result was the significant negative correlation of late life participation in art 
with performance on the BIRT Motor and Information Processing Battery Adjusted score (-
0.310, p = 0.036).   This was investigated further with an analysis of variance that did not 
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demonstrate a significant relationship (F(5,40) = 1.249, p = 0.305), however the means plot 
(Figure 4) demonstrated a trend for the mean to be lower above the response score of 1; 
never undertake artistic pastimes.  Participants were then split into two groups of those 
who had responded that they did not undertake any artistic activities in late life (N = 28) 
and those who participated in art at any regularity (N = 18).  A t-test of the between groups 
effects demonstrated a significant relationship (t = 2.572, p = 0.014, η2 = 0.131) with the 
group who participated in art activities having a mean BMIPB Adjusted Standard score an 
average of 9.29 points lower than participants who were not involved in artistic activities. 
 
Figure 4. BMIPB Adjusted Mean Score by LEQ Late participation in art activities 
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7.3.1 Age 
Age differences were examined using a one-way analysis of variance which did not 
demonstrate a relationship between age and cognitive decline.  Note that this relationship 
was also demonstrated by a regression analysis, the result of which can be seen in Table 
C.1 in Appendix C.  An additional variable was created to split participants into two age 
based groups (<65, 65+) based on which section of the LEQ life stages they were in (all 
participants were over the age of 30).  The results of a t-test conducted on the groups are 
show in Table 13. 
Table 13  
Age Groups and Cognitive Decline 
 Mean (N) Age 
< 65 
Mean (N) Age 
65+ 
t-value Significance (p) 
Cognitive Decline 8.06 (24) 17.61 (60) -2.809 0.006* 
 
7.3.2 Sex 
Differences in cognitive decline were examined for males and females using a one 
way analysis of variance (F(1,82) = 0.941, p = 0.335).  The result did not demonstrate a 
significant difference with female participants showing a slightly lower mean decline 
(13.09) than males (16.22). Note that this relationship was also analysed using a regression 
analysis with similar results that can be seen in Table C.1 in Appendix C. 
A further analysis was run using the age group split as a covariate.  This model 
demonstrated a significant difference between the sexes (F(2,81) = 4.343, p = 0.016, η2 = 
0.097).  This indicates a significant difference in decline between males and females that 
may be obscured by differences in age in the group, with increased age also significantly 
linked with increased decline. 
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RBANS total score and NART FSIQ score were also analysed against sex groups with 
the former demonstrating a significant relationship (F(2,83) = 7.863, p = 0.001, η2 = 0.159) 
and the latter a trend (F(2,82) = 2.522, p = 0.087, η2 = 0.058).  Means and standard 
deviations for these analyses are shown in Table 14, favouring females. 
Table 14 
Sex Difference in NART and RBANS Total Scores 
 NART RBANS 
Sex Mean Std Dev Mean Std Dev 
Male 104.9 10.6 83.9 16.1 
Female 108.8 8.0 93.1 13.6 
 
7.3.3 Disease Duration 
Disease duration did not demonstrate a relationship with cognitive decline 
(F(30,53) = 0.992, p = 0.498).  This indicates a lack of change in function being related to 
pre-morbid position post diagnosis of the disease. Note that this relationship was 
demonstrate using a regression analysis, the result of which can be seen in Table C.1 in 
Appendix C. 
Analyses of specific measures identified significant relationships between duration 
and RBANS total (F(30,55) = 1.918, p = 0.018, η2 = 0.511), FAS Decline (F(30,54) = 2.664, p = 
0.001, η2 = 0.595) and WAIS Digit Span Decline (F(30,54) = 1.921, p = 0.018, η2 = 0.516).  
However, the direction of these relationships is difficult to determine, as demonstrated in 
the means plots for RBANS Total (Figure 5) and FAS Decline (Figure 6). 
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Figure 5. Means Plot for RBANS total compared to disease duration 
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Figure 6. Means plot for change in FAS scores by disease duration 
 
Duration was split into groups and these analyses re-run to determine whether the 
direction of the effect was any clearer.  While the plots produced appear to clarify the 
direction for RBANS Total (Figure 7) at least, the relationship in this analysis was not 
significant (F(3,82) = 0.701, p = 0.554).   
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Figure 7. RBANS total scores by duration group 
 
Examination of the means and standard error terms of the various groups led to 
the decision to merge the less than two and two to five year groups (1 and 2 in figures 
above).   LEQ age group was also added to the analysis as a covariate.  The result of this 
analysis demonstrate a significant relationship (F(3,82)= 2.864, p = 0.042, η2 = 0.095) with 
the mean RBANS total score decreasing as disease duration increased.  
Analysis of disease duration with NART FSIQ scores demonstrated no significant 
relationship (F(30,54) = 1.297, p = 0.200).  This indicates that the pre-morbid IQ score is not 
affected by the progression of the disease, which is an indication that the NART is indeed 
not affected by Parkinson’s Disease and hence is a reliable measure of pre-morbid IQ in the 
Parkinson’s Disease population. 
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7.4 Discussion 
7.4.1 Life Experiences 
Overall participation in life activities measured by the Lifetime of Experiences 
Questionnaire (LEQ) did not demonstrate a relationship with decline in the Parkinson’s 
Disease population.  This is in contradiction to hypothesis four which predicted that there 
would be a relationship among these variables based on previous research in the 
Alzheimer’s Disease population.  However, deeper examination of individual types of life 
activity demonstrated that there were some relationships between particular activities and 
decline.  The most consistent relationship that had the effect of reducing decline was with 
the playing of musical instruments across the various life stages.  Playing an instrument at a 
regularity of monthly or more in either the young adult or mid-life stages demonstrated a 
reduction in overall cognitive decline and higher outcomes on both attention and language 
measures administered post decline.  Attention, being one of the cognitive domains that 
are typically associated with decline in Parkinson’s Disease, is likely the most significant of 
these.  Though the relationships were not present in the later life stage, there were too few 
participants in the older age group that actually played an instrument on a regular basis for 
this relationship to be statistically significant; only two of the forty six participants over the 
age of 65 played an instrument on a monthly basis.  The presence of this relationship 
warrants further investigation in a more evenly divided sample of musicians and non-
musicians. 
Playing a musical instrument is particularly interesting, both because it has been 
identified in previous literature, such as Zatorre et al. (2007), as being associated with the 
basal ganglia, and because it has a potential therapeutic application in the Parkinson’s 
Disease population.  The presence of the relationship with lower levels of decline at both 
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the young adult and mid-life stages suggests that it is not important when in life an 
instrument is taken up but rather just the act of regularly playing that contributes to a 
reduction in decline.  This would be strengthened by further investigation demonstrating 
that the relationship also exists at the late life stage.  The implication, then, is that people 
with Parkinson’s Disease could potentially take up playing an instrument on a monthly 
basis as part of their treatment program and that this may offer them some protection 
against deterioration; particularly in the domains of attention and language. 
Other factors that demonstrated relationships with overall decline are more 
difficult to control, but may be used as indicators to predict performance for individuals 
with Parkinson’s Disease.  While travelling at the young adult stage of life and undertaking 
further study at the mid-life stage demonstrated some indication of a protective 
relationship with decline, further analysis proved these relationships to be insignificant.  
Nevertheless, it is reasonable to assume that both of these factors are affected by both 
socio-economic status and cognitive ability at the life stages that they are associated with.  
Given the result of study one that indicated that individuals with more to lose tend to lose 
more, and these relationships indicate that those with more to lose tend to lose less, there 
is potential that this relationship is being obscured by variation in starting position.  In any 
case, neither of these factors are useful in any more than a predictive context; there is not 
the opportunity for someone, once diagnosed with Parkinson’s Disease, to increase their 
study or travel at a previous life stage. 
Time spent with family at the late life stage also demonstrated a strong protective 
relationship with both overall decline and executive function results measured by the 
Brixton Spatial Anticipation Test.  However, it should be noted that nearly all participants in 
the older age group indicated that they had daily contact with their family, the highest 
frequency that can be chosen on the LEQ.  There was, then, a lack of distribution across the 
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various groups and the analysis is sensitive to outlier results in the low membership group.  
It should also be considered that this relationship may be equally influenced in the other 
direction; it may be that individuals with less cognitive decline are more able to make 
regular contact with their family and hence do so more rather than that spending time with 
their family has the effect of reducing the decline that they experience as a result of the 
disease. 
There were a small number of other lifestyle factors that were associated with 
elevated cognitive decline.  Participation in moderate level sport at the mid-life stage was 
one factor that demonstrated a relationship in increasing overall cognitive decline.  This is 
in contrast to the anticipated result stated in hypothesis 5; physical activity was thought to 
potentially be useful in maintaining cognitive performance post diagnosis.  However, the 
finding that physical exercise was related to increased cognitive decline held only for the 
early mid-life stage dataset, and was not found in late-life.  There is the potential that a 
tendency for individuals to over report participation in socially desirable activities, 
particularly physical activities, has affected the data that this result is based on.  Similarly to 
travel and study, this factor is not something that is within the control of the individual to 
change once the diagnosis of Parkinson’s Disease is present and hence it only has utility as 
a predictive measure rather than having therapeutic application.  
Another factor that demonstrated a significant relationship to increasing cognitive 
decline was participation in artistic activities at the late life stage.  Increased decline in the 
information processing index (adjusted for motor speed) was found among the group 
reporting artistic activity in late life.  An analysis run between late life art participation and 
motor speed per se demonstrated no significant relationship, hence this result is not likely 
influenced by art participants maintaining higher motor speeds and hence having their 
procession speed scores adjusted down on this measure.  Unlike mid-life sport 
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participation, it is possible for individuals with Parkinson’s Disease to make the choice to 
stop participation in art activities at the late stage of life in order to attempt to preserve 
their information processing function.  While this result seems unintuitive, it is theoretically 
possible that by taking part in a particular activity, such as art, that utilises a particular part 
of the brain causes preservation of these areas of the brain at the expense of other 
functions in disease progression.   
It should be considered that the multiple levels of analyses used to investigate 
these LEQ factor relationships may have increased the chance of type I errors being 
responsible for the relationships that are demonstrated.  However, the effect size for the 
instrument result was large at both the young adult and mid-life stages, and the 
relationship between art participation and motor speed at the late life stage had a medium 
effect size.   
7.4.2 Age 
In accordance with hypothesis 1 age demonstrated a relationship with overall 
decline, with older participants demonstrating a larger change in cognition.  However, this 
relationship was not significant in a simple analysis of age against decline, but rather 
required grouping of participants to demonstrate a relationship.  LEQ age sections were 
used for this grouping, and with no participants in the young adult group this meant that 
participants fell into two age brackets, one group under 65 and one 65 and over.  This 
grouping demonstrated a dramatic difference in decline, with the older group 
demonstrating more than double the decline percentage of the younger group on average. 
Cognition is known to change as an individual ages, and this is seen particularly in 
populations experiencing degenerative dementias.  It is not surprising, then, that given the 
degenerative nature of Parkinson’s Disease and its effects on cognition, that the older age 
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group would demonstrate a greater overall decline than their younger counterparts.  
Nevertheless, this is a good check for validity amongst the data; with this result being as 
expected and generally indicative of the known disease process it is more likely that other 
results in the study are valid findings. 
The other contribution of this finding is to identify age grouping as a covariate that 
should be included in other analyses of decline in this population.  This methodology was 
applied to study one after this finding in study two, and, while not as important for the LEQ 
measurements which are at life stages for an individual anyway, was taken into 
consideration for other analyses in this study. 
7.4.3 Sex 
Interestingly, overall decline was found to be greater for males than females. As 
the literature review reports, females tend to incur less deterioration across a number of 
disease processes including Alzheimer’s Disease and deficits post traumatic brain injury, 
and this protection may extend to the Parkinson’s Disease population (de Lau & Breteler, 
2006).  A possible explanation that has been postulated in previous research is that 
oestrogen acts as a protective mechanism against cognitive deterioration (de Lau & 
Breteler, 2006).  It should be noted that the initial investigation did not demonstrate a 
significant relationship until age group was included as a covariate in the study. 
Further analysis of sex effects with RBANS total and NART scores further supported 
the validity of this finding.  RBANS total score was found to be an average of more than 8 
points lower for males than females, while there was not a significant relationship 
demonstrated between sex and NART FSIQ scores.  This indicates that although there is a 
difference between the sexes post-diagnosis or with disease progression there was not 
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already a split in the groups present before disease onset, and hence it follows that the 
difference is a result of the disease progression affecting the sexes differently. 
It should be noted that mean NART score for the female group, while not 
significantly different to the male group, is slightly higher.  Given the result of study one 
indicating that individuals with higher starting points tend to lose more, this makes the 
lower average decline for the female group from a slightly higher starting point stand out 
more in contrast to the overall pattern of decline. 
7.4.4 Disease Duration 
In contradiction to hypothesis 2, disease duration did not demonstrate a 
relationship with overall decline.  Parkinson’s Disease is a degenerative condition and 
hence it was anticipated that there would be a relationship in the time of disease 
progression and the amount of cognitive decline experienced by the individual.  
Interestingly, there was a relationship demonstrated between disease duration and RBANS 
total, though the direction of this relationship was unclear from the data.  Grouping of 
participants into durations of less than 5 years, 5 to 10 years and 10 years or more 
appeared to indicate that RBANS Total score reduced as disease duration increased; as 
would be anticipated in a degenerative condition.  However, the relationship demonstrated 
in this analysis was not statistically significant hence may simply be a quirk of the data 
collected rather than a reliable result.  Similar effects were identified for WAIS digit span 
and FAS semantic fluency scores, but their direction was equally uninterpretable. 
An explanation of why these disease duration results may not demonstrate the 
degenerative process is the methodology of measuring disease duration as time since 
diagnosis.  Many individuals with Parkinson’s Disease report, in retrospect, that their 
symptoms may have begun months, sometimes years before a formal diagnosis was made.  
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Most individuals are diagnosed after the onset of motor symptoms, namely a resting 
tremor.  However research suggests that some symptoms, such as cognitive deficits or 
mood symptoms, may pre-date the onset of motor symptoms by several years.  Due to the 
error variance in ascertaining actual disease duration (from first potential symptom) the 
disease duration in this study is measured from formal diagnosis.  If, then, the point of 
diagnosis is thought of as the point at which a person with PD reaches a particular level of 
functional interference rather than the point of onset of the disease it is conceivable that 
an amount of cognitive decline has occurred up to this point that is outside of the disease 
duration as measured by this process.  That is, two individuals with different starting IQs 
may already have declined to a similar point at the time of diagnosis and hence a flat 
relationship would be demonstrated between decline and duration post diagnosis. 
An alternative explanation is that the relationship may be masked by other 
processes occurring for individuals in the study population.  There exist many varying 
factors in Parkinson’s Disease such as the cluster of symptoms a person presents with, time 
from onset of symptoms to symptom treatment and what type of medication an individual 
is taking.  Similarly, as an individual gets older it becomes progressively more difficult to 
tease apart those cognitive symptoms attributable to Parkinson’s Disease from those 
attributable to  other potential dementing processes such as Alzheimer’s Disease and 
cognitive deficits from small vessel ischemia which can lead to vascular type dementias.  It 
is also important to examine the role mood disorders such as anxiety and depression can 
contribute to the overall cognitive presentation as both are known to cause cognitive 
deficits in the own right as well as compound the already existing deficits that may be 
occurring as a result of Parkinson’s Disease degeneration.  Study 3 will endeavour to 
examine the impact both depression and anxiety can have on cognition in Parkinson’s 
Disease to better understand the contributions these are making to this and other 
relationships. 
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7.5 Limitations 
Similarly to study one, the design of the decline measurement as a comparison 
between two separate measures that focus on a similar construct is less reliable than that 
which would be achieved in a longitudinal study using the same measures.  While every 
effort was taken to ensure the accuracy of decline measurements, including confirmatory 
analyses with overall performance post disease rather than relying on decline alone and a 
demonstration of the lack of interaction between the factor and the individual’s starting 
point, it must be noted that there is some error potential in the use of different measures 
to obtain pre and post scores. 
The overall strength of the study’s most useful finding, that playing musical 
instruments potentially contributes to protection against cognitive decline in Parkinson’s 
Disease, was limited by the lack of participants who played a musical instrument in the late 
life stage.  Further analysis in a group of elderly people with Parkinson’s Disease who play 
musical instruments would be useful in determining whether this is a useful therapeutic 
aid.  A study could even be constructed using a repeatable measure of cognition, such as 
the RBANS, for people with PD who played instruments and a control group who did not 
and their cognition be measured at a series of intervals to determine whether the music 
group did indeed experience less decline. 
As discussed, the measurement of disease duration based on diagnosis is 
troublesome because it relies on the individual reaching a threshold level of functioning to 
be diagnosed rather than giving a true indication of the time at which the disease progress 
began.  However, there is a lack of other options in terms of determining disease onset by 
another mean due to the current limitations of Parkinson’s Disease diagnosis.  Future 
understanding of the disease may lead to a test that can be performed on an individual to 
determine who will contract the disease or at what point the disease began to take effect, 
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and these may provide a measure of disease duration which, in turn, may demonstrate a 
relationship with cognitive decline. 
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Chapter 8: Study Three - Mood and Cognition in Parkinson’s 
Disease 
8.1 Aim and Hypotheses 
The effects of mood disorders such as anxiety and depression on cognition are well 
documented.  Performance on cognitive assessment tasks is detrimentally affected in 
individuals experiencing such mood disorders.  Anxiety and depression both occur 
commonly with Parkinson’s Disease, either organically or as a reactive process to disease 
progression.   
This study aims to examine whether mood disorders affect overall decline in 
cognitive performance for individuals with Parkinson’s Disease and whether this affects 
particular aspects of cognitive performance in this population. 
Based on previous research it is hypothesised that: 
1. A large number of sample participants will experience anxiety, depression or both 
at moderate to high levels. 
2. Individuals experiencing anxiety or depression will have worse performance on 
cognitive measures including RBANS Total, BMIPB Adjusted, Brixton Spatial 
Anticipation Test, WIAS Digit Span and FAS Semantic Fluency measures. 
3. Individuals with anxiety or depression will demonstrate a higher level of decline 
than their non-anxious / non-depressed counterparts. 
4. NART FSIQ scores will not be affected by levels of depression and anxiety. 
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8.2 Methodology 
8.2.1 Participants 
This study was investigated using data collected from the same research group as 
in studies one and two.  For information on participants in the study please see study one 
(section 6.2.1). 
8.2.2 Selection of Measures 
The rationale for the selection of the cognitive measures chosen for this study is 
the same as has been stated in study one (section 6.2.2). 
8.2.3 Materials 
The following materials were summarised in study one (section 6.2.2) and are 
described in more detail there. 
 The National Adult Reading Test (NART; Nelson & Willison, 1991)  
 Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; 
Randolph, 1998) 
 Wechsler Adult Intelligence Scale, 3rd ed, Digit Span Subtest. (WAIS-III Digit Span; 
Wechsler, 2002) 
 The Brixton Spatial Anticipation Test (Brixton; Burgess & Shallice, 1996) 
 Birt Adult Memory and Information Processing Battery (BMIPB - Information 
Processing Task A; Coughlan, Oddy & Crawford, 2007) 
 FAS Test of Verbal Fluency  (Benton & Hamsher, 1989) 
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The Hospital Anxiety and Depression Scale (HADS; Snaith & Zigmond, 1994):  
The HADS is a 14 item ordinal scale that is used in clinical non-psychiatric 
populations to measure levels of anxiety and depression on two separate scales via the use 
of one dichotomous scale. This measure is used most in clinical populations as it examines 
few somatic symptoms that can co occur in psychiatric illnesses such as fatigue, insomnia 
and hypersomnia. 
8.2.4 Procedure 
The battery of neuropsychological assessments was administered as per study one 
(section 6.2.4).   
8.2.5 Design and Analysis 
An additional variable, cognitive decline, was calculated from the instrument 
results collected in the study.  This variable was used to indicate change in cognitive 
function from pre-morbid to current functioning.  This variable was calculated by 
subtracting current IQ level (as measured by the RBANS) from pre-morbid IQ level (NART 
IQ) and dividing the result by the pre-morbid IQ and multiplying by 100 to give decline as a 
percentage of original function.  For example an individual with a NART score of 125 and a 
RBANS score of 100 would have a cognitive decline score of (125 – 100) / 125 * 100 or 20% 
decline.  This decline measure was used as to examine change of cognition in further 
analyses in this study. 
The NART-TriSplit variable was created to split the sample as evenly as possible into 
groups representing different levels of pre-morbid functioning.  These groups represented 
NART scores of < 102, 102 – 112, and > 112, resulting in three groupings of 29, 28 and 28 
participants respectively.   
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8.2.6 Anxiety 
Mean anxiety score was examined across the sample as a whole and for each of the 
NART Tri Split groups to determine the overall level of anxiety in participants and to 
determine whether there as a relationship between pre-morbid IQ and the level of anxiety 
experienced by an individual.   
One way analyses of variance were used to examine the relationship between 
anxiety and each of RBANS Total Score, each of the RBANS index scores, NART FSIQ, Brixton 
Spatial Anticipation Test, FAS Semantic Fluency Test, WAIS Digit Span and BIRT Memory 
and Information Processing Battery adjusted scores.  In each case, anxiety total score was 
used as the independent variable and the other measure was used as the dependent 
variable. 
In order to make effects clearer, these analyses were repeated with individuals 
placed into groups based on their anxiety scores.  These groups were low (<8), mild (8-10), 
moderate (11-15) and severe (16+) anxiety and were based on the thresholds specified in 
use of the HADS questionnaire. 
Cognitive decline was compared with anxiety total as measured by the Hospital 
Anxiety and Depression Scale (HADS).  This analysis was conducted as a one way analysis of 
variance with anxiety level as the independent variable and decline as the dependent 
variable.  The relationship between anxiety and cognitive decline was further examined by 
calculating correlations between cognitive decline and each of the questions related to 
anxiety on the HADS questionnaire. 
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8.2.7 Depression 
As with anxiety, one way analyses of variance were used to examine the 
relationship between depression and cognitive measures.  Depression was used as the 
independent variables in analyses with RBANS Total score, RBANS index scores, NART FSIQ, 
WAIS Digit Span, Brixton Spatial Anticipation Test, FAS Semantic Fluency and BIRT Memory 
and Information Processing Battery adjusted scores. 
In a similar fashion to the anxiety analysis, these effects were further examined by 
grouping participants based on their score on the HADS depression scale.  Groupings of low 
(<8), mild (8-10), moderate (11-15) and severe (16+) depression were based on the clinical 
guidelines for the HADS.  
The relationship between depression and cognitive decline was measured through 
a one way analysis of variance with HADS depression level as the independent variable and 
cognitive decline as the dependent variable.  Due to the findings of study two, this analysis 
was performed with and without age group included as a covariate.  This analysis was 
extended to examine correlations between each of the depression scores and cognitive 
decline. 
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8.3 Results 
8.3.1 Anxiety 
Mean HADS anxiety for the entire sample was 6.95 with a standard deviation of 
3.85.  This indicates that the average person with Parkinson’s Disease was experiencing 
anxiety just below the cut off for a mild level (8).  Analysis of the relationship between pre-
morbid IQ groupings and anxiety levels did not demonstrate a significant relationship, but 
did demonstrate a trend (F(2, 84) = 2.872, p = 0.062, η2 = 0.065).  The means and standard 
deviations for each of the NART TriSplit groups are shown in Table 15. 
Table 15  
Mean HADS Anxiety Scores by NART TriSplit Group 
NART Group Mean Anxiety Std Dev. 
1 ( <102 )  7.93 3.89 
2 ( 102 – 112 ) 7.40 4.37 
3 ( >112 ) 5.61 2.90 
 
Means and standard deviations were also calculated for each of the anxiety 
questions on the HADS to examine whether there were any particular questions that 
people with Parkinson’s Disease scored higher on.  Scores are a given a value of 0 to 3 on 
the questionnaire, with 0 representing no anxiety and 3 representing the highest anxiety 
response for the question.  These are shown in Table 16. 
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Table 16  
Mean Scores for each of the anxiety based questions on the HADS 
Question Mean Std Dev 
1 1.01 0.67 
2 0.83 0.85 
3 1.18 0.88 
4 0.95 0.56 
5 0.80 0.80 
6 1.26 0.91 
7 0.92 0.85 
 
RBANS total score was analysed by anxiety level to see if there was an effect on 
scores based on an individual’s anxiety.  This analysis did not demonstrate a significant 
relationship between anxiety and RBANS total score (F(16,67) = 0.837, p = 0.654).  HADS 
anxiety was then analysed against each of the RBANS Index scores to check for effects on 
particular indexes. 
Univariate analyses of variance between RBANS total score and each of the anxiety 
based questions on the HADS did not demonstrate any significant relationships. 
Table 17  
RBANS Index Score Relationships with HADS Anxiety Level 
Index df F η2 p 
Immediate Memory 16,69 0.472 0.099 0.952 
Visuospatial 16,68 0.686 0.122 0.798 
Language 16,68 2.177 0.339 0.014* 
Attention 16,68 0.585 0.121 0.884 
Delayed Memory 16,69 0.860 0.166 0.615 
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Anxiety did not have a significant effect on scores on the BMIPB Adjusted index 
(F(15,58) = 0.623, p = 0.836), WAIS Digit Span (F(16,69) = 0.587, p = 0.883), Brixton Spatial 
Anticipation (F(16,62) = 1.172, p = 0.315) or FAS Semantic Fluency (F(16,69) = 0.620, p = 
0.857).   
Cognitive decline was analysed against total HADS Anxiety level, and this did not 
return a significant relationship (F(16,67) = 0.573, p = 0.893). Note that this was also 
analysed using a regression analysis with similar results that can be found in Table C.2 in 
Appendix C. 
8.3.2 Depression 
Across the sample mean HADS depression score was 5.38, with a standard 
deviation of 3.52 indicating that the average person with Parkinson’s Disease was 
experiencing depression at a level below the clinical cut off for mild depression (8).  The 
relationship between pre-morbid IQ group and depression levels was not significant 
(F(2,82) = 1.834, p = 0.166).  Means for each of the pre-morbid IQ groups are shown in 
Table 18. 
Table 18  
Mean HADS Depression Scores by NART TriSplit Group 
NART Group Mean Depression Std Dev. 
1 ( <102 )  5.70 3.68 
2 ( 102 – 112 ) 5.97 3.26 
3 ( >112 ) 4.32 3.51 
 
Means and standard deviations for each of the depression based questions on the 
HADS are given in Table 19.  Similarly to the anxiety questions, these are calculated on a 
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score of 0 to 3 with 0 representing no depression and 3 representing the highest possible 
depression for that question. 
 
Table 19  
Mean scores for depression based questions on the HADS. 
Question Mean Std Dev 
1 0.82 0.76 
2 0.52 0.70 
3 0.45 0.61 
4 1.74 0.89 
5 0.78 0.85 
6 0.78 0.91 
7 0.36 0.72 
 
Similarly to anxiety, depression relationships were measured through an analysis of 
variance with RBANS total scores to examine whether depression levels could be affecting 
the reporting of cognitive symptoms for relationship.  HADS depression demonstrated a 
significant relationship with RBANS total (F(14,69) = 2.285, p = 0.012, η2 = 0.317).  The 
direction of this relationship is illustrated in Figure 8. 
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Figure 8. HADS Depression relationship with RBANS Total (mean) 
 
These results indicate an inverse relationship between depression and cognition 
measured by RBANS; RBANS scores were highest for those participants with the lowest 
depression scores, and vice versa.    
Further, each of the depression based questions on the HADS were analysed 
separately against RBANS total, with significant relationships demonstrate for questions 1 
(“I still enjoy the things I used to”) (F(3,78) = 3.095, p = 0.032, η2 = 0.154), 3 (“I feel 
cheerful”) (F(2,79) = 5.065, p = 0.009, η2 = 0.114) and 7 (“I can enjoy a good tv or radio 
program or book”) (F(2,79) = 3.546, p = 0.034, η2 = 0.082).  In all cases higher depression 
scores were paired with a lower performance on the RBANS Total measure. 
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Additional analyses of variance were performed to determine relationships 
between HADS depression level and RBANS index scores.  The results of these analyses are 
given in Table 20. 
Table 20  
RBANS Index scores relationship with HADS Depression 
Index df F η2 p 
Immediate Memory 14,71 1.186 0.189 0.305 
Visuospatial 14,70 1.116 0.182 0.360 
Language 14,70 2.533 0.336 0.005* 
Attention 14,70 2.314 0.316 0.011* 
Delayed Memory 14,71 1.533 0.232 0.122 
 
Examination of the table indicates that higher depression scores were associated 
with lower scores on the RBANS attention and language indices.  However, depression did 
not have a significant relationship with scores on the FAS Semantic Fluency Test (F(14,71) = 
1.253, p = 0.259), the BMIPB Adjusted index (F(14,59) = 1.087, p = 0.388), the WAIS Digit 
Span test (F(14,71) = 1.309, p = 0.224) or the Brixton Spatial Anticipation test(F(14,64) = 
1.086, p = 0.387).   
HADS depression was also analysed against the cognitive decline measure, 
returning a significant relationship (F(14,69) = 2.477, p = 0.007, η2 = 0.334).  Analysis of the 
associated means plot (Figure 9) indicates that higher depression score is paired with 
greater cognitive decline.  Note that this factor was also analysed using a regression 
analysis with similar results that can be found in Table C.2 in Appendix C. 
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Figure 9. HADS Depression and Cognitive Decline 
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8.4 Discussion 
Neither anxiety nor depression was present at a clinically mild or higher level on 
average across the study population.  While anxiety and depression are often discussed as 
being present concomitantly with the disease, this result does not support that trend.  It 
should be considered that there is considerable conjecture about the efficacy of measures 
of anxiety and depression accurately detecting these disorders in the PD population.  This 
could lead to either or both of depression and anxiety being under reported in this result. 
Pre-morbid IQ did not demonstrate significant relationships with either anxiety or 
depression.  However, a strong trend was demonstrated between pre-morbid IQ and 
anxiety.  Examination of the means demonstrated that individuals with higher pre-morbid 
IQ experienced lower levels of anxiety.  A similar effect can be observed in the means for 
depression, though this relationship is weaker based on the analyses performed. While 
these relationships are not statistically significant, they provide some possible indicator of 
outcomes for an individual with PD in terms of their likeliness to experience a mood 
disorder as part of the disease and of that mood disorder’s severity; particularly in regard 
to anxiety.  Further investigation of this relationship may have implications for approaches 
to treatment in the PD population. 
As anticipated in hypothesis 2, anxiety and depression levels were both associated 
with reduced performance on cognitive testing.  While anxiety did not demonstrate a 
significant relationship with overall cognitive function performance, as measured by the 
RBANS, there was a significant reduction seen in performance on the language index.  
Depression was significantly related to reduction in performance on overall cognitive 
scores and further was shown to significantly reduce scores on both the language and 
attention indexes.  Reduction in cognitive test performance has been associated with both 
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anxiety and depression, and these results demonstrate that this relationship is also present 
in the PD population meaning that there is advantage in treating mood disorders in the 
population. 
The fact that both anxiety and depression demonstrate a relationship with score 
reduction on the language index is interesting because it is an area of function that is not 
typically associated with decline in PD.  Indeed, this could imply that those individuals who 
do demonstrate lower levels of language ability with PD are in fact experiencing this decline 
as a result of a mood disorder rather than the disease itself and should receive treatment 
for the mood disorder to improve their language function.  Interestingly, there was no 
significant relationship demonstrated between performance on the FAS semantic fluency 
task and either anxiety or depression.  The FAS semantic fluency score correlates strongly 
with the language index in the normal population, and hence it could be anticipated that 
the effects seen between depression, anxiety and the language index would be reflected in 
the outcomes on the FAS.  The FAS semantic fluency test concentrates on the ability to 
generate words given a condition that must be met, e.g. words beginning with the letter f.  
Given the nature of the impediments in task initiation associated with PD, it is likely that 
performance on this task is impaired across the PD population, and hence there may be 
little relationship demonstrated with anxiety or depression.  That is, if all people with PD 
experience a level of impediment on this measure it is less likely to demonstrate 
differences between participants based on their level of anxiety or depression.   
The relationship between depression and reduction in performance on attention 
based tasks, unlike the relationship seen with language, is indicative of a worsening in 
performance on an affected function for individuals with PD.  Whether this is indicative of a 
reduced ability to adapt to modified function because of depression or a negative attitude 
reducing performance on testing, treating the depression in affected individuals with PD 
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may help to ameliorate the effects of their reduced attention abilities on their ability to 
perform activities of daily living. 
Change in cognitive function, measured by the derived variable cognitive decline, 
was also demonstrated to have a significant relationship with depression and not with 
anxiety.  At first glance this could be considered to be reflective of the relationship with 
performance on overall cognitive function, i.e. the reduction in overall performance of 
cognitive tasks due to depression exaggerates the difference of pre-morbid and current 
functioning. However, in combination with the fact that individuals with higher pre-morbid 
IQ experience lower levels of depression, it can be seen that this result may be due to 
under-reporting the effects of depression on cognitive decline.  The results of study one 
that suggest that individuals with higher pre-morbid IQ tend to experience more 
measurable decline as a result of PD lend weight to this hypothesis.  
It is interesting to note that despite the overall higher level of anxiety in the sample 
population it is depression that demonstrates a greater effect on cognitive outcomes.  This 
is particularly relevant in terms of the relationship with attention scores which are already 
impaired in the PD population.  The incidence of depression has been found to be under 
diagnosed in the PD population due to the overlap between PD and depression symptoms, 
with researchers estimating that around 50% of people with PD experience depression at a 
clinical level (Ravina et al., 2007).  Given this, the effects of depression on cognition in the 
population suggest that depression should not be ignored in treatment of individuals with 
PD.  Further research into this relationship may provide significant implications to 
treatment planning in PD. 
While some aspects of hypothesis 2 were supported by the effects on RBANS total 
and index scores, other tests of semantic fluency, attention, executive function and 
processing that were administered did not demonstrate relationships with anxiety or 
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depression.  This result is unexpected as both depression and anxiety have been 
demonstrated to negatively impact performance on cognitive tasks.  One possible 
explanation for this discrepancy is that the masking effect of symptom overlap between PD 
and the measured mood disorders leads to under diagnosis of anxiety and depression in 
the population. This may, in turn, reduce the accuracy of the results to the point where a 
statistically significant relationship cannot be demonstrated.  Alternatively, the discrepancy 
may be explained by the fact that the performance on these tasks is so impeded by the 
presence of the degenerative aspects of the disease that the effect of anxiety and 
depression is masked in the population.  If either case explains this discrepancy then 
treating mood disorders might be unlikely to significantly improve performance on these 
tasks. 
Examination of the average scores for each question of the HADS did not 
demonstrate any statistically interesting relationships.  It is interesting to note, however 
that the highest average scoring question on the anxiety section was “I feel restless as 
though I have to be on the move” and the highest average scoring question on the 
depression section was “I feel as if I am slowed down”.  Both of these questions can be 
related to movements on the person’s part, and each is affected by a physical symptom of 
PD; the anxiety question by the presence of tremors and the depression question by 
difficulties in initiation.  These mood based questions that relate back to physical 
symptomatology may be causing an over-reporting of the levels of anxiety and depression 
in the sample.  Further investigation into the validity of the HADS as a measure in the PD 
population may clarify the effect that the presence of these questions has in this 
population. 
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8.5 Limitations 
This study shares a limitation with studies one and two in terms of the calculation 
of cognitive decline being based on a comparison of two different measures rather than as 
a result of a longitudinal study.  This limits the study’s ability to examine decline over 
specific areas of cognition and is only indicative of a change in function rather than a true 
measure of it.  This is discussed further in the grand discussion. 
As noted, overlap between PD symptoms and symptoms of anxiety and depression 
make the diagnosis of these conditions difficult in the PD population.  The HADS is a short 
form questionnaire designed for speed of administration in a clinical setting that has 
demonstrated strong sensitivity and specificity, however there is some inherent risk that 
the overlap between PD symptoms influences the outcomes of this scale.  This is 
highlighted in the relationship between the questions that had highest average scores and 
the known symptoms of PD.  
There are a large number of statistical analyses performed to determine the results 
of this study and that can increase the incidence of type I errors in determining 
relationships.  However, the relationships that are demonstrated and commented on fall 
into the large category on Cohen’s effect size scale, and hence the likelihood of the 
relationships being due to type I errors is reduced. 
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Chapter 9: General Discussion 
The overall goal of the present research was to test whether common measures of 
“cognitive reserve” would mediate against cognitive decline in a Parkinson’s Disease (PD) 
population.  A secondary goal was to establish whether anxiety and depression influenced 
the cognitive functioning within the population. 
 Study 1 found that premorbid-IQ, a commonly used index of cognitive reserve, did 
not appear to have any protective influence on cognitive decline in a PD population.  In fact 
the opposite was true; people with higher premorbid IQ had a greater decline.  This finding, 
contrary to the hypotheses of the study and much previous research in cortical dementias, 
is likely explained in terms of Wilder’s law of initial values in which those who have more of 
“something-to-lose” show the greatest decline to a common level.  It is notable that unlike 
previous research in which the cognitive reserve theory is supported, the current study 
used an ipsative approach to measuring cognitive decline, not an approach based on 
thresholds of impairment.  The present finding agrees well with Pai and Chan (2001) who 
found an inverse relationship between cognitive decline and education in a PD population.  
The authors attributed the variation to individuals with higher levels of education being 
more sensitive to decline than their counterparts. This appears to be a very similar 
explanation to that offered in the current study; that people with “more of something to 
lose” are more vulnerable to dramatic loss than those with less to lose.  
Study 2 examined the possibility that cognitive reserved indexed via rich lifetime 
activities would help protect against cognitive decline in a Parkinson’s Disease population.  
Again, contrary to hypotheses, no consistent relationship was found.  Instead, just one 
factor (playing a musical instrument) appeared to potentially be associated with protection 
of cognition against disease pathology. Playing an instrument at a regularity of monthly or 
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more at various life stages was associated with higher levels of functioning on both the 
language and attention RBANS scores.  This finding may be interesting for two reasons.  
First, it was the only lifestyle factor or index of cognitive reserve found to have any 
protective effect on cognition.  Second, playing a musical instrument may have some 
potential practical and clinical application for disease treatment.  Playing a musical 
instrument regularly is something that can be taken up by a person post diagnosis whereas 
traditional cognitive reserve factors like education and pre-morbid IQ cannot, of course, be 
changed by the person at a later time.  There is a paucity of research available around the 
effects of lifestyle factors on cognitive performance, and this extends to the influence of 
playing a musical instrument.  Further research in this area may help to prove or disprove 
the presence of this relationship. 
Study 3 found that anxiety and depression were commonly found in a PD 
population and both were associated with poorer scores on cognitive tests. Depression, in 
particular, demonstrated a relationship with both language and attention outcome scores 
and a significant relationship with the level of overall decline.  The relationship indicated by 
this result may have important implications for both treatment and research; in terms of 
treatment it identifies the necessity of treating mood disorders to improve outcomes for 
people with PD and in terms of research it identifies the necessity of allowing for the 
effects of mood disorders when conducting research into the PD population.  These are 
emphasised by the conjecture in research around the accuracy of detecting mood disorders 
in PD and the apparent under-diagnosis that occurs as a result.  Further research into the 
accurate diagnosis of mood disorders in PD would allow for a better understanding of their 
incidence and to allow researchers to more accurately control for the effects of these 
concomitant conditions. 
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As a proviso to the above, the causative direction of the relationship between 
cognitive decline and mood disorders is worthy of further investigation.  The current study 
demonstrated a relationship between levels of depression and anxiety and levels of overall 
cognitive decline.  It is, however, possible that this relationship could be read the other 
way, i.e. that higher levels of decline imply a higher incidence of mood disorders, 
potentially due to a reduction in coping skills.  The causative direction of this relationship is 
worthy of future research. 
Interestingly, the indexes that demonstrated a relationship with playing a musical 
instrument were the same indexes affected by depression (language and attention) and 
anxiety (language).  These two indexes were also most preserved in the Pai and Chan 
(2001) study that demonstrated similar cognitive reserve results.  Hence, these seem to be 
the areas of functioning that are most variably affected in the course of PD.  The 
relationship between playing an instrument and the incidence of anxiety and depression 
was not examined in this study, but may be of interest in future research.   
In terms of personal outcomes, then, the points of interest identified in this study 
that may be worthy of consideration in future research are the use of musical instruments 
as a therapeutic tool, and the importance of treating mood disorders, particularly 
depression, in minimising the cognitive effects experienced by individuals with PD. 
While no commonly used measures of cognitive reserve  were reliably  found to 
moderate cognitive decline in PDs in the present research (potentially due to limitations 
covered later in this section) there were individual differences in cognitive deficits in the 
current PD which could not solely be explained by age, disease duration or mood effects.  
This may imply that other factors exist that affect the progression of the disease which 
were not measured or detectable in the current studies.  
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9.1 Limitations and Considerations 
In any research, there are factors that affect the outcome that are outside of the 
researcher’s control.  A number of such factors have been identified before and during the 
research, and allowed for where possible.  The following considerations and limitations 
should be considered when reviewing the findings of this research. 
9.1.1 Participant Recruitment and Demographics 
Participants were invited to participate in the research which may have skewed the 
study population as it is possible that a certain demographic were interested in 
participating than others (i.e. those who work in the area, have conducted research before 
etc).  Due to this it is possible that those of higher average intelligence may have chosen to 
participate in the research which may have led to inflation in the mean FSIQ of those 
participants. 
Due to the high incidence of depression within the population it is conversely 
possible that NART scores may have been artificially deflated with research by Watt and 
O’Carroll (1999) suggesting that an increased level of depression is associated with an 
increase in NART error scores. 
While the effect of motor speed impairment was allowed for in determining an 
individual’s processing speed by utilising both TMT A and BMIPB Motor Processing Task it is 
difficult to entirely and effectively remove the effect that motor impairment has on task 
performance. 
Due to the advanced age of participants, as is common with PD populations, many 
individuals had co-morbid conditions such as heart disease, diabetes and arthritis. While 
those with co-morbid neurological conditions such as a diagnosed Alzheimer’s Disease or 
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previous stroke or TBI were eliminated from the study this was reliant on self-report and 
not all conditions were able to be accounted for. 
9.1.2 Influence of Medication 
A major limitation of the present study was inability to control for the effects of 
medication.  Due to the physical ramifications of withholding dopaminergic medication 
(such as an increase in motor disturbance) participants were instructed to remain taking 
their medication as prescribed.  However, the time of day that participants were tested 
varied, depending on convenience of appointment time and similarly the time at which 
participants took their medication varied from person to person.  Because of this it was 
difficult to control for medication effects, in particular the decline in functioning that occurs 
when dopamine is decreasing as the next dose nears and the effects that people have 
immediately after taking their dose.  It is clear in the literature that the time of day in which 
someone has taken their medication can impact upon cognitive and physical functioning. 
Similarly, however, not taking medication can have adverse effects in terms of cognition 
and physical symptoms. Many studies note the difficulty in catering for this and generally, 
participants are instructed to take their medications as per usual so as little disturbance 
occurs to their overall PD symptoms as possible. 
Another factor difficult to control in the current study was whether or not 
participants were tested in an ‘on’ or ‘off’ motor state.  An ‘on’ motor state occurs when 
the person is getting good effect from their medication and they are able to control their 
movement freely.  An ‘off’ state occurs at times when a person is unable to initiate 
movements or to stop tremors.  These states are affected by variations of medication levels 
in the blood and are a normal, and cyclical, experience for people with PD.  Many authors 
note that cognitive performance can alter depending on which state an individual is in, 
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though Lyros, Messinis and Papathanasopolous (2008) indicated that these differences are 
only apparent for people with more progressed, dementia, symptoms.  Due to scheduling 
participants’ assessment at times that were convenient to them, the motor state of the 
participants could not be controlled.  Additionally, ‘on’ and ‘off’ states may occur at 
different times of the day on a daily basis for participants making it difficult for people to 
predict when their ‘on’ and ‘off’ motor states may be.  This makes the feasibility of 
controlling this aspect in research questionable.  
9.1.3 Difficulties in Measuring Cognitive Decline 
As discussed in study one, the method of calculating cognitive decline used in this 
research is less reliable than a calculation based on administering the same measure in a 
longitudinal methodology.  The comparison of different instrument scores adds a level of 
uncertainty to the decline calculation, though the research available correlating the 
measurements of the instruments used indicates that their comparison should be 
acceptably accurate.  Nevertheless, this does introduce a limitation in terms of assessing 
the decline of specific functions in the disease; while it is useful to compare current levels 
of functioning on say the attention index against pre-morbid levels of overall functioning it 
is less indicative of the nature of decline as a measure of pre-morbid attention would be.  
The expense and difficulty of conducting longitudinal methodology based studies is 
discussed briefly in study one, with factors such as the advanced age of participants and 
the difficulty of identifying individuals before they are diagnosed with the disease 
highlighted as key issues.  The difficulties in accurate and consistent diagnosis of PD must 
be considered again here; if there were a way to more efficiently diagnose PD through a 
medical test rather than observation it would be possible to more readily identify 
individuals at earlier stages of the disease and hence get a more accurate picture of 
functioning before significant disease progression has taken place.  The other method, in 
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terms of gathering a volume of pre-morbid data, is to conduct a large scale study examining 
cognitive function of a large section of the population and then conducting follow up 
studies with those individuals who develop the condition.  The expense, both in terms of 
the materials, interviewers, etc., and in terms of time that this type of study would require 
to yield results make it infeasible. 
Cross sectional studies such as this one, then, provide indicative results that can be 
further investigated via more robust, expensive and time consuming methodologies.  In 
many cases results, such as those around playing an instrument or treating mood disorders, 
lead to practical applications with minimal risks of negative outcomes and hence results 
may be enough to form the basis of experimental treatment regimes.  Longitudinal studies 
on the effects of these regimes, however, would be required to assess their value. 
9.1.4 Disease Duration 
Another confound in the PD literature is ascertaining disease duration. While the 
progression of cognitive decline in PD appears insidious in nature there is a lot of evidence 
suggestive that the cognitive effects of PD may precede diagnosis by several years. 
Additionally, the rate of decline differs amongst people with PD meaning that it is difficult 
to have everyone assessed at the same point of their disease.  Again, this may be alleviated 
by identification of more reliable methods of PD diagnosis that are able to determine the 
presence of disease earlier in its progression.   
9.1.5 Volume of Statistical Analyses 
A large amount of data was collected for all three studies and this resulted in a 
large number of analyses being conducted to determine the relationships that were 
discussed in each section.  Utilising a large number of statistical analyses has been 
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associated with an increase in type I errors, or false positives, and hence there should be 
reasonable doubt applied to all demonstrated relationships.  Effect sizes for all of the 
discussed relationships fell into the medium or large effect size category, going some way 
to alleviating this concern.  Nevertheless, the influence of the methodology used in 
reaching the conclusions should be considered when determining the strength of the 
results. 
9.1.6 Length of Assessment 
The length of the assessment may have had some impact on the results of the 
study, particularly around whichever subtest were administered later in the battery. The 
assessment took approximately 2 hours to complete and while all participants were offered 
a break throughout testing fatigue may have had an impact on tests taken later in the 
assessment. The order of the battery was not changed throughout the assessment either 
meaning that possible order effects may have occurred and that any effects caused by 
fatigue would have occurred on similar tests for all participants. 
9.2 Future Directions 
Future research into cognitive reserve in PD would benefit from using a larger 
sample size to see if the indicators of cognitive reserve that were present in this study 
population are present and identifiable in a larger PD population.  Similarly, it would be 
useful to examine cognitive reserve in other sub-cortical diseases such as MS, HD and 
progressive supranuclear palsy to determine whether the effects found within this study 
can be generalised to other sub cortical diseases or whether they are specific to PD.  
It would also be useful to examine whether cognitive reserve correlates with brain 
reserve with several studies suggesting that brain reserve can be identified via PET, SPECT 
125 
 
 
and MRI.  This was not feasible in this study due to budget constraints and access to 
equipment.  However the literature reviewed suggests that this is another area that may 
provide important information in predicting disease progression in the population. 
Future research could isolate whether the effects noted in the present research are 
specific to the particular tests used in this research, or whether they also hold when a 
variety of other cognitive tests.    This research would be valuable to clarify the current 
finding that anxiety and depression as measured by HADS were associated with RBANS 
language skills but not the related FAS semantic fluency test.  The cognitive reserve 
literature in cortical disease processes varies considerably depending upon test type, so 
examining the cognitive reserve question in PD using a large range of cognitive tests may 
also provide useful information for guiding clinicians in test usage in PD.  Further research 
could investigate whether people with PD benefit from increasing their social and 
occupational participation at the time of diagnosis, or whether increased activity at this 
stage has no minimal protective effect for cognition.   
In order to overcome some of the difficulties in the calculation of cognitive decline, 
the data collected for this study could be used as a baseline point in a longitudinal study.  
The RBANS has two forms and as such is a repeatable assessment which means that it is 
suitable for re-use with the population if they could be re-tested after a period of time.  
This would allow a direct comparison of test scores, and the calculation of a test-by-test 
based decline score, allowing better visibility of those functions which are continuing to 
degrade as a part of the disease process.  While this would not provide any greater clarity 
on the level of function prior to disease onset it would demonstrate whether decline is still 
occurring for the participants and at what rate it is occurring.  Similar analyses could be run 
to those in this study with the newly calculated decline variables in order to assess which 
domains are sensitive to which factors. 
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The relationship between regularly playing a musical instrument and performing 
better on the language and attention tests in PD is a valuable area for further study.  While 
the result was significant in the sample it was noted that there were only a relatively low 
number of participants in the study who had a background of regularly playing an 
instrument.  Nevertheless, the result is interesting both because of its presence indicating 
some measure of cognitive reserve in the PD population and because of its possibility to be 
used as a treatment in the disease and not just a predictor of disease progression.  There is 
a lack of research available about the effects that regularly playing an instrument has on 
cognition, and further investigation is required to determine whether this is a specific 
relationship with PD or whether the relationship between instruments and performance on 
these tasks is present throughout the general population.  There is also a need to examine 
a group with a higher representation of musicians, particularly in the older age grouping; 
there was only one over 65 in the study who regularly played an instrument and hence 
there was not the opportunity for the relationship to be statistically significant in that age 
group.  Another approach to this would be to conduct a study of non-musician people with 
PD with a baseline cognitive assessment and have them practice instruments regularly over 
a period before reassessment.  Results of such a study could provide information about the 
validity of such treatment programs in reducing the cognitive effects of the disease. 
Lastly it may be worthwhile investigating the strange result in Study 2  in which 
practice of artistic activity in late life was associated with reduced performance on 
cognitive processing speed tasks.  This result seems anomalous, and there is a lack of 
research to help determine whether this is a spurious result, a genuine result specific to PD 
or is something that could occur in the wider population.  There is value in conducting 
further research to investigate this odd finding.   
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Beyond the specific issues central to the current research, there are a series of 
issue for PD diagnosis which complicate any research into PD.  The first is in the diagnosis 
of PD itself, and extends to the diagnosis of MCI and PDD.  The diagnosis of PD is based on 
clinical examination of cardinal symptoms which overlap with other disorders and may not 
be the first to appear in disease progression.  Thus identifying how long the disease has 
been present in any individual is not easy and may lead to difficulties for research based 
around the stage of the disease.   Issues surrounding the diagnoses of MCI and PDD are 
discussed in chapter 3 and need not be recovered here.  However, diagnostic methods 
have led to some questionable research outcomes, such as those highlighted in study one.  
In these studies using a threshold based diagnosis for impairment that doesn’t take into 
account the individual’s pre-morbid level of functioning can over-report impairment in 
lower IQ populations and under report impairment in higher IQ populations.  An individual 
who had an impaired language score, for example, before disease onset, would contribute 
to the incidence of impairment in that group attributed to the disease.  Likewise a high 
function individual who declined to a low average level of functioning would indicate no 
change in function for the high IQ group in a threshold based diagnostic approach.  These 
types of research errors could be avoided with more accurate and defined diagnostic 
measures.  
Secondly, the diagnosis of mood disorders within the PD population is not entirely 
reliable as evidenced by the number of studies stating difficulties in determining their 
incidence in the population.  The measure used to determine anxiety and depression in this 
study, the HADS, is a widely used and well researched short form instrument that has been 
validated for use in the PD population.  Nevertheless, the symptom overlap between PD 
and mood disorders makes the results of this instrument questionable.  As discussed in 
study three, the most highly rated items on the questionnaire were those that shared 
overlap with the physical symptoms of PD, indicating that the mood disorders may be 
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overrepresented.  However, subjectively it is possible to consider that when asking 
someone with PD if they feel slowed down, for example, they could also attribute it to their 
disease and underrate their result leading depression being undervalued.  Whether it is 
over or underrated for a given individual or in general has implications for both research 
and treatment, particularly when relationships are demonstrated between mood disorders 
and cognition, both in the PD and general populations.  Even if this is only used as a basis to 
control for the effect of mood disorders while researching other effects on cognition, 
accuracy of detection of mood disorders in the PD population is essential.  As such, further 
research into the existing measures of anxiety and depression in the PD population, or the 
development of a new questionnaire specific to the population, would be of great value to 
future research into the condition. 
9.3 Clinical Implications 
It was the hope of this research that indicators of cognitive reserve would be found 
in the PD population to help clinicians to predict outcomes of cognitive degeneration and 
to allow them to tailor treatment regimes based on predicted loss of independence and 
support requirements.  Unfortunately, the current research was unable to reliably identify 
any general lifestyle factors predictive of cognitive decline in PD.  However, current results 
indicate that playing a musical instrument regularly, and minimising anxiety/depression 
both appear to protect somewhat against cognitive decline. The finding that individuals 
who play musical instruments regularly demonstrated higher language and attention scores 
than those who did not regularly play an instrument provides a basis for music based 
therapy in this population.  By introducing regular sessions of playing instruments for 
people with PD it may be possible to improve or retain functioning in these areas that 
would otherwise degrade as a part of the disease.  This is very much in accordance with the 
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‘use it or lose it’ therapies that have become popular in other degenerative diseases, such 
as Alzheimer’s Dementia, in recent times. 
Both anxiety and depression also demonstrated an influence on cognitive 
performance and cognitive decline.  Treatment of mood disorders in the PD population 
may thus help to improve or retain cognitive functions in the areas of language and, in the 
case of depression, attention.  .  It has been noted that the diagnosis of mood disorders 
within the population is difficult, and this may limit or reduce otherwise needed treatment. 
Nevertheless, such treatment could potentially be used to great effect within the PD 
population and it that would benefit from further research and treatment trials. 
  
130 
 
 
References 
Aarsland, D., Andersen, K., Larsen, J. P., Lolk, A., Nielsen, H. & Karagh-Sorensen, P. (2001), 
Risk of dementia in Parkinson’s Disease; a community-based, prospective study, 
Neurology, 56, 730-736. doi: 10.1212/WNL.56.6.730. 
Adams, S. A., Matthews, C. E., Ebbeling, C. B., Moore, C. G., Cunningham, J. E., Fulton, K. & 
Herbert, J. R. (2005), The effect of social desirability and social approval on self-
reports of physical activity, American Journal of Epidemiology, 161, 389-398. doi: 
10.1093/aje/kwi054. 
Albanese, A. (2003), Diagnostic criteria for Parkinson’s Disease, Neurological Science, 24, 
S23-S26. doi: 10.1007/s100720300032. 
Albert, S. M. & Teresi, J. A. (1999), Reading ability, education and cognitive status 
assessment among older adults in Harlem, New York City, American Journal of 
Public Health, 89, 95-97. doi: 10.2105/AJPH.89.1.95. 
Antoniou, M., Gunasekera, G. & Wong, P. C. M (2013), Foreign language training as 
cognitive therapy for age-related cognitive decline: a hypothesis for future 
research, Neuroscience and Biobehavioural Reviews. doi: 
10.1016/j.neubiorev.2013.09.004. 
Armstrong, M. J., Naglie, G., Duff-Canning, S., Meaney, C., Gill, D., Eslinger, P. J., Zadikoff, C., 
Mapstone, M., Chou, K. L., Persad, C., Litvan, I., Mast, B. T., Fox, S., Tang-Wai, D. F. 
& Marras, C. (2012). Roles of education and IQ in cognitive reserve in Parkinson’s 
disease-mild cognitive impairment, Dementia and Geriatric Cognitive Disorders, 2, 
343-352. doi: 10.1159/000341782. 
Balsamo, S., Willardson, J. M, Santos de Santana, F., Prestes, J., Balsamo, D. C., Nascimento, 
D. C., Santos-Neto, L. & Nobrega, O. T. (2013), Effectiveness of exercise on cognitive 
131 
 
 
impairment and Alzheimer’s Disease, International Journal of General Medicine, 
2013:6, 387-391. doi: 10.2147/IJGM.S35315. 
Barnett, J. H., Salmond, C. H., Jones, P. B. & Sahakian, B. J. (2006), Cognitive reserve in 
neuropsychiatry, Psychological Medicine, 36, 1053-1064. doi: 
10.1017/S0033291706007501. 
Barnes, J., & Boubert, L. (2008), Executive functions are impaired in patients with 
Parkinson’s disease with visual hallucinations, Journal of Neurology, Neurosurgery 
and Psychiatry, 79, 190-192. doi: 10.1136/jnnp.2007.116202. 
Barone, P., Aarsland, D., Burn, D., Emre, M., Kulisevsky, J., & Weintraub, D. (2011). 
Cognitive impairment in nondemented Parkinson's disease. Movement 
Disorders, 26(14), 2483-2495. doi: 10.1002/mds.23919. 
Beatty, W. W., Ryder, K. A., Gontkovsky, S. T., Scott, J. G., McSwan, K. L. & Bharucha, K. J. 
(2003), Analyzing the subcortical dementia syndrome of Parkinson’s Disease using 
the RBANS, Archives of Clinical Neuropsychology, 18, 509-520. doi: 
10.1093/arclin/18.5.509. 
Benton, A. L. & Hamser, K . deS (1989). Multilingual Aphasia Examination. Iowa City: AJA 
Associates. 
Bialystok, E. (2011), Reshaping the mind: the benefits of bilingualism, Canadian Journal of 
Experimental Psychology, 65, 229-235. doi: 10.1037/a0025406. 
Bohnen, N. I., Koeppe, R. A., Minoshima, S., Giordani, B., Albin, R. L., Frey, K. A. & Kuhl, D. E. 
(2011). Cerebral glucose metabolic features of Parkinson Disease and incident 
dementia: longitudinal study. Journal of Nuclear Medicine, 52. doi: 
10.2967//jnumed.111.089946. 
132 
 
 
Breen, K. & Drutyte, G. (2013), Non-motor symptoms of Parkinson’s Disease: the patient’s 
perspective, Journal of Neural Transmission, 120, 531-535. doi: 10.1007/s00702-
012-0928-2. 
Burgess, P. W. & Shallice, T. (1997). The Hayling and Brixton Test. Bury St Edmonds, Suffolk: 
Thames Valley Test Company. 
Ceravola, R., Rossie, C., Kiferle, L., & Bonuccelli, U. (2010), Nonmotor symptoms in 
Parkinson’s Disease: the dark side of the moon, Future Neurology, 5, 851-871. doi: 
10.2217/fnl.10.69. 
Christensen, H., Anstey, K. J., Parslow, R. A., Maller, J., Mackinnon, A. & Sachdev, P. (2007), 
The brain reserve hypothesis, brain atrophy and aging, Gerontology, 53, 82-95. doi: 
10.1159/000096482. 
Coughlan, A. K., Oddy, M. J. & Crawford, J. R. (2007). BIRT memory and information 
processing battery (BMIPB), London: Brain Injury Rehabilitation Trust. 
Demakis, G. J. (2007), The neuropsychology of Parkinson’s Disease, Disease a Month, 53, 
152-155. doi: 10.1016/j.disamonth.2007.04.005. 
Dik, M. G., Deeg, D. J. H., Visser, M. & Jonker, C. (2003), Early life physical activity and 
cognition at old age, Journal of Clinical and Experimental Neuropsychology, 25, 5, 
643-653. doi: 0.1076/jcen.25.5.643.14583. 
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, 
K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A. & Tanner, C. M. (2007). 
Projected number of people with Parkinson disease in the most populous nations, 
2005 through 2030. Neurology, 68(5), 384-386. doi: 
10.1212/01.wnl.0000247740.47667.03 
Dubois, B., Burn, D., Goetz, C., Aarsland, D., Brown, R. G., Broe, G.A., Dickson, D., 
Duyckaerts, C., Cummings, J., Gauthier, S., Korczyn, A., Lees, A., Levy, R., Litvan, I., 
133 
 
 
Mizuno, Y., McKeith, I. G., Olanow, C. W., Poewe, W., Sampaio, C., Tolosa, E. & 
Emre, M. (2007), Diagnostic procedures for Parkinson’s Disease dementia: 
recommendations from the Movement Disorder Society Task Force, Movement 
Disorders, 22, 16, 2314-2324. doi: 10.1002/mds.21844. 
Emre, M. (2003), Dementia associated with Parkinson’s Disease, Lancet Neurology, 2, 229-
237. doi: 0.1016/S1474-4422(03)00351-X. 
Emre, M. (2003), What causes mental dysfunction in Parkinson’s Disease?, Movement 
Disorders, 18:6, S63-S71. doi: 10.1002/mds.10565. 
Ferreri, F., Agbokou, C. & Gauthier, S. (2006). Recognition and management of 
neuropsychiatric complications in Parkinson’s disease, Canadian Medical 
Association Journal, 175, 12, 1545-1552. doi: 10.1503/cmaj.060542. 
Giovannini, P., Piccolo, I., Genitrini, S., Soliveri, P., Girotti, F., Geminiani, G., Scigliano, G. & 
Caraceni, T. (1991). Early-onset Parkinson’s disease, Movement Disorders, 6, 1, 36-
42. doi: 10.1002/mds.870060107. 
Gold, B. T., Johnson, N. F. & Powell, D. K. (2013), Lifelong bilingualism contributes to 
cognitive reserve against white matter integrity declines in aging, 
Neuropsychologica. doi: 10.1016/j.neuropsychologia.2013.09.037i. 
Goldman, J. G., Weis, H., Stebbins, G., Bernard, B., & Goetz, C. G. (2012). Clinical differences 
among mild cognitive impairment subtypes in Parkinson's disease. Movement 
Disorders, 27(9), 1129-1136. doi: 10.1002/mds.25062. 
Green, A., Garrick, T., Sheedy, D., Blake, H., Shores, A. & Harper, C. (2008), Repeatable 
Battery for the Assessment of Neurological Status (RBANS): preliminary Australian 
normative data, Australian Journal of Psychology, 60, 72-79. doi: 
10.1080/00049530701656257. 
134 
 
 
Green, J., McDonald, W. M., Vitek, J. L., Evatt, M., Freeman, A., Haber, M., Bakay, R. A. E., 
Triche, S., Sirockman, B. & DeLong, M. R. (2002), Cognitive impairments in 
advanced PD without dementia, Neurology, 59, 1320-1324. doi: 
10.1212/01.WNL.0000031426.21683.E2. 
Hanna, K. K., & Cronin-Golomb, A. (2011). Impact of Anxiety on Quality of Life in 
Parkinson's Disease. Parkinson's disease, 2012. doi:10.1155/2012/640707. 
Hanna-Pladdy, B. & Gajewski, B. (2012), Recent and past musical activity predicts aging 
variability: direct comparison with general lifestyle activities, Frontiers in Human 
Neuroscience, 6. doi: 10.3389/fnhum.2012.00198. 
Hanna-Pladdy, B. & MacKay, A. (2011), The relation between instrumental musical activity 
and cognitive aging, Neuropsychology, 25, 378-386. doi: 10.1037/a0021895. 
Hanna-Pladdy, B., Jones, K., Cabanban, R., Pahwa, R. & Lyons, K.E. (2013), Predictors of mild 
cognitive impairment in early-stage Parkinson’s Disease, Dementia and Geriatric 
Cognitive Disorders, 3, 168-178. doi: 10.1159/000351421. 
Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M. & Morris, J. G. L. (2008), The Sydney 
Multicentre Study of Parkinson’s Disease: the inevitability of dementia at 20 years, 
Movement Disorders, 6, 837-844. doi: 10.1002/mds.21956. 
Hennessy M., & Mackenzie, B. D. (1995). AUSNART: The development of an Australian 
version of the NART. The 18th Annual Brain Impairment Conference, Hobart, 183-
188. 
Hindle, J.V., Martyr, A., & Clare, L. (2013). Cognitive reserve in Parkinson’s disease: a 
systematic review and meta-analysis. Parkinsonism & Related Disorders. Advance 
online publication. doi: 10.1016/j.parkreldis.2013.08.010 
135 
 
 
Hirano, S., Shinotoh, H., & Eidelberg, D. (2012). Functional brain imaging of cognitive 
dysfunction in Parkinson's disease. Journal of Neurology, Neurosurgery & 
Psychiatry, 83(10), 963-969. doi: 10.1136/jnnp-2011-301818. 
Hubble, J. P., Cao, T., Hassenein, R. E.S., Neuberger, J. S. & Koller, W. C. (1993). Risk factors 
for Parkinson’s disease, Neurology, 43, 1693-1697. doi: 10.1212/WNL.43.9.1693. 
Jones, R. N., Manly, J., Glymour, M. M., Rentz, D. M., Jefferson, A. L., & Stern, Y. (2011). 
Conceptual and measurement challenges in research on cognitive reserve. Journal 
of the International Neuropsychological Society,17(4), 593. 
doi:10.1017/S1355617710001748. 
Klepac, N., Trkulja, V., Relja, M. & Babic, T. (2008), Is quality of life in non-demented 
Parkinson’s disease patients related to cognitive performance? A clinic-based cross-
sectional study, European Journal of Neurology, 15, 128-133. doi: 10.1111/j.1468-
1331.2007.02011.x. 
Koerts, J., Tucha, L., Lange, K. & Tucha, O. (2013), The influence of cognitive reserve on 
cognition in Parkinson’s Disease, Journal of Neural Transmission, 120, 593-596. doi: 
10.1007/s00702-012-0916-6. 
Koziol, L. F. & Budding, D. E. (2009), Subcortical structures and cognition: implications for 
neuropsychological assessment, New York: Springer. 
Kudlicka, A., Clare, L. & Hindle, J. (2013), Pattern of executive impairment in mild to 
moderate Parkinson’s Disease, Dementia and Geriatric Cognitive Disorders, 36, 50-
66. doi: 10.1159/000348355. 
Kudlicka, A., Clare, L., & Hindle, J. V. (2011). Executive functions in Parkinson's disease: 
Systematic review and meta‐analysis. Movement Disorders, 26(13), 2305-2315. doi: 
10.1002/mds.23868. 
136 
 
 
Kulisevsky, J. & Pagonabarraga, J. (2009), Cognitive impairment in Parkinson’s Disease: 
tools for diagnosis and assessment, Movement Disorders, 24, 8, 1103-1110. doi: 
10.1002/mds.22506. 
de Lau, L. M. L. & Breteler, M. M. B. (2006), Epidemiology of Parkinson’s Disease, Lancet 
Neurology, 5, 525-535. doi: 10.1016/S1474-4422(06)70471-9. 
Lee, J. E., Cho, K. H., Song, S. K., Kim, H. J., Lee, H. S., Sohn, Y. H. & Lee, P. H. (2013) 
Exploratory analysis of neuropsychological and neuroanatomical correlates or 
progressive mild cognitive impairment in Parkinson’s Disease, Journal of Neurology, 
Neurosurgery and Psychiatry, 0, 1-10. doi: 10.1136/jnnp-2013-305062. 
Lee, W., Williams, D. R., & Storey, E. (2012). Cognitive testing in the diagnosis of 
parkinsonian disorders: A critical appraisal of the literature. Movement 
Disorders, 27(10), 1243-1254. doi: 10.1002/mds.25113. 
Leentjens, A. F. G., Dujardin, K., Marsh, L., Martinez-Martin, P., Richard, I. H., Starksthein, S. 
E., Weintraub, D., Sampaio, C., Poewe, W., Rascol, O., Stebbins, G. T. & Goetz, C. G. 
(2008), Anxiety rating scales in Parkinson’s disease: critique and recommendations, 
Journal of Movement Disorders, 23 (14), 2015-2025. doi: 10.1002/mds.22233. 
Leentjens, A. F. G, Moonen, A. J. H., Dujardim, K., Marsh, L., Martinez-Martin, P., Richard, I. 
H., Starkstein, S. E. & Kohler, S. (2013). Modeling depression in Parkinson disease: 
disease-specific and nonspecific risk factors, Journal of Neurology, 81, 1-8. doi: 
10.1212/WNL.0b013e3182a4a503. 
Lemke, M. R., Fuchs, G., Gemende, I., Herting, B., Oelhlwein, C., Reichmann, H., Rieke, J. & 
Volkmann, J. (2004). Depression and Parkinson’s Disease, Journal of Neurology, 21, 
24-27. doi: 10.1007/s00415-004-1606-6. 
Lezak, M.D., Howieson, D.B., & Loring, D.W. (2004). Neuropsychological assessment (4th 
ed.). New York: Oxford University Press. 
137 
 
 
Litvan, I., Aarsland, D., Adler, C.H., Goldman, J.G., Kulisevsky, J., Mollenhaur, B., Rodriguez-
Oroz, M.C., Troster, A.I. Weintraub, D. (2011), MDS task force on mild cognitive 
impairment in Parkinson’s Disease: critical review of PD-MCI, Movement Disorders, 
26,1814-1824. doi: 10.1002/mds.23823. 
Luk, G., Bialystok, E., Craik, F. I. M. & Grady, C. L. (2011), Lifelong bilingualism maintains 
white matter integrity in older adults, Journal of Neuroscience, 31, 16808-16813. 
doi: 10.1523/JNEUROSCI.4563-11.2011. 
Lyros, E. Messinis, L. & Papathanasopoulos, P. (2008), Does motor subtype influence 
neurocognitive performance in Parkinson’s Disease without dementia?, European 
Journal of Neurology, 15, 262-267. doi: 10.1111/j.1468-1331.2007.02046.x. 
Mak, E., Zhou, J., Tan L. C. S., Au, W. L., Sitoh, Y. Y. & Kandiah, N. (2013), Cognitive deficits 
in mild Parkinson’s Disease are associated with distinct areas of grey matter 
atrophy,  Journal of Neurology Neurosurgery and Psychiatry. doi:10.1136/jnnp- 
2013-305805 
Marinus, J., Visser, M., Verwey, N. A., Verhey, F. R. J., Middelkoop, H. A. M., Stiggelbout, A. 
M. & van Hilten, J. J. (2003), Assessment of cognition in Parkinson’s Disease, 
Neurology, 61, 1222-1228. doi: 10.1212/01.WNL.0000091864.39702.1C. 
Marras, C., Armstrong, M. J., Meaney, C. A., Fox, S., Rothberg, B., Reginold, W., Tang-Wai, 
D. F., Gill, D., Eslinger, P. J., Zadikoff, C., Kennedy, N., Marshall, F. J., Mapstone, M., 
Chou, K. L., Persad, C., Litvan, I., Mast, B. T., Gerstenecker, A. T., Weintraub, S. & 
Duff-Canning, S. (2013). Measuring mild cognitive impairment in patients with 
Parkinson’s Disease, Movement Disorders, 28, 5, 626-633. doi: 0.1002/mds.25426. 
Marsh, L., McDonald, W. M., Cummings, J., Ravina, B. & NINDS/NIMH Work Group on 
Depression and Parkinson’s Disease (2006). Provisional diagnostic criteria for 
depression in Parkinson’s disease: report of an NINDS/NIMH work group, 
Movement Disorders, 21, 2, 148-158. doi: 10.1002/mds.20723. 
138 
 
 
Menza, M., Dobkin, R.D., Marin, H., Mark, M.H., Gara, M., Buyske, S., Bienfait, K. & Dicke, A. 
(2009). A controlled trial of antidepressants in patients with Parkinson Disease and 
depression, Neurology, 72, 886-892. doi: 10.1212/01.wnl.0000336340.89821.b3.  
Mitchell, M. B., Cimino, C. R., Benitez, A., Brown, C. L., Gibbons, L. E., Kennison, R. E., Shirk, 
S. D., Atri, A., Robitaille, A., MacDonald, s. W. S., Lindwall, M., Zelinski, E. M., Willis, 
S. L., Warner-Schaie, K., Johansson, B., Dixon, R. A., Mungas, D. M., Hofer, S. M. & 
Piccinin, A. M. (2012), Cognitively stimulating activities: effects on cognition across 
four studies with up to 21 years of longitudinal data, Journal of Aging Research, 
2012, 1-12. doi: 10.1155/2012/461592. 
Montel, S. & Bungener, C. (2008), To what extent does frontal type executive impairment 
affect coping strategies in Parkinson’s disease?, European Journal of Neurology, 15, 
1131-1134. doi: 0.1111/j.1468-1331.2008.02251.x. 
Morgan, D. R., Linck, J., Scott, J., Adams, R. & Mold, J. (2010), Assessment of the RBANS 
visual and verbal indices in a sample of neurologically impaired elderly participants, 
The Clinical Neuropsychologist, 24, 8, 1365-1378. doi: 
10.1080/13854046.2010.516769. 
Mortimer, J. A., Snowdon, D. A., & Markesbery, W. R. (2003), Head circumference, 
education and risk of dementia: findings from the nun study, Journal of Clinical and 
Experimental Neuropsychology, 25, 671-679. doi: 10.1076/jcen.25.5.671.14584. 
Muangpaisan, W., Mathews, A., Hori, H., & Seidel, D. (2011). A systematic review of the 
worldwide prevalence and incidence of Parkinson's disease. Journal of the Medical 
Association of Thailand= Chotmaihet thangphaet, 94(6), 749. 
Muslimovic, D., Post, B., Speelman, J. & Schmand, B. (2005), Cognitive profile of patients 
with newly diagnosed Parkinson Disease, Neurology, 65, 1239-1245. doi: 
10.1212/01.wnl.0000180516.69442.95. 
139 
 
 
Muslimovic, D., Schmand, B., Speelman, J. D. & De Haan, R. J. (2007), Course of cognitive 
decline in Parkinson’s Disease: a meta-analysis, Journal of the International 
Neuropsychological Society, 13, 920-932. doi: 10.1017/S1355617707071160. 
Naismith, S. L., Mowszowski, L., Diamond, K. & Lewis, S. J. G. (2013), Improving memory in 
Parkinson’s Disease: a healthy brain ageing cognitive training program, Movement 
Disorders, 28, 8, 1097-1103. doi: 10.1002/mds.25457. 
Nelson, H. E. & Willison, J. R. (1991). The National Adult Reading Test (NART): Test manual 
(2nd Ed). Windsor: NFER, 14 - 21. 
Pai, M. C. & Chan, S. H. (2001), Education and cognitive decline in Parkinson’s Disease: a 
study of 102 patients, Acta Neurology Scandinavia, 103, 243-247. doi: 
10.1034/j.1600-0404.2001.103004243.x. 
Paolo, A. M., Tröster, A. I., Ryan, J. J., & Koller, W .C. (1997). Comparison of NART and 
Barona demographic equation premorbid IQ estimates in Alzheimer’s disease. 
Journal of Clinical Psychology, 53, 713-722. doi: 10.1002/(SICI)1097-
4679(199711)53:7%3C713::AID-JCLP8%3E3.0.CO;2-I. 
Perneczky, R., Drzezga, A., Boecker, H., Ceballos-Baumann, A. O., Granert, O., Forstl, H., 
Kurz, A. & Haussermann, P. (2008), Activities of daily living, cerebral glucose 
metabolism, and cognitive reserve in Lewy body and Parkinson’s Disease, Dementia 
and Geriatric Cognitive Disorders, 26, 475-481. doi: 10.1159/000167791. 
Possin, K.L., Filoteo, J.V., Song, D. D. & Salmon, D. P. (2008), Spatial and object working 
memory deficits in Parkinson’s Disease are due to impairment in different 
underlying processes, Neuropsychology, 22, 5, 585-595. doi: 10.1037/a0012613. 
Qui, C., De Ronchi, D., & Fratiglioni, L. (2007), The epidemiology of the dementias: an 
update, Current Opinion in Psychiatry, 20, 380-385.  
140 
 
 
Randolph, C. (1998), Repeatable Battery for the Assessment of Neuropsychological Status 
(RBANS), San Antonio, TX: Psychological Corporation.  
Ravina, B., Camicioli, R., Como, P.G., Marsh, L., Jankovic, J., Weintraub, D., & Elm, J. (2007), 
The impact of depressive symptoms in early Parkinson’s Disease, Neurology, 69, 
342- 347. 
Reijnders, J. S. A. M., Ehrt, U., Weber, W. E. J, Aarsland, D. & Leentjens, A. F. G. (2008). A 
systematic review of prevalence studies of depression in Parkinson’s disease, 
Movement Disorders, 23, 183-189. doi: 10.1002/mds.21803. 
Reyes, M. A., Lloret, S. P., Gerscovich, E. R., Martin, M. E., Leiguarda, R. & Merello, M. 
(2009). Addenbrooke’s cognitive examination validation in Parkinson’s Disease. 
European Journal of Neurology, 16, 142-147. doi: 10.1111/j.1468-
1331.2008.02384.x. 
Richards, M. & Sacker, A. (2003), Lifetime antecedents of cognitive reserve, Journal of 
Clinical and Experimental Neuropsychology, 25, 614-624. doi: 
10.1076/jcen.25.5.614.14581. 
Rzewnicki, R., Auweele, Y. V. & De Bourdeaudhuij, I. (2003), Addressing overreporting on 
the International Physical Activity Questionnaire (IPAQ) telephone survey with a 
population sample, Journal of Public Health Nutrition, 6, 299-305. doi: 
10.1079/PHN2002427. 
Rodriguez-Blazquez, C., Frades-Payo, B., Forjaz, M.J., de Pedro-Cuesta, J. & Martinez-
Martin, P. (2009), Psychometric attributes of the Hospital Anxiety and Depression 
Scale in Parkinson’s Disease, Movement Disorders, 24, 519-525. doi: 
10.1002/mds.22321. 
Sachdev, P. S., & Valenzuela, M. (2009), Brain and cognitive reserve, The American Journal 
of Geriatric Psychiatry, 17, 175-178. doi: 0.1097/JGP.0b013e318196a661. 
141 
 
 
Scarmeas, N. & Stern, Y. (2003), Cognitive reserve and lifestyle, Journal of Clinical and 
Experimental Neuropsychology, 25, 5, 625-633. doi: 10.1076/jcen.25.5.625.14576. 
Schoenberg, M. R., Rinehart, E., Duff, K., Mattingly, M., Bharucha, K. J. & Scott, J. G. (2012), 
Assessing reliable changes using the Repeatable Battery for Assessment of 
Neuropsychological Status (RBANS) for patients with Parkinson’s Disease 
undergoing Deep Brain Stimulation (DBS) surgery, The Clinical Neuropsychologist, 
26, 2, 255-270. doi: 10.1080/13854046.2011.653587. 
Schweizer, T., Ware, J., Fischer, C.E., Craik, F.I.M., & Bialystok, E. (2012). Bilingualism as a 
contributor to cognitive reserve: Evidence from brain atrophy in Alzheimer’s 
disease. Cortex, 48, 991-996.  
Snaith, R. P. & Zigmond, A. S. (1994). HADS: Hospital Anxiety and Depression Scale. 
Windsor: NFER Nelson. 
Starr, J. M. & Lonie, J. (2008), Estimated pre-morbid IQ effects on cognitive and functional 
outcomes in Alzheimer Disease: a longitudinal study in a treated cohort, BMC 
Psychiatry, 8. doi:10.1186/1471-244X-8-27 
Stella, F., Gobbi, L. T. B., Gobbi, S., Oliani, M. M., Tanaka, K. & Pieruccini-Faria, F. (2007), 
Early impairment of cognitive functions in Parkinson’s Disease, Journal of 
Neuropsychiatry, 65, 406-410. doi: 10.1590/S0004-282X2007000300008. 
Stern, Y. (2002), What is cognitive reserve? Theory and research application of the reserve 
concept, Journal of the International Neuropsychological Society, 8, 448-460. doi: 
10.1017/S1355617702813248. 
Stern, Y. (2003), The concept of cognitive reserve:  a catalyst for research, Journal of Clinical 
and Experimental Neuropsychology, 25, 589-593. doi: 
10.1076/jcen.25.5.589.14571. 
142 
 
 
Stern, Y. (2012), Cognitive reserve in ageing and Alzheimer’s Disease, Lancet Neurology, 11, 
1006-1012. doi: 10.1016/S1474-4422(12)70191-6. 
Stern, Y., Habeck, C., Moeller, J., Scarmeas, N., Anderson, K. E., Hilton, H. J., Flynn, J., 
Sackeim, H. & van Heertum, R. (2005), Brain networks associated with cognitive 
reserve in healthy young and old adults, Cerebral Cortex, 15, 4, 394-402. doi: 
10.1093/cercor/bhh142. 
Stern, Y., Zarahn, E., Hilton, H. J., Flynn, J., DeLaPaz, R. & Rakitin, B. (2003), Exploring the 
neural basis of cognitive reserve, Journal of Clinical and Experimental 
Neuropsychology, 25, 5, 691-701. doi: 10.1076/jcen.25.5.691.14573. 
Stuss, D. T. & Alexander, M. P. (2000), Executive functions and the frontal lobes, a 
conceptual view, Psychological Research, 63, 289-298. doi: 
10.1007/s004269900007. 
Tremblay, C., Achim, A. M., Macoir, J., & Monetta, L. (2013), The heterogeneity of cognitive 
symptoms in Parkinson's disease: a meta-analysis. Journal of Neurology, 
Neurosurgery & Psychiatry. doi: 10.1136/jnnp-2013-305021. 
Tolosa, E., Wenning, G. & Poewe, W. (2006), The diagnosis of Parkinson’s Disease, Lancet 
Neurology, 5, 75-86. doi: 10.1016/S1474-4422(05)70285-4. 
Uekermann, J., Daum, I., Peters, S., Wiebel, B., Przuntek, H. & Muller, T. (2003), Depressed 
mood and executive dysfunction in early Parkinson’s Disease, Acta Neurologica 
Scandinavia, 107, 5, 341-348. doi: 10.1034/j.1600-0404.2003.02155.x. 
Valenzuela, M. J. (2008), Brain reserve and the prevention of dementia, Current Opinion in 
Psychiatry, 21, 296-302. doi: 10.1097/YCO.0b013e3282f97b1f. 
Valenzuela, M. J. (2012), Brain and heart targets for better dementia prevention, Medicine 
Today, 13, 38-43.  
143 
 
 
Valenzuela, M. J. & Sachdev, P. (2007), Assessment of complex mental activity across the 
lifespan: development of the Lifetime of Experiences Questionnaire (LEQ), 
Psychological Medicine, 37, 1015-1025. doi: 10.1017/S003329170600938X. 
Valenzuela, M. J. & Sachdev, P. (2006), Brain reserve and dementia: a systematic 
review, Psychological Medicine, 36, 441-454.  doi: 10.1017/S0033291705006264. 
Valenzuela, M. J. & Sachdev, P. (2006), Brain reserve and cognitive decline: a non-
parametric systematic review, Psychological Medicine, 36, 1065-1073. doi: 
10.1017/S0033291706007744. 
Vingerhoets, G., Verleden, S., Santens, P., Miatton, M. & de Reuck J. (2003), Predictors of 
cognitive impairment in advanced Parkinson’s Disease, Journal of Neurology, 
Neurosurgery and Psychiatry, 74, 793-796.  doi: 10.1136/jnnp.74.6.793. 
Watt, K. J. & O’Carroll, R. E. (1999), Evaluating methods for estimating premorbid 
intellectual ability in closed head injury, Journal of Neurology, Neurosurgery and 
Psychiatry, 66, 474-479. doi: 10.1136/jnnp.66.4.474. 
Wechsler, D. (1997), Wechsler Adult Intelligence Scale – Revised.  San Antonio, TX: 
Psychological Corporation. 
Weintraub, D., & Burn, D. J. (2011), Parkinson's disease: the quintessential neuropsychiatric 
disorder. Movement Disorders, 26(6), 1022-1031. doi:10.1002/mds.23664. 
Wickremaratchi, M. M., Ben-Shlomo, Y. & Morris, H. R. (2009), The effect of onset age on 
the clinical features of Parkinson’s Disease, European Journal of Neurology, 16, 
450-456. doi: 10.1111/j.1468-1331.2008.02514.x. 
Wilder, J. (1967). Stimulus and response: the law of initial value, Bristol: John Wright and 
Sons. 
144 
 
 
Wilson, R. S., Barnes, L. L. & Bennett, D. A. (2003), Assessment of lifetime participation in 
cognitively stimulating activities. Journal of Clinical and Experimental 
Neuropsychology, 25(5)634-642. doi: 10.1076/jcen.25.5.634.14572 
Yang, C., Garrett-Mayer, E., Schneider, J. S., Gollomp, S. M. & Tilley, B. C. (2009), 
Repeatable Battery for Assessment of Neuropsychological Status in early 
Parkinson’s Disease, Movement Disorders, 24, 10, 1453-1460. doi: 
10.1002/mds.22552. 
Zatorre, R. J., Chen, J. L. & Penhune, V. B. (2007), When the brain plays music: auditory-
motor interactions in music perception and production, Nature Reviews: 
Neuroscience, 8, 547-558. doi: 10.1038/nrn2152. 
  
145 
 
 
 
 
 
 
 
Appendix A 
 
 
 
 
Lifetime of Experiences Questionnaire 
 
162 
 
 
 
 
 
 
 
Appendix B 
 
 
 
 
Data Analysis Output (CD) 
  
163 
 
 
 
 
 
 
 
Appendix C 
 
 
 
 
Regression Analyses 
 
 
 
 
 
 
 
 
  
164 
 
 
Table C.1  
Regression Coefficients for demographic variables effect on Cognitive Decline 
Step Variable Standardised Coefficient t-value (p) 
1 Constant  -0.527 (0.600) 
1 Age 0.195 1.724 (0.089) 
1 Sex -0.106 -0.964 (0.338) 
1 Disease Duration 0.078 0.686 (0.495) 
 
The fit of this model was assessed as F(2,80) = 1.818, p = 0.151. 
 
Table C.2  
Regression Coefficients for mood variables effect on Cognitive Decline 
Step Variable Standardised Coefficient t-value (p) 
1 Constant  3.540 (0.001) 
1 HADS Anxiety -0.066 -0.512 (0.610) 
1 HADS Depression 0.199 1.543 (0.127) 
 
The fit of this model was assessed as F(2,81) = 1.252, p = 0.291. 
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Table C.3  
Regression Coefficients for LEQ Young Adult variables effect on Cognitive Decline 
Step Variable Standardised Coefficient t-value (p) 
1 Constant  0.427 (0.671) 
1 Time with Family 0.019 0.159 (0.874) 
1 Playing an 
Instrument 
-0.284 -2.290 (0.025) 
1 Art Activities 0.068 0.555 (0.581) 
1 Mild Sport -0.067 -0.552 (0.583) 
1 Moderate Sport 0.056 0.360 (0.720) 
1 Vigorous Sport -0.009 -0.061 (0.952) 
1 Reading 0.105 0.854 (0.396) 
1 Speaking a second 
language 
0.114 0.895 (0.374) 
 
The fit of this model was assessed as F(8,67) =0.828, p = 0.581. 
 
Table C.4  
Regression Coefficients for LEQ Mid Life variables effect on Cognitive Decline 
Step Variable Standardised Coefficient t-value (p) 
1 Constant  -0.261 (0.795) 
1 Time with Family 0.041 0.274 (0.785) 
1 Playing an 
Instrument 
-0.299 -2.486 (0.015) 
1 Art Activities 0.134 1.133 (0.261) 
1 Mild Sport -0.149 -0.986 (0.328) 
1 Moderate Sport 0.389 2.785 (0.007) 
1 Vigorous Sport .0.175 -1.260 (0.212) 
1 Reading 0.118 1.055 (0.295) 
1 Speaking a second 
language 
0.088 0.749 (0.457) 
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The fit of this model was assessed as F(8,66) =2.027, p = 0.057. 
 
Table C.5  
Regression Coefficients for LEQ Late Life variables effect on Cognitive Decline 
Step Variable Standardised Coefficient t-value (p) 
1 Constant  1.641 (0.109) 
1 Time with Family -0.257 -1.525 (0.135) 
1 Playing an 
Instrument 
-0.090 -0.565 (0.575) 
1 Art Activities -0.031 -0.192 (0.849) 
1 Mild Sport -0.088 -0.542 (0.591) 
1 Moderate Sport 0.219 0.872 (0.389) 
1 Vigorous Sport 0.076 0.314 (0.755) 
1 Reading 0.058 0.361 (0.720) 
1 Speaking a second 
language 
-0.071 -0.453 (0.653) 
 
The fit of this model was assessed as F(8,40) =0.563, p = 0.720. 
 
Based on the outcomes of the above models, 3 step regressions were performed at each of 
the LEQ life stages with demographic factors at step 1, mood factors at step 2 and LEQ 
factors at step 3.  
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Table C.6  
Three Step Regression Coefficients for LEQ Young Adult variables effect on Cognitive Decline 
Step Variable Standardised Coefficient t-value (p) 
1 Constant  -0.357 (0.722) 
1 Age 0.165 1.280 (0.205) 
1 Disease Duration 0.055 0.427 (0.671) 
1 Sex -0.052 -0.407 (0.686) 
2 HADS Anxiety -0.080 -0.539 (0.592) 
2 HADS Depression 0.128 0.846 (0.401) 
3 Time with Family 0.023 0.188 (0.851) 
3 Playing an 
Instrument 
-0.259 -2.028 (0.047) 
3 Art Activities 0.064 0.502 (0.617) 
3 Mild Sport -0.082 -0.655 (0.515) 
3 Moderate Sport 0.072 0.457 (0.650) 
3 Vigorous Sport -0.011 -0.068 (0.946) 
3 Reading 0.080 0.637 (0.527) 
3 Speaking a second 
language 
0.143 1.072 (0.288) 
 
The fit of this model was assessed as F(13,62) = 0.840, p = 0.618. 
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Table C.7  
Three Step Regression Coefficients for LEQ Mid Life variables effect on Cognitive Decline 
Step Variable Standardised Coefficient t-value (p) 
1 Constant  -0.199 (0.843) 
1 Age 0.190 1.566 (0.122) 
1 Disease Duration 0.046 0.370 (0.712) 
1 Sex -0.056 -0.460 (0.647) 
2 HADS Anxiety 0.010 0.070 (0.944) 
2 HADS Depression 0.038 0.252 (0.802) 
3 Time with Family 0.009 0.057 (0.955) 
3 Playing an 
Instrument 
-0.269 -2.239 (0.029) 
3 Art Activities 0.131 1.079 (0.285) 
3 Mild Sport -0.151 -0.918 (0.362) 
3 Moderate Sport 0.378 2.607 (0.011) 
3 Vigorous Sport -0.175 -1.185 (0.241) 
3 Reading 0.089 0.765 (0.447) 
3 Speaking a second 
language 
0.081 -0.666 (0.508) 
 
The fit of this model was assessed as F(13,61) = 1.524, p = 0.135. 
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Table C.8  
Three Step Regression Coefficients for LEQ Late Life variables effect on Cognitive Decline 
Step Variable Standardised Coefficient t-value (p) 
1 Constant  0.411 (0.683) 
1 Age 0.300 1.582 (0.123) 
1 Disease Duration 0.077 0.427 (0.672) 
1 Sex -0.024 -0.139 (0.890) 
2 HADS Anxiety -0.113 -0.498 (0.622) 
2 HADS Depression 0.011 0.046 (0.964) 
3 Time with Family -0.170 -0.898 (0.375) 
3 Playing an 
Instrument 
-0.089 -0.538 (0.594) 
3 Art Activities -0.062 -0.383 (0.704) 
3 Mild Sport -0.153 -0.918 (0.365) 
3 Moderate Sport 0.208 0.754 (0.456) 
3 Vigorous Sport 0.100 0.389 (0.700) 
3 Reading 0.029 0.175 (0.862) 
3 Speaking a second 
language 
-0.113 -0.676 (0.504) 
 
The fit of this model was assessed as F(13,35) = 0.795, p = 0.660. 
 
 
 
 
 
 
 
 
